The O
secondary O
effectiveness O
measure O
, O
the B-Sec
horizontal I-Sec
VAS I-Sec
according I-Sec
to I-Sec
Jensen I-Sec
, O
has O
been O
analyzed O
at O
each O
follow-up O
moment O
by O
a O
t-test O
. O

secondary O
outcomes O
related O
to O
the O
person O
with O
dementia O
are O
behavioural B-Sec
and I-Sec
psychological I-Sec
symptoms I-Sec
of I-Sec
dementia I-Sec
( I-Sec
Neuropsychiatric I-Sec
Inventory I-Sec
– I-Sec
NPI-Q I-Sec
) I-Sec
80 I-Sec
and O
quality B-Sec
of I-Sec
life I-Sec
( I-Sec
DEMQoL I-Sec
) I-Sec
102 I-Sec
. O

The O
second O
question O
was O
what O
the O
secondary O
end O
point O
would O
be O
. O

The O
guidelines O
contained O
14 O
recommendations O
on O
antibiotics O
, O
asthma O
/ O
COPD O
drugs O
and O
cholesterol O
drugs O
The O
secondary O
outcome O
measures O
were O
prescription B-Sec
data I-Sec
of I-Sec
a I-Sec
three-year I-Sec
period I-Sec
( I-Sec
one I-Sec
year I-Sec
before I-Sec
and I-Sec
2 I-Sec
years I-Sec
after I-Sec
guideline I-Sec
dissemination I-Sec
) I-Sec
and O
proportion B-Sec
of I-Sec
change I-Sec
according I-Sec
to I-Sec
recommendations I-Sec
. O

secondary O
outcome O
measure O
The O
changes O
on O
the O
secondary O
outcome O
measurement O
, O
the B-Sec
CCQ I-Sec
, O
will O
be O
analysed O
with O
the O
repeated O
measurements O
ANOVA O
technique O
. O

The O
secondary O
outcome O
of O
this O
study O
is O
clinical B-Sec
improvement I-Sec
of I-Sec
incontinence I-Sec
as I-Sec
measured I-Sec
with I-Sec
the I-Sec
validated I-Sec
Dutch I-Sec
version I-Sec
of I-Sec
the I-Sec
Urinary I-Sec
Distress I-Sec
Inventory I-Sec
( I-Sec
UDI I-Sec
) I-Sec
. O

secondary O
Outcome O
birth B-Sec
< I-Sec
37 I-Sec
weeks I-Sec
gestation I-Sec
following I-Sec
spontaneous I-Sec
onset I-Sec
of I-Sec
labour I-Sec
or I-Sec
following I-Sec
preterm I-Sec
prelabour I-Sec
rupture I-Sec
of I-Sec
membranes I-Sec
. O

secondary O
variables O
: O
Utilization B-Sec
of I-Sec
health I-Sec
services I-Sec
, O
number B-Sec
and I-Sec
severity I-Sec
of I-Sec
somatic I-Sec
symptoms I-Sec
. O

secondary O
and O
secondary O
measures O
are O
completed O
at O
baseline O
( O
T0 O
) O
before O
the O
iCST O
programme O
, O
first O
follow-up O
at O
13 O
weeks O
after O
baseline O
( O
T1 O
) O
and O
second O
follow-up O
and O
secondary O
endpoint O
at O
26 O
weeks O
after O
baseline O
( O
T2 O
) O
. O

secondary O
inclusion O
criterion O
: O
scoring O
3 O
or O
more O
on O
a O
disability O
case-finding O
tool O
. O

The O
secondary O
iQuit O
trial O
outcome O
is O
whether B-Sec
or I-Sec
not I-Sec
participants I-Sec
have I-Sec
abstained I-Sec
from I-Sec
smoking I-Sec
( I-Sec
self-reported I-Sec
three I-Sec
months I-Sec
prolonged I-Sec
abstinence I-Sec
) I-Sec
and O
the O
secondary O
research O
question O
is O
whether O
or O
not O
tailored O
materials O
are O
more O
effective O
than O
generic O
materials O
in O
helping O
participants O
achieving O
this O
. O

Because O
POD O
is O
associated O
with O
worse O
outcomes O
in O
the O
future O
, O
some O
may O
argue O
that O
hospital O
mortality O
or O
longer-term O
mortality O
assessments O
be O
considered O
as O
the O
secondary O
outcome O
to O
judge O
the O
efficacy O
of O
critical O
care O
interventions O
2 O
. O

The O
clinical O
significance O
of O
0.6 O
in O
the O
secondary O
outcome O
score O
is O
based O
on O
the O
estimation O
of O
discriminant O
validity O
showing O
that O
patients O
with O
diabetes O
, O
who O
could O
be O
compared O
with O
patients O
with O
CHD O
in O
terms O
of O
life-long O
disease O
, O
who O
reported O
poor O
self-rated O
health O
scored O
around O
3 O
in O
several O
subscales O
of O
SWE-DES O
– O
23 O
scale O
; O
corresponding O
figures O
for O
those O
who O
reported O
good O
self-rated O
health O
was O
around O
0.6 O
above O
3 O
31 O
. O

The O
secondary O
outcome O
will O
be O
the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
with I-Sec
a I-Sec
reduction I-Sec
in I-Sec
systolic I-Sec
blood I-Sec
pressure I-Sec
≥ I-Sec
10 I-Sec
mmHg I-Sec
at I-Sec
eight I-Sec
months I-Sec
after I-Sec
the I-Sec
start I-Sec
of I-Sec
the I-Sec
trial I-Sec
. O

Statistical O
analysis O
Sample O
size O
and O
power O
With O
regard O
to O
re-visits B-Sec
to I-Sec
the I-Sec
program I-Sec
( O
first O
secondary O
outcome O
measure O
) O
, O
it O
is O
estimated O
that O
approximately O
50 O
% O
of O
the O
respondents O
of O
the O
no-prompting O
condition O
will O
visit O
the O
site O
more O
often O
than O
four O
times O
( O
after O
the O
baseline O
, O
and O
the O
first O
three O
post O
tests O
after O
six O
, O
twelve O
and O
eighteen O
months O
) O
. O

Sample O
size O
The O
sample O
size O
is O
based O
on O
the O
secondary O
outcome O
parameter O
and O
the O
secondary O
analysis O
. O

secondary O
outcomes O
are O
autonomic B-Sec
and I-Sec
neuroendocrine I-Sec
regulation I-Sec
and O
affective B-Sec
responses I-Sec
. O

Linear O
regression O
models O
, O
adjusting O
for O
baseline O
covariates O
, O
will O
be O
used O
to O
compare O
the O
treatment O
groups O
at O
6 O
weeks O
for O
the O
secondary O
outcome O
, O
and O
any O
other O
continuous O
secondary O
outcomes O
that O
fit O
the O
assumptions O
. O

To O
assess O
the O
secondary O
outcome O
, O
patients O
are O
asked O
to O
perform O
a O
straining O
maneuver O
in O
a O
sitting O
position O
( O
patients O
not O
able O
to O
sit O
will O
be O
assessed O
in O
a O
lateral O
decubitus O
position O
) O
. O

The O
functional O
exercise O
intervention O
begins O
at O
week O
12 O
and O
all O
patients O
will O
complete O
the O
secondary O
and O
Secondary O
outcome O
assessments O
at O
this O
point O
. O

secondary O
outcomes O
related O
to O
the O
caregiver O
are O
caregiver B-Sec
role I-Sec
strain I-Sec
( I-Sec
Zarit I-Sec
caregiver I-Sec
burden I-Sec
interview I-Sec
) I-Sec
, O
psychological B-Sec
distress I-Sec
( I-Sec
SRQ I-Sec
20 I-Sec
) I-Sec
, O
and O
quality B-Sec
of I-Sec
Life I-Sec
( I-Sec
the I-Sec
17 I-Sec
item I-Sec
WHO-QoL I-Sec
Bref I-Sec
) I-Sec
101 I-Sec
. O

The O
secondary O
parameters O
in O
the O
model O
( O
V O
c O
, O
k O
12 O
, O
and O
k O
21 O
) O
were O
estimated O
by O
applying O
a O
non-linear O
least-squares O
regression O
routine O
( O
fminsearch O
) O
by O
using O
Matlab O
R2010a O
software O
( O
The O
MathWorks O
, O
Inc. O
, O
Natick O
, O
MA O
, O
USA O
) O
, O
whereas O
k O
10 O
was O
calculated O
as O
a O
secondary O
parameter O
as O
follows O
: O
k O
10 O
= O
∑ O
urine O
volume O
/ O
AUC O
for O
( O
v O
c O
- O
V O
c O
) O
, O
where O
AUC O
is O
the O
area O
under O
the O
curve O
. O

secondary O
outcome O
The O
secondary O
outcome- O
perinatal B-Sec
mortality- I-Sec
will O
be O
evaluated O
using O
surveillance O
data O
. O

Randomisation O
takes O
place O
after O
the O
whole O
assessment O
has O
been O
completed O
, O
so O
that O
the O
first O
assessment O
is O
not O
dependent O
on O
the O
participant’s O
knowledge O
of O
treatment O
condition O
. O

It O
was O
also O
decided O
to O
change O
the O
secondary O
outcome O
for O
subgroup O
analyses O
to O
look O
at O
the O
effects O
of O
fenofibrate O
in O
subjects O
with O
and O
without O
prior O
cardiovascular O
disease O
( O
CVD O
) O
( O
originally O
those O
with O
and O
without O
prior O
MI O
) O
. O

The O
secondary O
outcome O
is O
Health-Related B-Sec
Quality I-Sec
of I-Sec
Life I-Sec
at I-Sec
12 I-Sec
months I-Sec
, I-Sec
measured I-Sec
using I-Sec
the I-Sec
Assessment I-Sec
of I-Sec
Quality I-Sec
of I-Sec
Life I-Sec
instrument I-Sec
. O

secondary O
endpoint O
was O
the B-Sec
Sum I-Sec
of I-Sec
Pain I-Sec
Intensity I-Sec
Differences I-Sec
( I-Sec
SPID I-Sec
) I-Sec
of I-Sec
the I-Sec
CSTP I-Sec
Intensity I-Sec
scale I-Sec
by I-Sec
the I-Sec
child I-Sec
. O

The O
measurement O
of O
the O
secondary O
variables O
of O
the O
study O
relies O
on O
three O
strategies O
: O
video O
recording O
of O
facial O
actions O
, O
monitoring O
of O
cardio-respiratory O
measures O
and O
oxygen O
saturations O
, O
collection O
of O
salivary O
cortisol O
and O
chart O
review O
( O
Table O
1 O
) O
. O

The O
secondary O
outcome O
from O
our O
double-blind O
RCT O
is O
that O
amoxicillin O
significantly O
increased O
the O
proportion O
of O
children O
achieving O
normal O
middle O
ears O
( O
bilaterally O
aerated O
) O
at O
consecutive O
monthly O
examinations O
. O

The O
precise O
relation O
between O
the O
secondary O
endpoint O
and O
the O
time O
between O
start O
of O
symptoms O
and O
start O
of O
EN O
will O
be O
analyzed O
using O
a O
generalized O
linear O
model O
with O
logarithmic O
link O
function O
and O
Bernouilli O
distribution O
, O
with O
independent O
variables O
time O
( O
between O
start O
of O
symptoms O
and O
start O
of O
EN O
) O
, O
time O
* O
time O
, O
APACHE-II O
score O
prior O
to O
randomization O
, O
hospital O
and O
co-morbidity O
( O
i.e. O

Power O
The O
sample O
size O
is O
based O
on O
power O
analysis O
, O
calculated O
on O
the O
basis O
of O
a O
change O
in O
the O
secondary O
outcome O
during O
the O
period O
from O
the O
baseline O
to O
3 O
months O
post O
intervention O
. O

secondary O
outcomes O
will O
include O
: O
1 B-Sec
) I-Sec
pain I-Sec
severity I-Sec
at I-Sec
two-weeks I-Sec
, I-Sec
measured I-Sec
as I-Sec
the I-Sec
mean I-Sec
of I-Sec
average I-Sec
and I-Sec
worst I-Sec
pain I-Sec
and O
2 B-Sec
) I-Sec
pain-related I-Sec
impairment I-Sec
at I-Sec
2 I-Sec
weeks I-Sec
. O

Sample O
size O
The O
secondary O
outcome O
in O
this O
trial O
is O
the B-Sec
change I-Sec
of I-Sec
the I-Sec
Visual I-Sec
Analogue I-Sec
Score I-Sec
( I-Sec
VAS I-Sec
) I-Sec
of I-Sec
average I-Sec
pain I-Sec
in I-Sec
the I-Sec
menstrual I-Sec
period I-Sec
between I-Sec
the I-Sec
baseline I-Sec
( I-Sec
Visit I-Sec
2 I-Sec
) I-Sec
and I-Sec
after I-Sec
treatment I-Sec
( I-Sec
Visit I-Sec
4 I-Sec
) I-Sec
. O

No O
significant O
difference O
in O
secondary O
endpoint O
was O
found O
after O
1 O
year O
follow O
up O
( O
composite B-Sec
death I-Sec
, I-Sec
reinfarction I-Sec
, I-Sec
stroke I-Sec
, I-Sec
or I-Sec
new I-Sec
myocardial I-Sec
ischemia I-Sec
) O
. O

The O
secondary O
outcome O
is O
dual-task B-Sec
effect I-Sec
on I-Sec
gait I-Sec
speed I-Sec
and O
cognition B-Sec
( I-Sec
reaction I-Sec
time I-Sec
and I-Sec
accuracy I-Sec
) I-Sec
during I-Sec
unobstructed I-Sec
walking I-Sec
at I-Sec
preferred I-Sec
and I-Sec
fastest I-Sec
comfortable I-Sec
walking I-Sec
speeds I-Sec
. O

The O
secondary O
outcome O
measure O
is O
a B-Sec
5 I-Sec
% I-Sec
between-group I-Sec
difference I-Sec
in I-Sec
left I-Sec
ventricular I-Sec
ejection I-Sec
fraction I-Sec
measured I-Sec
by I-Sec
cardiac I-Sec
magnetic I-Sec
resonance I-Sec
imaging I-Sec
at I-Sec
12 I-Sec
months I-Sec
compared I-Sec
to I-Sec
baseline I-Sec
. O

The O
secondary O
outcome O
is O
fatigue B-Sec
severity I-Sec
. O

While O
ideally O
we O
would O
have O
detection O
of O
melanoma O
as O
the O
secondary O
outcome O
, O
this O
would O
require O
a O
much O
larger O
trial O
to O
have O
sufficient O
statistical O
power O
. O

Discussion O
We O
adopted O
the B-Sec
visual I-Sec
analogue I-Sec
scale I-Sec
for I-Sec
bothersomeness I-Sec
( I-Sec
not I-Sec
pain I-Sec
) I-Sec
as O
the O
secondary O
outcome O
measurement O
. O

Outcomes O
secondary O
endpoints O
Two O
co-Secary O
endpoints O
measuring O
number B-Sec
of I-Sec
antibiotic I-Sec
prescriptions I-Sec
and O
disease B-Sec
burden I-Sec
are O
considered O
. O

• O
An O
independent O
adjudication O
committee O
will O
be O
established O
to O
adjudicate O
all O
instances O
of O
a O
secondary O
outcome O
( O
vaginal B-Sec
erosion I-Sec
or I-Sec
other I-Sec
serious I-Sec
adverse I-Sec
outcome I-Sec
) O
. O

Analytical O
plan O
Outcome O
1 O
- O
malaria B-Sec
morbidity I-Sec
The O
secondary O
endpoint O
is O
a B-Sec
comparison I-Sec
of I-Sec
the I-Sec
incidence I-Sec
of I-Sec
clinical I-Sec
episodes I-Sec
of I-Sec
malaria I-Sec
in I-Sec
children I-Sec
in I-Sec
the I-Sec
2 I-Sec
intervention I-Sec
groups I-Sec
, I-Sec
measured I-Sec
by I-Sec
PCD I-Sec
. O

In O
case O
the O
secondary O
endpoint O
is O
fulfilled O
, O
additional O
post-hoc O
analyses O
will O
be O
performed O
. O

Study O
population O
HbA1c B-Sec
was O
used O
as O
the O
secondary O
variable O
for O
calculating O
the O
sample O
size O
. O

Hence O
, O
the O
participant O
may O
have O
been O
included O
by O
one O
member O
of O
the O
team O
; O
have O
been O
counselled O
by O
another O
; O
and O
have O
had O
secondary O
outcome O
assessed O
by O
a O
third O
member O
of O
the O
intervention O
team O
. O

There O
was O
no O
significant O
improvement O
in O
our O
secondary O
outcome O
measure O
( O
the B-Sec
proportion I-Sec
with I-Sec
peak I-Sec
flow I-Sec
compared I-Sec
to I-Sec
best I-Sec
/ I-Sec
predicted I-Sec
) O
at O
either O
the O
6 O
or O
12 O
month O
time O
points O
after O
adjustment O
for O
baseline O
and O
practice O
effects O
. O

We O
did O
not O
correct O
for O
multiple O
testing O
; O
plasma O
cytokine O
data O
represent O
our O
secondary O
endpoints O
with O
additional O
traits O
analyzed O
to O
provide O
complementary O
information O
regarding O
the O
model O
impact O
on O
diverse O
cardio-metabolic O
and O
biological O
pathways O
. O

Outcome O
measurements O
The O
secondary O
endpoint O
shall O
be O
the B-Sec
prevalence I-Sec
of I-Sec
colorectal I-Sec
polyps I-Sec
and O
number B-Sec
of I-Sec
polyps I-Sec
after I-Sec
1-year's I-Sec
intervention I-Sec
. O

On O
the O
basis O
of O
an O
intention-to O
are O
measured O
with O
95 O
% O
confidence O
intervals O
at O
2 O
and O
12 O
weeks O
for O
both O
secondary O
and O
secondary O
outcomes O
. O

After O
the O
intake O
procedure O
, O
which O
will O
include O
the O
first O
assessment O
of O
outcome O
variables O
, O
patients O
will O
be O
stratified O
in O
those O
with O
some O
dexterity O
and O
those O
with O
minimal O
control O
of O
paretic O
wrist O
and O
finger O
extension O
. O

To O
estimate O
the O
variance O
accounted O
for O
therapeutic O
relationship O
on O
the O
secondary O
outcome O
variable O
( O
IES-R B-Sec
) O
multiple O
regression O
analyses O
were O
used O
to O
further O
explore O
possible O
mediator O
or O
suppressor O
effects O
of O
the O
patients' O
ratings O
of O
the O
working O
alliance O
. O

To O
detect O
possible O
dose-response O
relationships O
, O
we O
used O
a O
logistic O
regression O
model O
to O
regress O
the O
secondary O
outcome O
( O
prolonged B-Sec
abstinence I-Sec
) O
at O
t2 O
on O
the O
number O
of O
times O
logged O
in O
to O
the O
StopSite O
; O
only O
the O
respondents O
randomised O
to O
the O
StopSite O
( O
the O
experimental O
group O
) O
were O
included O
in O
the O
dose-response O
analyses O
. O

The O
relative O
effectiveness O
of O
self-management O
and O
patient O
education O
interventions O
for O
diabetes O
is O
varied O
9 O
and O
the O
secondary O
outcomes O
similarly O
broad O
with O
some O
suggestion O
that O
only O
clinically O
relevant O
diabetes O
end-points O
( O
e.g. O

The O
secondary O
outcome O
assessed O
was O
HSV-2 B-Sec
seroconversion I-Sec
during I-Sec
the I-Sec
study I-Sec
period I-Sec
. O

Further O
analysis O
plans O
The O
above O
analysis O
plans O
will O
be O
used O
for O
the O
analysis O
of O
intervention O
effects O
on O
the O
secondary O
outcome O
measures O
. O

Results O
secondary O
outcomes O
Significant O
differences O
in O
muscle O
strength O
were O
noted O
both O
in O
favour O
of O
Group O
I O
( O
PRE O
+ O
nutritional O
supplementation O
) O
and O
Group O
II O
( O
PRE O
+ O
placebo O
) O
, O
as O
compared O
to O
Group O
III O
( O
SE O
+ O
nutritional O
supplementation O
) O
and O
Group O
IV O
( O
SE O
+ O
placebo O
) O
. O

The O
secondary O
outcome O
measure O
( O
change B-Sec
in I-Sec
waist I-Sec
circumference I-Sec
between I-Sec
T1 I-Sec
and I-Sec
T2 I-Sec
) O
will O
be O
compared O
between O
groups O
at O
T2 O
both O
crude O
( O
unadjusted O
) O
and O
adjusted O
for O
baseline O
waist O
circumference O
using O
analysis O
of O
covariance O
. O

Therefore O
, O
a O
second O
broader O
definition O
will O
include O
in O
the O
numerator O
all O
women O
with O
≥ O
500 O
mL O
measured O
blood O
loss O
OR O
women O
receiving O
a O
treatment O
dose O
of O
oxytocin O
( O
regardless O
of O
secondary O
measured O
blood O
loss O
) O
and O
will O
be O
assessed O
among O
all O
enrolled O
women O
. O

The O
secondary O
endpoint O
is O
the B-Sec
rate I-Sec
of I-Sec
bowel I-Sec
obstruction I-Sec
within I-Sec
30 I-Sec
days I-Sec
after I-Sec
ileostomy I-Sec
closure I-Sec
. O

Data O
collection O
The O
secondary O
study O
outcome O
measures O
will O
be O
rates B-Sec
of I-Sec
performance I-Sec
of I-Sec
process I-Sec
of I-Sec
care I-Sec
and O
the B-Sec
patient I-Sec
based I-Sec
measures I-Sec
of I-Sec
functional I-Sec
and I-Sec
psychosocial I-Sec
wellbeing I-Sec
. O

Out O
of O
the O
100 O
patients O
who O
underwent O
the O
surgical O
intervention O
, O
91 O
were O
included O
in O
the O
secondary O
assessment O
at O
24 O
months O
( O
91 O
% O
) O
. O

Outcomes O
The O
secondary O
outcome O
measure O
and O
endpoint O
will O
be O
the B-Sec
WOMAC I-Sec
Pain I-Sec
score I-Sec
measured I-Sec
1 I-Sec
year I-Sec
following I-Sec
knee I-Sec
arthroplasty I-Sec
63 O
64 O
65 O
66 O
67 O
. O

Results O
There O
was O
no O
significant O
effect O
of O
multivitamin O
supplementation O
on O
the O
secondary O
endpoint O
of O
the O
trial O
: O
weight B-Sec
gain I-Sec
after I-Sec
eight I-Sec
weeks I-Sec
. O

During O
the O
first O
baseline O
measurement O
( O
T0 O
) O
, O
boys O
will O
try O
to O
fit O
the O
arm O
support O
under O
supervision O
of O
an O
experienced O
representative O
of O
Focal O
( O
the O
manufacturer O
of O
the O
TOP O
arm O
support O
) O
and O
the O
secondary O
investigator O
. O

No O
secondary O
outcome O
measure O
was O
determined O
, O
since O
the O
study O
has O
an O
exploratory O
character O
. O

The O
secondary O
outcome O
measure O
is O
BMI B-Sec
; O
secondary O
outcomes O
measures O
are O
body B-Sec
fat I-Sec
from I-Sec
bioelectrical I-Sec
impedance I-Sec
, O
muscular B-Sec
fitness I-Sec
, O
objectively B-Sec
measured I-Sec
PA I-Sec
, O
dietary B-Sec
and I-Sec
sedentary I-Sec
behaviors I-Sec
and O
physical B-Sec
self-perception I-Sec
. O

We O
further O
examined O
the O
dose O
effects O
of O
statins O
on O
the O
secondary O
and O
secondary O
outcomes O
by O
stratifying O
patients O
on O
the O
basis O
of O
doses O
equivalent O
to O
< O
40 O
mg O
and O
≥ O
40 O
mg O
of O
simvastatin O
. O

secondary O
outcome O
measures O
As O
in O
previous O
research O
by O
our O
team O
, O
the O
secondary O
outcome O
measure O
for O
the O
study O
is O
the B-Sec
change I-Sec
in I-Sec
SADQ I-Sec
score I-Sec
at I-Sec
6 I-Sec
months I-Sec
post I-Sec
randomisation I-Sec
. O

The O
effects O
of O
baseline O
covariates O
expected O
to O
have O
an O
important O
influence O
on O
the O
secondary O
outcome O
variables O
will O
be O
controlled O
for O
, O
by O
comparing O
covariate-adjusted O
analyses O
with O
unadjusted O
analyses O
. O

Although O
de O
facto O
a O
composite O
score O
of O
secondary O
and O
secondary O
outcomes O
, O
' B-Sec
treatment I-Sec
response I-Sec
' I-Sec
is O
considered O
secondary O
outcome O
as O
well O
. O

The O
secondary O
outcome O
is O
to B-Sec
measure I-Sec
whether I-Sec
the I-Sec
child I-Sec
has I-Sec
become I-Sec
caries I-Sec
active I-Sec
( I-Sec
caries I-Sec
into I-Sec
dentine I-Sec
) I-Sec
. O

The O
secondary O
outcome O
for O
this O
study O
was O
chosen O
to O
be O
mortality B-Sec
in I-Sec
the I-Sec
period I-Sec
from I-Sec
supplementation I-Sec
to I-Sec
6 I-Sec
months I-Sec
of I-Sec
age I-Sec
. O

Economic O
evaluation O
The O
economic O
evaluation O
will O
examine O
whether O
the O
intervention O
is O
associated O
with O
overall O
cost O
increases O
or O
cost O
decreases O
and O
will O
link O
the O
cost O
changes O
to O
incremental O
gains O
in O
effectiveness O
and O
secondary O
outcomes O
. O

GRA1 O
will O
collect O
the O
socio-demographic O
and O
clinical O
characteristics O
, O
followed O
by O
secondary O
outcome O
( O
HRQOL B-Sec
and O
physical B-Sec
function I-Sec
) O
and O
secondary O
outcome O
variables O
( O
physical B-Sec
fitness I-Sec
, O
psychosocial-cognitive B-Sec
functions I-Sec
, O
and O
physical B-Sec
activity I-Sec
) O
. O

Phase O
1 O
Nurses O
The O
first O
patient O
assessment O
will O
be O
discussed O
with O
a O
coach O
directly O
before O
and O
after O
completing O
the O
assessment O
. O

While O
the O
secondary O
outcome O
composite O
score O
will O
provide O
a O
summary O
of O
the O
overall O
effectiveness O
of O
the O
intervention O
program O
, O
we O
will O
also O
examine O
each O
outcome O
component O
for O
a O
more O
detailed O
interpretation O
. O

Outcome O
measurements O
One O
secondary O
and O
four O
secondary O
outcome O
measurements O
were O
used O
. O

Significant O
differences O
were O
observed O
in O
the O
decline O
of O
vital O
capacity O
( O
VC B-Sec
; O
secondary O
endpoint O
) O
between O
placebo O
group O
and O
high-dose O
( O
1800 O
mg O
/ O
day O
) O
group O
; O
and O
in O
the O
secondary O
end O
point O
, O
the B-Sec
progression I-Sec
free I-Sec
survival I-Sec
( I-Sec
PFS I-Sec
) I-Sec
time I-Sec
, O
between O
the O
two O
groups O
. O

secondary O
outcome O
measures O
are O
symptoms B-Sec
of I-Sec
challenging I-Sec
behaviour I-Sec
( I-Sec
measured I-Sec
with I-Sec
the I-Sec
Cohen-Mansfield I-Sec
Agitation I-Sec
Inventory I-Sec
( I-Sec
CMAI I-Sec
) I-Sec
and I-Sec
the I-Sec
Neuropsychiatric I-Sec
Inventory-Nursing I-Sec
Home I-Sec
version I-Sec
( I-Sec
NPI-NH I-Sec
) I-Sec
) I-Sec
, O
and O
pain B-Sec
( I-Sec
measure I-Sec
with I-Sec
the I-Sec
Dutch I-Sec
version I-Sec
of I-Sec
the I-Sec
Pain I-Sec
Assessment I-Sec
Checklist I-Sec
for I-Sec
Seniors I-Sec
( I-Sec
PACSLAC-D I-Sec
) I-Sec
and I-Sec
the I-Sec
Minimum I-Sec
Data I-Sec
Set I-Sec
of I-Sec
the I-Sec
Resident I-Sec
Assessment I-Sec
Instrument I-Sec
( I-Sec
MDS-RAI I-Sec
) I-Sec
pain I-Sec
scale I-Sec
) I-Sec
. O

secondary O
outcome O
The O
secondary O
outcome O
of O
this O
study O
is O
the B-Sec
psychological I-Sec
health I-Sec
of I-Sec
mothers I-Sec
in I-Sec
terms I-Sec
of I-Sec
anxiety I-Sec
and I-Sec
depression I-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
Hospital I-Sec
Anxiety I-Sec
and I-Sec
Depression I-Sec
Scale I-Sec
( I-Sec
HADS I-Sec
) I-Sec
. O

The O
secondary O
outcome O
is O
change B-Sec
in I-Sec
wheal I-Sec
and I-Sec
flare I-Sec
responses I-Sec
. O

Sample O
size O
was O
calculated O
based O
on O
an O
overall O
difference O
between O
participants O
in O
the O
intervention O
and O
control O
groups O
in O
the O
secondary O
outcome O
measure O
of O
depression B-Sec
scores I-Sec
at I-Sec
6 I-Sec
months I-Sec
, O
where O
a O
sample O
size O
of O
n O
= O
100 O
was O
sufficient O
to O
detect O
a O
difference O
in O
mean O
CDS O
scores O
of O
6.8 O
, O
assuming O
a O
between-patient O
SD O
of O
12 O
29 O
. O

There O
were O
two O
secondary O
outcome O
parameters O
in O
this O
study O
: O
change B-Sec
in I-Sec
SBP I-Sec
and O
change B-Sec
in I-Sec
HOMA I-Sec
index I-Sec
, I-Sec
from I-Sec
week I-Sec
0 I-Sec
( I-Sec
pre-treatment I-Sec
) I-Sec
to I-Sec
week I-Sec
6. I-Sec

Balance O
performance O
on O
the O
two O
secondary O
outcome O
measures O
and O
the O
secondary O
outcome O
measures O
will O
be O
made O
using O
repeated O
measures O
ANOVA O
between O
the O
two O
groups O
, O
with O
variables O
differing O
between O
groups O
at O
baseline O
being O
used O
as O
covariates O
. O

Statistical O
analysis O
Because O
the O
distribution O
of O
the O
secondary O
outcome O
was O
skewed O
and O
groups O
were O
small O
, O
continuous O
variables O
were O
compared O
using O
the O
Mann-Whitney O
U O
test O
. O

With O
a O
planned O
number O
of O
138 O
patients O
providing O
post-baseline O
data O
, O
a O
drop O
out O
rate O
for O
the O
secondary O
outcome O
of O
less O
than O
5 O
% O
and O
an O
expected O
screening O
to O
inclusion O
ratio O
of O
5 O
: O
1 O
, O
750 O
patients O
will O
have O
to O
be O
assessed O
for O
eligibility O
in O
all O
8 O
centers O
, O
and O
150 O
will O
be O
allocated O
for O
trial O
participation O
. O

The O
secondary O
endpoint O
will O
be O
analysed O
also O
at O
the O
end O
of O
the O
follow-up O
period O
. O

Outcome O
measures O
Our O
secondary O
study O
endpoint O
will O
be O
the B-Sec
proportion I-Sec
of I-Sec
women I-Sec
reporting I-Sec
a I-Sec
live I-Sec
birth I-Sec
defined I-Sec
as I-Sec
the I-Sec
delivery I-Sec
of I-Sec
one I-Sec
or I-Sec
more I-Sec
living I-Sec
infants I-Sec
, I-Sec
> I-Sec
20 I-Sec
weeks I-Sec
gestation I-Sec
or I-Sec
400 I-Sec
g I-Sec
or I-Sec
more I-Sec
birth I-Sec
weight I-Sec
. O

Setting O
secondary O
Care O
Outcomes O
secondary O
outcome O
the B-Sec
therapeutic I-Sec
adherence I-Sec
considered I-Sec
as I-Sec
the I-Sec
percentage I-Sec
of I-Sec
patients I-Sec
classified I-Sec
as I-Sec
good I-Sec
adherent I-Sec
. O

The O
secondary O
outcome O
measure O
is O
the B-Sec
time I-Sec
between I-Sec
study I-Sec
inclusion I-Sec
and I-Sec
first I-Sec
competitive I-Sec
employment I-Sec
that I-Sec
lasted I-Sec
three I-Sec
months I-Sec
or I-Sec
longer I-Sec
. O

Sample O
size O
Power O
calculations O
are O
based O
on O
the O
secondary O
outcome O
measurement O
PACIC B-Sec
. O

At O
the O
12-month O
follow-up O
, O
all O
groups O
will O
be O
re-examined O
regarding O
the O
secondary O
outcome O
variable O
and O
all O
secondary O
variables O
. O

A O
separate O
paper O
17 O
reports O
the O
design O
, O
methodology O
, O
and O
secondary O
service O
user O
outcomes O
. O

The O
secondary O
endpoint O
is O
the B-Sec
change I-Sec
in I-Sec
prevalence I-Sec
of I-Sec
atypical I-Sec
cells I-Sec
and O
cell B-Sec
proliferation I-Sec
( I-Sec
measured I-Sec
by I-Sec
Ki67 I-Sec
) I-Sec
in I-Sec
DL I-Sec
or I-Sec
fine I-Sec
needle I-Sec
aspirate I-Sec
samples I-Sec
, I-Sec
after I-Sec
12 I-Sec
months I-Sec
of I-Sec
treatment I-Sec
and I-Sec
12 I-Sec
months I-Sec
after I-Sec
treatment I-Sec
cessation I-Sec
. O

Binomial O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
calculated O
for O
the O
difference O
between O
the O
2 O
groups O
in O
achieving O
the O
secondary O
efficacy O
endpoint O
. O

A O
factorial O
or O
multiple-arm O
RCT O
design O
would O
have O
been O
optimal O
from O
the O
methodological O
perspective O
, O
and O
could O
shed O
light O
on O
the O
effectiveness O
of O
the O
individual O
ingredients O
of O
this O
multifaceted O
intervention O
in O
terms O
of O
the O
secondary O
outcomes O
. O

A O
third O
measurement O
is O
performed O
if O
differences O
of O
0.1 O
cm O
and O
0.1 O
kg O
respectively O
are O
observed O
between O
the O
first O
and O
second O
measurements O
. O

To O
decrease O
the O
probability O
of O
finding O
positive O
results O
by O
chance O
as O
a O
result O
of O
multiple O
hypothesis O
testing O
28 O
, O
we O
limited O
our O
secondary O
endpoints O
to O
a O
combination O
of O
one O
patient O
outcome O
and O
one O
organizational O
process O
measure O
. O

Repeated O
measures O
analysis O
of O
variance O
( O
RM-ANOVA O
) O
will O
be O
employed O
to O
compare O
the O
secondary O
outcome O
variables O
( O
nutritional B-Sec
status I-Sec
and O
body B-Sec
composition I-Sec
) O
in O
participants O
with O
and O
without O
food O
supplements O
. O

Usual O
Care O
, O
Talk O
Study O
, O
TALK O
Plus O
) O
will O
be O
the O
secondary O
independent O
variable O
for O
intent-to-treat O
analysis O
23 O
. O

Outcome O
measures O
The O
secondary O
outcome O
measures O
will O
be O
: O
The B-Sec
Simple I-Sec
Shoulder I-Sec
Test I-Sec
( I-Sec
SST I-Sec
) I-Sec
27 I-Sec
measuring I-Sec
shoulder I-Sec
function I-Sec
. O

The O
secondary O
efficacy O
variable O
( O
mean B-Sec
PID I-Sec
3 I-Sec
– I-Sec
5 I-Sec
hours I-Sec
after I-Sec
dose I-Sec
) O
was O
similar O
to O
those O
used O
in O
other O
single-dose O
studies O
of O
COX-2 O
selective O
inhibitors O
in O
acute O
pain O
26 O
or O
in O
patients O
with O
OA O
flare O
27 O
. O

The O
secondary O
endpoint O
of O
the O
trial O
was O
pulmonary B-Sec
or I-Sec
cardiac I-Sec
toxicity I-Sec
, O
and O
the O
secondary O
endpoint O
was O
locoregional B-Sec
recurrence I-Sec
. O

The B-Sec
Northwick I-Sec
Park I-Sec
Neck I-Sec
Pain I-Sec
Questionnaire I-Sec
( I-Sec
NPQ I-Sec
) I-Sec
is O
used O
as O
the O
secondary O
outcome O
measure O
, O
and O
the B-Sec
McGill I-Sec
Pain I-Sec
Questionnaire I-Sec
( I-Sec
MPQ I-Sec
) I-Sec
and O
The B-Sec
Short I-Sec
Form I-Sec
( I-Sec
36 I-Sec
) I-Sec
Health I-Sec
Survey I-Sec
( I-Sec
SF-36 I-Sec
) I-Sec
are O
applied O
as O
secondary O
outcome O
measures O
. O

Study O
Outcomes O
secondary O
Outcome O
[ B-Sec
1 I-Sec
] I-Sec
Proportion I-Sec
of I-Sec
eligible I-Sec
patients I-Sec
enrolled I-Sec
in I-Sec
the I-Sec
CHAT I-Sec
pilot I-Sec
study I-Sec
. O

The O
secondary O
outcome O
measure O
is O
a B-Sec
well-validated I-Sec
outcome I-Sec
measure I-Sec
for I-Sec
upper I-Sec
limb I-Sec
function I-Sec
and O
disability B-Sec
. O

The O
secondary O
desired O
outcomes O
of O
the O
SSS O
components O
were O
: O
empathy O
, O
venting O
and O
problem O
solving O
. O

Since O
all O
previous O
studies O
34 O
35 O
36 O
investigating O
the O
effect O
of O
PCOMS O
have O
used O
the O
Outcome O
Rating O
Scale O
( O
ORS O
) O
as O
secondary O
outcome O
, O
we O
included O
the B-Sec
ORS I-Sec
and O
the B-Sec
Session I-Sec
Rating I-Sec
Scale I-Sec
( I-Sec
SRS I-Sec
) I-Sec
as O
secondary O
outcome O
measures O
30 O
. O

secondary O
outcome O
variables O
Differences O
between O
treatment O
groups O
were O
not O
significant O
for O
any O
of O
the O
four O
secondary O
outcome O
variables O
( O
force B-Sec
platform I-Sec
variables I-Sec
PVF I-Sec
and O
impulse B-Sec
, O
the B-Sec
HCPI I-Sec
and O
rescue B-Sec
NSAIDs I-Sec
) O
. O

Oxidative O
stress O
and O
inflammation O
The O
secondary O
outcome O
measure O
for O
oxidative O
stress O
will O
plasma B-Sec
isoprostanes I-Sec
measured I-Sec
using I-Sec
gas I-Sec
chromatography I-Sec
mass I-Sec
spectrometry I-Sec
39 I-Sec
and O
for O
inflammation O
, O
pentraxin B-Sec
3 I-Sec
using I-Sec
an I-Sec
ELISA I-Sec
assay I-Sec
40 I-Sec
. O

Measure O
and O
data O
collection O
procedures O
The O
secondary O
outcome O
in O
this O
study O
is O
performance B-Sec
of I-Sec
functional I-Sec
tasks I-Sec
( I-Sec
mobility I-Sec
and I-Sec
self-care I-Sec
) I-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
Pediatric I-Sec
Evaluation I-Sec
of I-Sec
Disability I-Sec
Inventory I-Sec
( I-Sec
PEDI I-Sec
) I-Sec
65 I-Sec
. O

The O
duration O
of O
the O
medical O
treatment O
is O
not O
restricted O
, O
but O
counted O
as O
treatment O
failure O
if O
medication O
is O
needed O
in O
the O
last O
three O
weeks O
before O
measurement O
of O
the O
secondary O
endpoint O
in O
week O
26. O

The O
secondary O
outcome O
measure O
was O
claim B-Sec
duration I-Sec
( I-Sec
in I-Sec
days I-Sec
) I-Sec
during I-Sec
12 I-Sec
months I-Sec
follow-up I-Sec
. O

The O
magnitude O
of O
any O
observed O
rates O
of O
secondary O
outcome O
differences O
by O
treatment O
status O
and O
what O
to O
consider O
a O
" O
substantial O
" O
difference O
will O
be O
revisited O
at O
each O
interim O
looks O
. O

Recruitment O
and O
retention O
The O
study O
successfully O
recruited O
526 O
individuals O
in O
from O
4 O
sites O
in O
just O
over O
29 O
months O
, O
with O
the O
secondary O
outcome O
recorded O
for O
372 O
individuals O
. O

secondary O
inclusion O
criterion O
is O
the O
GP's O
suspicion O
of O
LRTI O
being O
the O
secondary O
cause O
of O
the O
acute O
cough O
episode O
. O

Multiple O
imputation O
was O
used O
to O
construct O
secondary O
ITT O
assessments O
of O
relative O
effectiveness O
that O
allowed O
inclusion O
of O
all O
randomized O
subjects O
with O
comparable O
results O
. O

a O
) O
Ease O
of O
Care O
The O
secondary O
outcome O
to O
assess O
ease O
of O
care O
and O
comfort O
will O
be O
the B-Sec
Canadian I-Sec
Occupational I-Sec
Performance I-Sec
Measure I-Sec
( I-Sec
COPM I-Sec
) I-Sec
44 I-Sec
. O

The O
secondary O
outcome O
measure O
for O
the O
cost-effectiveness O
analysis O
is O
depression B-Sec
measured I-Sec
by I-Sec
the I-Sec
BDI-II I-Sec
, O
and O
for O
the O
cost-utility O
analysis O
the B-Sec
QALY I-Sec
based I-Sec
on I-Sec
the I-Sec
EQ-5D I-Sec
. O

Intervention O
and O
control O
group O
will O
be O
compared O
on O
the O
secondary O
outcomes O
( O
place B-Sec
of I-Sec
death I-Sec
, O
number B-Sec
of I-Sec
transitions I-Sec
and O
out B-Sec
of I-Sec
hours I-Sec
contact I-Sec
, O
amount B-Sec
of I-Sec
identified I-Sec
patients I-Sec
) O
. O

Some O
patients O
may O
have O
remained O
in O
the O
trial O
because O
of O
other O
benefits O
apart O
from O
the O
secondary O
outcome O
, O
such O
as O
sleeping O
better O
. O

The O
secondary O
and O
secondary O
outcomes O
in O
LBW O
babies O
, O
the O
outcomes O
in O
all O
infants O
and O
their O
mothers O
, O
and O
the O
process O
outcomes O
( O
to O
be O
measured O
only O
in O
the O
intervention O
clusters O
) O
are O
shown O
in O
Table O
1 O
. O

To O
examine O
secondary O
outcomes O
, O
the O
differences O
between O
study O
groups O
will O
be O
assessed O
using O
Student's O
t-tests O
( O
as O
described O
above O
for O
secondary O
outcome O
) O
. O

This O
is O
directly O
analogous O
to O
the O
secondary O
endpoint O
of O
our O
study O
, O
the B-Sec
VTE I-Sec
threshold I-Sec
. O

For O
male O
patients O
, O
the O
first O
criterion O
had O
a O
K O
value O
of O
0.472 O
, O
a O
moderate O
level O
of O
agreement O
. O

For O
analysis O
of O
the O
secondary O
variable O
, O
the O
study O
populations O
were O
analysed O
separately O
. O

The O
secondary O
outcomes O
were O
changes B-Sec
in I-Sec
pain I-Sec
as I-Sec
measured I-Sec
on I-Sec
a I-Sec
verbal I-Sec
rating I-Sec
scale I-Sec
from I-Sec
0 I-Sec
to I-Sec
10 I-Sec
during I-Sec
a I-Sec
flexion-extension I-Sec
range I-Sec
of I-Sec
motion I-Sec
evaluation I-Sec
and O
changes B-Sec
in I-Sec
disc I-Sec
height I-Sec
as I-Sec
measured I-Sec
on I-Sec
CT I-Sec
scans I-Sec
. O

secondary O
outcomes O
are O
headache B-Sec
days I-Sec
and O
medication B-Sec
days I-Sec
per I-Sec
month I-Sec
comparing I-Sec
the I-Sec
two I-Sec
arms I-Sec
and I-Sec
change I-Sec
compared I-Sec
to I-Sec
baseline I-Sec
. O

Efficacy O
end-point O
criteria O
The O
secondary O
end-point O
criteria O
used O
to O
determine O
the O
efficacy O
of O
treatment O
were O
absence B-Sec
of I-Sec
parasites I-Sec
and O
clinical B-Sec
signs I-Sec
on I-Sec
days I-Sec
14 I-Sec
and I-Sec
28 I-Sec
, O
and O
good B-Sec
clinical I-Sec
and I-Sec
biological I-Sec
tolerability I-Sec
. O

secondary O
outcome O
: O
Table O
2 O
presents O
the O
results O
of O
the O
logistic O
regressions O
. O

These O
issues O
include O
the O
choice O
of O
intermediate O
and O
secondary O
outcome O
measures O
, O
sample O
size O
calculations O
and O
the O
impact O
of O
varying O
the O
assumptions O
, O
the O
process O
for O
moving O
between O
trial O
stages O
, O
stopping O
accrual O
to O
each O
trial O
arm O
and O
overall O
, O
and O
issues O
around O
perceived O
trial O
complexity O
. O

The O
secondary O
outcome O
measure O
will O
be O
the B-Sec
proportion I-Sec
of I-Sec
inappropriate I-Sec
antibiotic I-Sec
prescription I-Sec
in I-Sec
each I-Sec
group I-Sec
. O

secondary O
Study O
Endpoints O
Serious B-Sec
adverse I-Sec
outcomes I-Sec
for I-Sec
the I-Sec
infant I-Sec
defined I-Sec
as I-Sec
: I-Sec
Perinatal I-Sec
/ I-Sec
Neonatal I-Sec
Mortality I-Sec
( I-Sec
defined I-Sec
as I-Sec
any I-Sec
fetal I-Sec
death I-Sec
after I-Sec
study I-Sec
entry I-Sec
or I-Sec
death I-Sec
of I-Sec
a I-Sec
liveborn I-Sec
infant I-Sec
within I-Sec
28 I-Sec
days I-Sec
of I-Sec
age I-Sec
( I-Sec
excluding I-Sec
lethal I-Sec
congenital I-Sec
anomalies I-Sec
) I-Sec
; O
or O
Serious B-Sec
neonatal I-Sec
morbidity I-Sec
( I-Sec
defined I-Sec
as I-Sec
one I-Sec
or I-Sec
more I-Sec
of I-Sec
the I-Sec
following I-Sec
, I-Sec
excluding I-Sec
lethal I-Sec
congenital I-Sec
anomalies I-Sec
: I-Sec
birth I-Sec
trauma I-Sec
( I-Sec
subdural I-Sec
or I-Sec
intracerebral I-Sec
haemorrhage I-Sec
, I-Sec
spinal I-Sec
cord I-Sec
injury I-Sec
, I-Sec
basal I-Sec
skull I-Sec
fracture I-Sec
, I-Sec
other I-Sec
fracture I-Sec
, I-Sec
peripheral I-Sec
nerve I-Sec
injury I-Sec
present I-Sec
at I-Sec
discharge I-Sec
from I-Sec
hospital I-Sec
) I-Sec
; O
seizures B-Sec
at I-Sec
< I-Sec
24 I-Sec
hours I-Sec
age I-Sec
or I-Sec
requiring I-Sec
two I-Sec
or I-Sec
more I-Sec
drugs I-Sec
to I-Sec
control I-Sec
; O
Apgar B-Sec
score I-Sec
< I-Sec
4 I-Sec
at I-Sec
5 I-Sec
minutes I-Sec
; O
cord B-Sec
pH I-Sec
< I-Sec
7.18 I-Sec
; O
base B-Sec
deficit I-Sec
< I-Sec
-8 I-Sec
( I-Sec
arterial I-Sec
or I-Sec
venous I-Sec
cord I-Sec
blood I-Sec
) I-Sec
; O
neonatal B-Sec
encephalopathy I-Sec
stage I-Sec
3 I-Sec
( I-Sec
Sarnat I-Sec
& I-Sec
Sarnat I-Sec
1976 I-Sec
) I-Sec
; O
admission B-Sec
to I-Sec
the I-Sec
neonatal I-Sec
intensive I-Sec
care I-Sec
unit I-Sec
( I-Sec
NICU I-Sec
) I-Sec
> I-Sec
4 I-Sec
days I-Sec
; O
severe B-Sec
neonatal I-Sec
lung I-Sec
disease I-Sec
( I-Sec
defined I-Sec
as I-Sec
MAP I-Sec
> I-Sec
10 I-Sec
and I-Sec
or I-Sec
FiO I-Sec
2 I-Sec
> I-Sec
0.80 I-Sec
with I-Sec
need I-Sec
for I-Sec
ventilation I-Sec
) I-Sec
; O
proven B-Sec
necrotising I-Sec
enterocolitis I-Sec
; O
proven B-Sec
systemic I-Sec
infection I-Sec
in I-Sec
first I-Sec
48 I-Sec
hours I-Sec
of I-Sec
life I-Sec
treated I-Sec
with I-Sec
antibiotics I-Sec
) I-Sec
. O

secondary O
outcome O
measure O
was O
HbA1c B-Sec
. O

For O
each O
performance O
indicator O
potential O
effects O
on O
our O
secondary O
outcomes O
will O
be O
measured O
. O

The O
secondary O
outcome O
measures O
will O
be O
assessed O
by O
the O
same O
researcher O
( O
AN O
) O
for O
all O
participants O
at O
each O
location O
. O

Statistics O
The O
secondary O
outcome O
was O
the B-Sec
hands-on I-Sec
time I-Sec
during I-Sec
the I-Sec
first I-Sec
three I-Sec
minutes I-Sec
of I-Sec
the I-Sec
cardiac I-Sec
arrest I-Sec
. O

It O
was O
assumed O
≥ B-Sec
Grade I-Sec
2 I-Sec
( I-Sec
G2 I-Sec
) I-Sec
toxicity I-Sec
incidence I-Sec
as O
secondary O
end O
point O
. O

Assessment O
of O
muscle O
mass O
Muscle O
mass O
was O
evaluated O
with O
US O
, O
by O
measuring O
the O
Cross O
Sectional O
Diameter O
( O
CSD O
) O
of O
the O
quadriceps O
muscle O
( O
rectus O
femoris O
- O
vastus O
intermedius O
) O
26 O
27 O
28 O
on O
the O
day O
of O
randomization O
( O
second O
day O
of O
admission O
) O
and O
seven O
or O
eight O
days O
after O
the O
first O
assessment O
29 O
. O

The O
secondary O
outcome O
measure O
is O
the' O
Medication B-Sec
Appropriateness I-Sec
Index' I-Sec
. O

In O
Part O
B O
, O
the O
data O
set O
used O
for O
analysis O
of O
the O
secondary O
efficacy O
end O
point O
included O
all O
Part O
B O
randomized O
patients O
who O
participated O
in O
the O
WOMAC O
study O
( O
n O
= O
145 O
) O
. O

secondary O
outcome O
measures O
included O
coma B-Sec
recovery I-Sec
time I-Sec
; O
time B-Sec
to I-Sec
sit I-Sec
unsupported I-Sec
, O
begin B-Sec
oral I-Sec
intake I-Sec
; O
duration B-Sec
of I-Sec
hospitalization I-Sec
; O
death B-Sec
and O
adverse B-Sec
effects I-Sec
. O

The O
secondary O
outcomes O
are O
disability B-Sec
( I-Sec
patients I-Sec
) I-Sec
and O
strain B-Sec
( I-Sec
carers I-Sec
) I-Sec
. O

They O
showed O
that O
an O
electronic O
key O
feature O
assessment O
is O
feasible O
and O
can O
produce O
reliable O
assessment O
results O
. O

One O
year O
secondary O
outcome O
will O
be O
mobility B-Sec
limitation I-Sec
assessed I-Sec
by I-Sec
interviewing I-Sec
the I-Sec
subjects I-Sec
for I-Sec
the I-Sec
ability I-Sec
to I-Sec
getting I-Sec
in I-Sec
and I-Sec
out I-Sec
of I-Sec
bed I-Sec
, I-Sec
rising I-Sec
from I-Sec
a I-Sec
chair I-Sec
, I-Sec
walking I-Sec
across I-Sec
a I-Sec
room I-Sec
, I-Sec
walking I-Sec
one I-Sec
block I-Sec
, I-Sec
and I-Sec
climbing I-Sec
stairs I-Sec
10 I-Sec
. O

The O
secondary O
outcome O
measure O
, O
change B-Sec
in I-Sec
insulin I-Sec
sensitivity I-Sec
, O
is O
measured O
at O
3 O
, O
6 O
and O
12 O
months O
. O

Additionally O
, O
although O
this O
study O
examined O
potential O
baseline O
patient O
/ O
disease O
characteristics O
and O
key O
treatment O
outcomes O
that O
may O
influence O
treatment O
satisfaction O
, O
data O
on O
other O
important O
ongoing O
treatment O
factors O
such O
as O
burden O
and O
compliance O
were O
not O
collected O
. O

Although O
there O
is O
a O
concern O
that O
generic O
measures O
may O
be O
less O
responsive O
than O
disease O
specific O
measures O
, O
the O
physical O
functioning O
and O
bodily O
pain O
scales O
of O
the O
SF-36 O
( O
which O
contribute O
most O
of O
the O
variation O
in O
the B-Sec
PCS I-Sec
summary I-Sec
measure I-Sec
used O
as O
the O
secondary O
outcome O
in O
this O
trial O
) O
compare O
reasonably O
well O
with O
disease O
specific O
measures O
in O
patients O
with O
musculoskeletal O
problems O
40 O
41 O
42 O
43 O
. O

Outcomes O
HbA1c O
The O
secondary O
outcome O
of O
the O
DIAPERIO O
trial O
will O
be O
the B-Sec
difference I-Sec
in I-Sec
change I-Sec
of I-Sec
HbA1c I-Sec
from I-Sec
V1 I-Sec
to I-Sec
V4 I-Sec
between I-Sec
the I-Sec
two I-Sec
groups I-Sec
. O

A B-Sec
comparison I-Sec
of I-Sec
intra- I-Sec
and I-Sec
post-dialytic I-Sec
complications I-Sec
among I-Sec
study I-Sec
groups I-Sec
constitutes O
the O
secondary O
endpoint O
. O

Statistical O
issues O
Sample O
size O
The O
sample O
size O
is O
calculated O
based O
on O
the O
secondary O
outcome' B-Sec
bad I-Sec
neonatal I-Sec
outcome' I-Sec
. O

Calculating O
effect O
size O
for O
the O
secondary O
outcome O
using O
Cohen's O
method O
and O
a O
standardised O
mean O
difference O
( O
SMD O
) O
to O
draw O
comparisons O
with O
the O
2010 O
Cochrane O
review O
8 O
, O
the O
effect O
size O
of O
0.71 O
is O
larger O
than O
the O
moderate O
, O
non-significant O
SMD O
reported O
previously O
; O
exercise O
of O
preferred O
intensity O
appears O
to O
promote O
greater O
benefits O
. O

Our O
secondary O
outcome O
is O
refractive B-Sec
predictability I-Sec
, I-Sec
which I-Sec
is I-Sec
one I-Sec
of I-Sec
several I-Sec
standard I-Sec
refractive I-Sec
outcomes I-Sec
, I-Sec
defined I-Sec
as I-Sec
the I-Sec
proportion I-Sec
of I-Sec
eyes I-Sec
achieving I-Sec
a I-Sec
postoperative I-Sec
spherical I-Sec
equivalent I-Sec
( I-Sec
SE I-Sec
) I-Sec
within I-Sec
± I-Sec
0.50 I-Sec
D I-Sec
of I-Sec
the I-Sec
intended I-Sec
target I-Sec
. O

Of O
particular O
interest O
is O
the O
effect O
on O
the O
secondary O
outcome O
, O
knowledge B-Sec
, O
thereby O
allowing O
an O
assessment O
of O
knowledge O
retention O
. O

Statistical O
analysis O
The O
secondary O
outcome O
is O
the B-Sec
proportion I-Sec
of I-Sec
persons I-Sec
with I-Sec
at I-Sec
least I-Sec
one I-Sec
fall I-Sec
and O
will O
be O
analysed O
by O
using O
a O
chi-square O
test O
adjusted O
for O
cluster O
randomisation O
17 O
. O

Results O
of O
this O
trial O
showed O
that O
the O
intervention O
had O
favourable O
effects O
on O
all O
secondary O
outcomes O
: O
fear B-Sec
of I-Sec
falling I-Sec
, O
avoidance B-Sec
of I-Sec
activity I-Sec
, O
and O
daily B-Sec
activity I-Sec
. O

ITT O
analysis O
( O
n O
= O
85 O
intervention O
, O
n O
= O
70 O
control O
) O
showed O
improvement O
of O
physical O
performance O
( O
intervention O
+8 O
% O
; O
control O
−7 O
% O
) O
and O
no O
differences O
on O
other O
secondary O
and O
secondary O
outcome O
measures O
. O

The O
first O
variable O
is O
branching O
pathways O
through O
the O
VP O
, O
present O
or O
absent O
. O

Adverse O
events O
Sample O
size O
determination O
The O
secondary O
endpoint O
for O
this O
study O
was O
the B-Sec
mean I-Sec
number I-Sec
of I-Sec
detected I-Sec
polyps I-Sec
. O

In O
study O
B O
, O
the O
secondary O
efficacy O
endpoints O
were O
the B-Sec
slope I-Sec
of I-Sec
decline I-Sec
in I-Sec
FEV I-Sec
1 I-Sec
from I-Sec
2 I-Sec
hours I-Sec
post-dose I-Sec
, O
the B-Sec
area I-Sec
under I-Sec
the I-Sec
FEV I-Sec
1 I-Sec
curve I-Sec
( I-Sec
AUC I-Sec
) I-Sec
( I-Sec
0 I-Sec
– I-Sec
24 I-Sec
hours I-Sec
) I-Sec
and O
the B-Sec
mean I-Sec
change I-Sec
from I-Sec
pre-dose I-Sec
FEV I-Sec
1 I-Sec
at I-Sec
12 I-Sec
hours I-Sec
post I-Sec
dose I-Sec
. O

The O
secondary O
effectiveness O
analyses O
will O
be O
conducted O
on O
an O
intention O
to O
treat O
basis O
, O
with O
secondary O
( O
explanatory O
) O
analyses O
conducted O
first O
comparing O
outcomes O
in O
all O
control O
schools O
to O
outcomes O
only O
in O
those O
schools O
that O
completed O
at O
least O
70 O
% O
of O
the O
lessons O
, O
and O
secondly O
employing O
instrumental O
variables O
regression O
models O
to O
address O
the O
question O
of O
causal O
effect O
if O
the O
intervention O
were O
applied O
as O
intended O
37 O
. O

The O
secondary O
outcome O
was O
HbA1c B-Sec
, O
lipid B-Sec
levels I-Sec
, O
blood B-Sec
pressure I-Sec
, O
BMI B-Sec
after I-Sec
24 I-Sec
months I-Sec
of I-Sec
follow-up I-Sec
. O

Methods O
/ O
Design O
Objectives O
of O
the O
study O
The O
aim O
of O
this O
study O
is O
a O
first O
assessment O
of O
the O
safety O
of O
A-Part O
® O
Gel O
applied O
as O
an O
adhesion O
prophylaxis O
after O
major O
abdominal O
surgery O
, O
by O
specific O
observation O
of O
two O
major O
complications O
of O
abdominal O
surgery O
; O
wound O
healing O
impairment O
or O
peritonitis O
; O
in O
comparison O
to O
a O
non O
treated O
control O
group O
( O
secondary O
objective O
) O
within O
28 O
( O
+10 O
) O
days O
after O
surgery O
( O
for O
definition O
see O
table O
1 O
) O
. O

Intra-cluster O
( O
practice O
) O
correlation O
coefficients O
will O
be O
determined O
and O
published O
for O
all O
secondary O
outcome O
variables O
to O
assist O
future O
research O
. O

The O
sample O
size O
has O
been O
estimated O
to O
be O
sufficiently O
large O
to O
achieve O
significant O
results O
with O
concerns O
to O
the O
secondary O
outcome O
of O
the O
study O
. O

However O
, O
the O
results O
of O
the O
NSABP-C08 O
study O
published O
in O
2011 O
was O
negative O
for O
its O
secondary O
endpoint O
. O

The O
secondary O
endpoint O
was O
the B-Sec
percentage I-Sec
of I-Sec
patients I-Sec
who I-Sec
reached I-Sec
25 I-Sec
( I-Sec
OH I-Sec
) I-Sec
D I-Sec
levels I-Sec
of I-Sec
30 I-Sec
ng I-Sec
/ I-Sec
ml I-Sec
or I-Sec
above I-Sec
on I-Sec
day I-Sec
7. I-Sec

123 O
, O
which O
is O
based O
on O
this O
model O
, O
the O
secondary O
target O
( O
and O
therefore O
a O
key O
outcome O
) O
of O
our O
intervention O
is O
optimal B-Sec
( I-Sec
physical I-Sec
) I-Sec
functioning I-Sec
. O

The O
secondary O
endpoint O
bowel B-Sec
obstruction I-Sec
is O
relevant O
from O
the O
patient O
perspective O
as O
well O
as O
from O
a O
health O
care O
perspective O
. O

Because O
of O
the O
large O
number O
of O
parameters O
that O
are O
measured O
, O
it O
is O
important O
to O
distinguish O
the O
secondary O
outcome O
measure O
from O
the O
aetiological O
factors O
that O
are O
studied O
. O

The B-Sec
frequency I-Sec
, O
duration B-Sec
and O
severity B-Sec
of I-Sec
exacerbations I-Sec
were O
combined O
as O
secondary O
outcome O
measures O
for O
testing O
as O
multiple O
criteria O
. O

Preliminary O
information O
on O
the O
first O
measure O
designed O
to O
specifically O
capture O
the O
impact O
of O
antipsychotic-emergent O
weight O
gain O
on O
patients' O
psychosocial O
functioning O
was O
only O
recently O
published O
52 O
. O

The O
secondary O
outcome O
measure O
will O
be O
the B-Sec
difference I-Sec
in I-Sec
NSCL I-Sec
/ I-Sec
P I-Sec
recurrence I-Sec
rates I-Sec
between I-Sec
the I-Sec
two I-Sec
groups I-Sec
and O
the B-Sec
associated I-Sec
confidence I-Sec
interval I-Sec
. O

Based O
on O
earlier O
studies O
7 O
10 O
11 O
14 O
and O
recommendations O
of O
an O
expert O
review O
15 O
, O
the B-Sec
15th I-Sec
percentile I-Sec
point I-Sec
was O
chosen O
as O
the O
parameter O
for O
the O
secondary O
endpoint O
and O
expressed O
as O
the O
15th O
percentile O
lung O
density O
( O
PD15 O
) O
. O

Clinical O
outcomes O
measures O
The O
secondary O
outcome O
is O
the B-Sec
number I-Sec
of I-Sec
participants I-Sec
with I-Sec
at I-Sec
least I-Sec
one I-Sec
fall I-Sec
at I-Sec
12 I-Sec
months I-Sec
. O

Sample O
size O
calculation O
A O
sample O
size O
calculation O
has O
been O
performed O
, O
based O
on O
the O
secondary O
outcome O
measure O
, O
i.e. O

Attempts O
to O
estimate O
sample O
size O
for O
a O
definitive O
trial O
were O
unproductive O
because O
of O
uncertainty O
in O
the O
distribution O
of O
the O
key O
variables O
. O

NHS O
Stop O
Smoking O
Study O
Helpline O
NHS O
Stop O
Smoking O
Study O
Helpline O
will O
provide O
call O
centre O
services O
: O
the O
consent O
call O
for O
participant O
enrollment O
, O
and O
the O
secondary O
call O
to O
determine O
the O
secondary O
outcome O
( O
self B-Sec
reported I-Sec
smoking I-Sec
at I-Sec
34 I-Sec
to I-Sec
38 I-Sec
weeks I-Sec
gestation I-Sec
) O
. O

Systolic O
/ O
diastolic O
blood O
pressure O
was O
measured O
in O
a O
standard O
way O
( O
Omron O
705IT O
) O
: O
the O
first O
measurement O
was O
made O
after O
5 O
min O
rest O
in O
sitting O
position O
and O
the O
mean O
of O
the O
three O
measurements O
per O
visit O
was O
used O
. O

The O
pre-specified O
secondary O
outcome O
measure O
of O
the O
trial O
was O
the B-Sec
proportion I-Sec
of I-Sec
pregnant I-Sec
women I-Sec
who I-Sec
attended I-Sec
ANC I-Sec
with I-Sec
their I-Sec
partners I-Sec
at I-Sec
the I-Sec
subsequent I-Sec
antenatal I-Sec
visit I-Sec
. O

But O
this O
study O
misses O
a O
clearly O
defined O
secondary O
endpoint O
and O
a O
detailed O
sample O
size O
calculation O
and O
has O
the O
disadvantage O
of O
using O
sham-acupuncture O
instead O
of O
a O
real O
placebo O
acupuncture O
technique O
in O
the O
control O
group O
. O

The O
secondary O
outcome O
measure O
for O
the O
participants O
with O
stroke O
is O
depressed B-Sec
mood I-Sec
, I-Sec
which I-Sec
will I-Sec
be I-Sec
assessed I-Sec
by I-Sec
the I-Sec
GDS-15 I-Sec
. O

Statistical O
Analysis O
secondary O
outcome O
Mortality B-Sec
at I-Sec
28 I-Sec
days I-Sec
post-randomisation I-Sec
will O
be O
compared O
between O
the O
groups O
by O
the O
risk O
ratio O
and O
95 O
% O
confidence O
interval O
. O

A O
p O
value O
< O
0.05 O
( O
2-sided O
) O
was O
considered O
significant O
for O
the O
secondary O
outcome O
; O
p O
< O
0.01 O
was O
considered O
significant O
for O
secondary O
outcomes O
to O
account O
for O
multiple O
analyses O
in O
a O
small O
sample O
. O

In O
fact O
, O
all O
3 O
groups O
showed O
secondary O
and O
secondary O
outcomes O
scores O
similar O
to O
those O
obtained O
following O
the O
non-randomised O
, O
symptomatic O
phase O
. O

secondary O
outcome O
measure O
was O
the B-Sec
proportion I-Sec
of I-Sec
eligible I-Sec
( I-Sec
aged I-Sec
≤ I-Sec
80 I-Sec
and I-Sec
symptom I-Sec
onset I-Sec
≤ I-Sec
6 I-Sec
hours I-Sec
) I-Sec
stroke I-Sec
patients I-Sec
referred I-Sec
to I-Sec
a I-Sec
stroke I-Sec
unit I-Sec
( I-Sec
SU I-Sec
) I-Sec
. O

secondary O
Outcome O
Measures O
The B-Sec
Conners' I-Sec
ADHD I-Sec
Index I-Sec
is O
used O
to O
distinguish O
ADHD O
children O
from O
non-clinical O
children O
, O
and O
is O
considered O
a O
good O
screening O
tool O
55 O
59 O
. O

Secondary O
endpoints O
• O
Progression-free B-Sec
survival I-Sec
will O
be O
analyzed O
analogously O
to O
the O
secondary O
endpoints O
. O

In O
the O
first O
measurement O
, O
subjects O
will O
lay O
prone O
on O
a O
padded O
table O
. O

secondary O
outcome O
measures O
The O
secondary O
outcomes O
will O
be O
change B-Sec
in I-Sec
pain I-Sec
and O
change B-Sec
in I-Sec
self-reported I-Sec
physical I-Sec
function I-Sec
at I-Sec
13 I-Sec
weeks I-Sec
( O
Table O
3 O
) O
. O

The O
secondary O
efficacy O
outcome O
was O
all-cause B-Sec
mortality I-Sec
over I-Sec
3 I-Sec
years I-Sec
, O
regardless O
of O
whether O
patients O
withdrew O
from O
the O
study O
early O
. O

In O
order O
to O
maintain O
blindness O
the O
secondary O
research O
assessment O
will O
be O
carried O
out O
by O
a O
different O
person O
. O

The O
secondary O
efficacy O
end O
point O
for O
the O
study O
was O
progression-free B-Sec
survival I-Sec
( I-Sec
PFS I-Sec
) I-Sec
per I-Sec
central I-Sec
radiology I-Sec
review I-Sec
, I-Sec
according I-Sec
to I-Sec
RECIST I-Sec
15 I-Sec
. O

Table O
1 O
Dependents O
variables O
to O
evaluate O
the O
secondary O
and O
secondary O
outcomes O
. O

Other O
secondary O
outcome O
measures O
are O
perceived B-Sec
recovery I-Sec
and O
intensity B-Sec
of I-Sec
leg I-Sec
pain I-Sec
and O
low B-Sec
back I-Sec
pain I-Sec
. O

Sample O
size O
Cognition B-Sec
( I-Sec
ADAS-Cog I-Sec
) I-Sec
will O
be O
the O
secondary O
outcome O
measure O
. O

A O
key O
secondary O
outcome O
of O
the O
pilot O
RCT O
is O
to B-Sec
evaluate I-Sec
clinician I-Sec
acceptance I-Sec
of I-Sec
the I-Sec
weaning I-Sec
and I-Sec
sedation I-Sec
protocols I-Sec
. O

The O
secondary O
endpoint O
is O
time B-Sec
to I-Sec
failure I-Sec
of I-Sec
strategy I-Sec
( I-Sec
TFS I-Sec
) I-Sec
. O

The B-Sec
FEV I-Sec
1 I-Sec
and O
exacerbations B-Sec
will O
be O
used O
as O
the O
secondary O
outcome O
measures O
. O

Alas O
, O
our O
study O
failed O
to O
prove O
the O
secondary O
outcome O
hypothesis O
of O
better O
clinical O
cure O
in O
the O
Infusion O
group O
( O
83 O
% O
vs. O
75 O
% O
; O
P O
= O
0.180 O
) O
. O

The O
secondary O
outcome O
was O
the B-Sec
change I-Sec
in I-Sec
serum I-Sec
methylmalonic I-Sec
acid I-Sec
( I-Sec
MMA I-Sec
) I-Sec
levels I-Sec
after I-Sec
one I-Sec
month I-Sec
of I-Sec
treatment I-Sec
. O

Vaginal O
temperature O
was O
not O
affected O
by O
bST O
treatment O
, O
day O
relative O
to O
TAI O
, O
or O
interactions O
between O
these O
secondary O
effects O
and O
other O
variables O
. O

The O
perspective O
adopted O
will O
be O
that O
of O
the O
NHS O
, O
that O
is O
, O
the O
economic O
evaluation O
will O
only O
consider O
costs O
to O
the O
NHS O
and O
health O
benefits O
to O
patients O
Endpoints O
of O
the O
study O
secondary O
outcomes O
: O
Change B-Sec
in I-Sec
HbA1c I-Sec
between I-Sec
baseline I-Sec
and I-Sec
12 I-Sec
months I-Sec
and I-Sec
24 I-Sec
months I-Sec
post I-Sec
recruitment I-Sec
. O

There O
were O
no O
differences O
between O
the O
groups O
in O
the O
secondary O
outcome O
at O
baseline O
( O
Table O
5 O
; O
17.7 O
% O
in O
the O
Intervention O
Group O
versus O
22.7 O
% O
in O
the O
Control O
Group O
) O
. O

Outcome O
measures O
Our O
secondary O
outcome O
measure O
was O
percentage B-Sec
aggregation I-Sec
on I-Sec
day I-Sec
5 I-Sec
( I-Sec
2 I-Sec
hours I-Sec
after I-Sec
drug I-Sec
administration I-Sec
, I-Sec
) I-Sec
expressed I-Sec
as I-Sec
percentage I-Sec
of I-Sec
baseline I-Sec
, I-Sec
using I-Sec
1.1 I-Sec
μg I-Sec
/ I-Sec
ml I-Sec
collagen I-Sec
as I-Sec
an I-Sec
agonist I-Sec
. O

To O
avoid O
any O
possibility O
that O
the O
interviews O
could O
, O
themselves O
, O
affect O
the O
participants' O
responses O
to O
the O
secondary O
outcome O
measures O
, O
data O
from O
these O
participants O
will O
not O
be O
included O
in O
the O
secondary O
analysis O
. O

Sample O
size O
calculation O
regarding O
the O
secondary O
outcome O
measure O
OMAS B-Sec
showed O
that O
a O
sample O
size O
of O
51 O
individuals O
per O
group O
was O
needed O
to O
detect O
a O
difference O
of O
10 O
points O
between O
groups O
with O
an O
alfa O
level O
of O
0.05 O
and O
80 O
% O
power O
. O

The O
secondary O
outcomes O
are O
educational B-Sec
achievement I-Sec
and O
anaemia B-Sec
. O

Trial O
participation O
payments O
In O
order O
to O
minimize O
loss O
to O
follow-up O
, O
particularly O
among O
control O
participants O
, O
£ O
25 O
will O
be O
given O
to O
all O
participants O
if O
they O
provide O
secondary O
outcome O
information O
( O
and O
required O
samples O
to O
corroborate O
abstinence O
) O
at O
34 O
and O
38 O
weeks O
gestation O
. O

Typical O
symptoms O
for O
the O
secondary O
outcome O
, O
bowel B-Sec
obstruction I-Sec
, O
like O
productive O
vomiting O
, O
gastric O
tube O
placement O
, O
severe O
constipation O
are O
detected O
during O
regular O
patient O
care O
and O
documented O
in O
the O
medical O
record O
. O

The O
secondary O
outcome O
measures O
were O
glycated B-Sec
hemoglobin I-Sec
A1c I-Sec
, O
body B-Sec
mass I-Sec
index I-Sec
( I-Sec
BMI I-Sec
) I-Sec
, O
blood B-Sec
pressure I-Sec
, O
lipids B-Sec
and O
control B-Sec
criteria I-Sec
during I-Sec
the I-Sec
2-year I-Sec
follow-up I-Sec
period I-Sec
. O

A O
descriptive O
analysis O
of O
the O
secondary O
outcome O
variable O
is O
performed O
applying O
a O
Cox-regression O
model O
including O
the O
covariates O
RPA O
class O
, O
age O
, O
Karnofsky O
index O
and O
extent O
of O
previous O
surgery O
. O

Statistical O
analysis O
Analysis O
of O
the O
secondary O
and O
secondary O
outcomes O
will O
be O
based O
on O
the O
intention-to-treat O
principle O
. O

Participants O
that O
show O
an O
improvement O
exceeding O
minimal O
clinically O
important O
difference O
for O
the O
secondary O
outcomes O
( O
6 O
NDI O
% O
or O
15 O
NRS O
% O
) O
, O
at O
follow-up O
1 O
( O
one O
week O
after O
intervention O
) O
, O
will O
be O
classified O
as O
“ O
improved O
” O
. O

The O
consequent O
secondary O
outcomes O
are O
musculoskeletal B-Sec
disorders I-Sec
, O
work B-Sec
ability I-Sec
, O
physical B-Sec
capacity I-Sec
, O
body B-Sec
mass I-Sec
index I-Sec
( I-Sec
BMI I-Sec
) I-Sec
, O
kinesiophobia B-Sec
, O
rate B-Sec
of I-Sec
physical I-Sec
exertion I-Sec
during I-Sec
work I-Sec
and O
sickness B-Sec
absence I-Sec
. O

Clinical O
and O
parasitological O
efficacy O
: O
secondary O
endpoint O
The B-Sec
PCR-corrected I-Sec
ACPR I-Sec
rate I-Sec
at I-Sec
follow-up I-Sec
on I-Sec
day I-Sec
28 I-Sec
after I-Sec
the I-Sec
first I-Sec
malaria I-Sec
episode I-Sec
for O
the O
ASAQ O
group O
was O
98.4 O
% O
versus O
96.2 O
% O
for O
the O
AL O
group O
in O
the O
intent-to O
( O
Table O
2 O
) O
. O

Microbial O
identification O
Microorganisms O
cultured O
from O
the O
skin O
of O
patients O
with O
a O
positive O
secondary O
end O
point O
were O
identified O
by O
using O
VITEK-2 O
( O
BioMérieux O
, O
Boxtel O
, O
the O
Netherlands O
) O
and O
classic O
biochemical O
determination O
. O

secondary O
parameters O
such O
as O
AUC O
, O
AUC O
120 O
or O
Cmax O
showed O
very O
small O
punctual O
differences O
( O
5 O
% O
or O
less O
) O
, O
but O
standard O
deviations O
, O
although O
similar O
between O
treatment O
groups O
, O
were O
large O
( O
coefficients O
of O
variation O
around O
50 O
% O
) O
. O

secondary O
outcome O
measure O
Roland B-Sec
Disability I-Sec
Questionnaire I-Sec
for I-Sec
Sciatica I-Sec
( I-Sec
RDQ I-Sec
) I-Sec
. O

Only O
if O
the O
adjudication O
committee O
agrees O
on O
both O
counts O
, O
will O
the O
adverse O
outcome O
be O
considered O
a O
secondary O
outcome O
. O

Sample O
size O
For O
the O
power O
calculation O
, O
recurrent B-Sec
sickness I-Sec
absence I-Sec
days I-Sec
are O
considered O
the O
secondary O
outcome O
measure O
. O

The O
secondary O
study O
end O
point O
was O
a B-Sec
difference I-Sec
of I-Sec
≥ I-Sec
20 I-Sec
% I-Sec
in I-Sec
the I-Sec
microvascular I-Sec
flow I-Sec
index I-Sec
of I-Sec
small I-Sec
vessels I-Sec
among I-Sec
groups I-Sec
. O

secondary O
and O
secondary O
measures O
will O
be O
administered O
at O
all O
time O
points O
. O

Outcome O
measures O
The O
secondary O
outcome O
measure O
was O
change B-Sec
in I-Sec
weight I-Sec
from I-Sec
randomization I-Sec
( I-Sec
0-M I-Sec
) I-Sec
to I-Sec
12 I-Sec
months I-Sec
post I-Sec
randomization I-Sec
. O

secondary O
outcome O
measures O
were O
' B-Sec
first-step' I-Sec
pain I-Sec
( I-Sec
measured I-Sec
on I-Sec
a I-Sec
100 I-Sec
mm I-Sec
Visual I-Sec
Analogue I-Sec
Scale I-Sec
) I-Sec
and O
the B-Sec
Foot I-Sec
Health I-Sec
Status I-Sec
Questionnaire I-Sec
domains I-Sec
of I-Sec
foot I-Sec
pain I-Sec
, I-Sec
foot I-Sec
function I-Sec
and I-Sec
general I-Sec
foot I-Sec
health I-Sec
. O

Study O
endpoints O
The O
secondary O
endpoint O
of O
the O
study O
was O
28-day B-Sec
mortality I-Sec
from I-Sec
all I-Sec
causes I-Sec
. O

Measures O
secondary O
outcome O
measure O
: O
Moderate B-Sec
- I-Sec
Vigorous I-Sec
MET I-Sec
minutes I-Sec
of I-Sec
Physical I-Sec
Activity I-Sec
The O
secondary O
outcome O
measure O
was O
the B-Sec
total I-Sec
MET I-Sec
minutes I-Sec
of I-Sec
moderate I-Sec
and I-Sec
vigorous I-Sec
physical I-Sec
activity I-Sec
accrued I-Sec
over I-Sec
the I-Sec
past I-Sec
7 I-Sec
days I-Sec
. O

Sample O
size O
Power O
calculation O
was O
performed O
on O
the O
secondary O
outcome O
( O
all B-Sec
kind I-Sec
of I-Sec
surgeries I-Sec
together I-Sec
) O
. O

The O
secondary O
outcome O
variable O
( O
number B-Sec
of I-Sec
falls I-Sec
) O
will O
be O
analysed O
using O
a O
linear O
mixed O
model O
, O
with O
the O
intervention O
specified O
as O
a O
fixed O
effect O
and O
care O
homes O
included O
as O
a O
random O
effect O
. O

Because O
this O
approach O
is O
novel O
, O
we O
will O
validate O
the O
secondary O
outcome O
( O
preterm B-Sec
birth I-Sec
) O
by O
reviewing O
the O
medical O
records O
of O
all O
women O
identified O
in O
the O
computerised O
databases O
as O
delivering O
preterm O
, O
those O
where O
gestational O
age O
is O
missing O
( O
usually O
< O
1 O
% O
) O
and O
a O
random O
sample O
of O
those O
recorded O
as O
term O
deliveries O
. O

secondary O
outcome O
measures O
are O
BPD B-Sec
, I-Sec
described I-Sec
as I-Sec
oxygen I-Sec
dependency I-Sec
by I-Sec
day I-Sec
28 I-Sec
according I-Sec
to I-Sec
the I-Sec
definition I-Sec
of I-Sec
Jobe I-Sec
and I-Sec
Bancalari I-Sec
, O
and O
/ O
or O
mortality B-Sec
by I-Sec
day I-Sec
28. I-Sec

secondary O
outcome O
will O
be O
time B-Sec
to I-Sec
progression I-Sec
. O

The O
secondary O
outcome O
measures O
will O
be O
taken O
at O
Session O
5. O

Endpoint O
responsiveness O
The O
comparison O
between O
prednisone O
15 O
mg O
daily O
and O
placebo O
at O
Day O
15 O
in O
Panel O
A O
yielded O
a O
statistically O
significant O
treatment O
effect O
( O
effect O
size O
= O
1.17 O
, O
P O
= O
0.013 O
) O
in O
change O
from O
baseline O
in O
the O
secondary O
endpoint O
, O
10 B-Sec
MCP I-Sec
Trans I-Sec
PDA I-Sec
, O
but O
not O
for O
Panel O
B O
( O
prednisone O
7.5 O
mg O
daily O
versus O
placebo O
) O
( O
effect O
size O
= O
0.61 O
, O
P O
= O
0.071 O
) O
. O

Three O
secondary O
outcome O
parameters O
for O
the O
assessment O
of O
efficacy O
are O
specified O
in O
the O
study O
protocol O
: O
change B-Sec
in I-Sec
waist I-Sec
circumference I-Sec
, O
change B-Sec
in I-Sec
subscapular I-Sec
skinfold I-Sec
thickness I-Sec
and O
change B-Sec
in I-Sec
6-min I-Sec
run I-Sec
performance I-Sec
, O
changes O
are O
calculated O
as O
differences O
between O
follow-up O
measurement O
and O
baseline O
measurement O
. O

Diagnosis B-Sec
of I-Sec
depression I-Sec
and O
Hamilton B-Sec
Depression I-Sec
Scale I-Sec
are O
the O
secondary O
outcome O
measures O
. O

Written O
and O
face O
to O
face O
feedback O
focused O
on O
key O
trial O
outcomes O
but O
also O
provided O
information O
on O
inappropriate O
antibiotic O
use O
for O
non-bloody O
diarrhoea O
amongst O
many O
other O
indicators O
of O
quality O
of O
care O
. O

secondary O
Outcome O
Measure O
Aberrant B-Sec
Behaviour I-Sec
Checklist-Community I-Sec
( I-Sec
ABC-C I-Sec
) I-Sec
Our O
secondary O
outcome O
measure O
was O
the B-Sec
ABC I-Sec
Irritability I-Sec
subtest I-Sec
score I-Sec
because O
previous O
experience O
with O
patients O
in O
this O
population O
suggested O
that O
it O
would O
be O
the O
most O
sensitive O
to O
the O
benefits O
of O
minocycline O
. O

Sample O
Size O
and O
Power O
The O
secondary O
outcome O
measure O
in O
this O
study O
is O
the B-Sec
DASH I-Sec
score I-Sec
. O

While O
the O
secondary O
outcome O
of O
the O
present O
study O
is O
physical B-Sec
activity I-Sec
, O
dog-based O
interventions O
might O
in O
fact O
have O
a O
greater O
impact O
on O
other O
outcomes O
of O
considerable O
public O
health O
importance O
, O
such O
as O
total O
time O
spent O
sedentary O
, O
or O
the O
patterning O
of O
sedentary O
behaviour O
34 O
47 O
48 O
49 O
50 O
. O

If O
they O
failed O
to O
return O
the O
secondary O
outcome O
measure O
, O
the B-Sec
BDI-II I-Sec
, O
they O
were O
telephoned O
by O
the O
practice O
research O
nurse O
to O
prompt O
them O
to O
return O
the O
questionnaire O
. O

The O
secondary O
efficacy O
variable O
is O
the B-Sec
percentage I-Sec
of I-Sec
patients I-Sec
with I-Sec
no I-Sec
vomiting I-Sec
over I-Sec
0 I-Sec
to I-Sec
72 I-Sec
h I-Sec
postoperatively I-Sec
across I-Sec
the I-Sec
two I-Sec
treatment I-Sec
groups I-Sec
. O

If O
the O
secondary O
outcome O
is O
normally O
distributed O
it O
will O
be O
compared O
using O
a O
t O
-test O
, O
ANCOVA O
adjusting O
for O
the O
minimization O
factors O
( O
secondary O
analysis O
) O
and O
ANCOVA O
with O
further O
adjustment O
for O
prognostic O
factors O
. O

In O
addition O
, O
conditional O
power O
/ O
stochastic O
curtailment O
method O
124 O
may O
be O
used O
if O
requested O
by O
the O
DSMB O
due O
to O
small O
observed O
differences O
in O
secondary O
outcome O
rates O
between O
treatments O
. O

Study O
Endpoints O
The O
secondary O
outcome O
was O
a B-Sec
composite I-Sec
endpoint I-Sec
of I-Sec
all-cause I-Sec
mortality I-Sec
or I-Sec
all-cause I-Sec
hospitalization I-Sec
. O

The O
secondary O
outcome O
is O
the B-Sec
timed-up-and-go I-Sec
test I-Sec
( I-Sec
TUGT I-Sec
) I-Sec
, I-Sec
measured I-Sec
at I-Sec
baseline I-Sec
and I-Sec
14 I-Sec
weeks I-Sec
post-randomisation I-Sec
. O

secondary O
outcomes O
are O
time B-Sec
to I-Sec
first I-Sec
and I-Sec
second I-Sec
falls I-Sec
. O

The O
secondary O
outcome O
variables O
in O
this O
part O
of O
the O
study O
are O
: O
rate B-Sec
of I-Sec
complications I-Sec
, O
adverse B-Sec
events I-Sec
, O
near B-Sec
misses I-Sec
and O
information B-Sec
transfer I-Sec
between I-Sec
care I-Sec
providers I-Sec
. O

The O
secondary O
outcome O
parameter O
will O
be O
the B-Sec
expansion I-Sec
of I-Sec
the I-Sec
visual I-Sec
field I-Sec
after I-Sec
3 I-Sec
and I-Sec
6 I-Sec
months I-Sec
of I-Sec
treatment I-Sec
as I-Sec
determined I-Sec
by I-Sec
static I-Sec
visual I-Sec
field I-Sec
perimetry I-Sec
and I-Sec
high I-Sec
resolution I-Sec
perimetry I-Sec
. O

Power O
and O
sample O
size O
We O
have O
powered O
our O
study O
to O
detect O
an O
0.5 O
SD O
effect O
size O
for O
the O
secondary O
outcome O
. O

To O
ensure O
the O
highest O
possible O
follow-up O
the O
intention O
was O
to O
contact O
patients O
after O
18 O
months O
to O
be O
reminded O
of O
the O
2 O
year O
assessment O
, O
and O
if O
for O
any O
reason O
( O
eg O
being O
out O
of O
the O
country O
) O
, O
the O
secondary O
assessment O
might O
be O
made O
earlier O
. O

The O
secondary O
outcome O
for O
this O
study O
is O
relapse B-Sec
of I-Sec
psychotic I-Sec
symptoms I-Sec
. O

Outcomes O
The O
secondary O
outcome O
measure O
was O
objective B-Sec
functional I-Sec
capacity I-Sec
, I-Sec
assessed I-Sec
using I-Sec
a I-Sec
25 I-Sec
m I-Sec
walk I-Sec
test I-Sec
, I-Sec
a I-Sec
repeated I-Sec
chair I-Sec
rise I-Sec
test I-Sec
, I-Sec
and I-Sec
a I-Sec
stair I-Sec
climb I-Sec
test I-Sec
. O

The O
secondary O
outcomes O
were O
the B-Sec
mean I-Sec
change I-Sec
in I-Sec
1 I-Sec
) I-Sec
the I-Sec
child's I-Sec
asthma I-Sec
control I-Sec
score I-Sec
, O
2 B-Sec
) I-Sec
the I-Sec
parent's I-Sec
quality I-Sec
of I-Sec
life I-Sec
score I-Sec
, O
and O
3 B-Sec
) I-Sec
the I-Sec
number I-Sec
of I-Sec
urgent I-Sec
care I-Sec
events I-Sec
assessed I-Sec
at I-Sec
12 I-Sec
and I-Sec
24 I-Sec
months I-Sec
. O

It O
should O
be O
noted O
that O
some O
patients O
( O
for O
both O
secondary O
and O
secondary O
outcome O
measures O
) O
will O
become O
" O
at O
risk O
" O
between O
the O
time O
of O
the O
baseline O
data O
collection O
and O
the O
follow O
up O
data O
collections O
. O

The O
failure O
to O
find O
a O
significant O
difference O
on O
the O
secondary O
efficacy O
measure O
at O
week O
8 O
could O
in O
part O
be O
explained O
by O
the O
small O
sample O
size O
as O
well O
as O
the O
heterogeneous O
study O
group O
. O

A O
table O
providing O
full O
definitions O
of O
acute O
respiratory O
infection O
for O
this O
study O
Click O
here O
for O
file O
Major O
secondary O
outcomes O
: O
▪ O
Rate B-Sec
of I-Sec
hospitalizations I-Sec
for I-Sec
ARI I-Sec
: O
same O
case O
definition O
as O
secondary O
outcome O
measure O
. O

The O
secondary O
outcome O
measures O
were O
adherence B-Sec
and O
participation B-Sec
. O

Quantitative O
data O
collection O
secondary O
outcome O
Smoking B-Sec
status I-Sec
at I-Sec
34 I-Sec
to I-Sec
38 I-Sec
weeks I-Sec
gestation I-Sec
, I-Sec
towards I-Sec
the I-Sec
end I-Sec
of I-Sec
pregnancy I-Sec
. O

Our O
secondary O
outcome O
is O
based O
on O
self-report O
, O
which O
likely O
will O
falsely O
increase O
quit O
rates O
( O
as O
compared O
to O
biochemical O
verification O
) O
. O

The B-Sec
functional I-Sec
outcome I-Sec
of I-Sec
the I-Sec
patient I-Sec
, I-Sec
as I-Sec
assessed I-Sec
by I-Sec
the I-Sec
Roland I-Sec
Disability I-Sec
Questionnaire I-Sec
for I-Sec
Sciatica I-Sec
at I-Sec
8 I-Sec
weeks I-Sec
and I-Sec
1 I-Sec
year I-Sec
after I-Sec
treatment I-Sec
, O
is O
the O
secondary O
outcome O
measure O
. O

In O
an O
additional O
multiple O
logistic O
regression O
model O
, O
the O
effect O
of O
treatment O
on O
the O
secondary O
endpoint O
will O
be O
assessed O
in O
relation O
to O
important O
risk O
factors O
for O
pain O
( O
younger O
age O
, O
severe O
pain O
in O
the O
postoperative O
period O
and O
severe O
preoperative O
pain O
27 O
) O
. O

Sample O
size O
, O
power O
calculation O
, O
and O
statistical O
analysis O
The O
secondary O
endpoint O
of O
the O
study O
was O
the B-Sec
determination I-Sec
of I-Sec
the I-Sec
perioperative I-Sec
concentration I-Sec
of I-Sec
IL-1β I-Sec
in I-Sec
the I-Sec
patient's I-Sec
peritoneal I-Sec
fluid I-Sec
. O

Deciding O
on O
a O
secondary O
outcome O
in O
OA O
research O
is O
challenging O
as O
it O
is O
common O
for O
OA O
patients O
to O
rate O
different O
domains O
of O
the O
disease O
experience O
, O
e.g. O

Women O
will O
receive O
incentive O
payments O
outlined O
below O
: O
£ O
50 O
for O
attending O
a O
face-to-face O
appointment O
with O
their O
NSPS O
adviser O
and O
setting O
a O
quit O
date O
; O
£ O
50 O
if O
quit O
4 O
weeks O
after O
their O
quit O
date O
corroborated O
by O
a O
carbon O
monoxide O
breath O
test O
result O
less O
than O
10 O
ppm O
collected O
by O
a O
research O
nurse O
; O
£ O
100 O
if O
quit O
after O
12 O
weeks O
corroborated O
by O
a O
carbon O
monoxide O
breath O
test O
collected O
by O
a O
research O
nurse O
; O
£ O
200 O
if O
they O
self O
report O
quit O
for O
at O
least O
2 O
months O
when O
contacted O
for O
secondary O
outcome O
assessment O
by O
the O
Helpline O
at O
34 O
to O
38 O
weeks O
gestation O
. O

Results O
The O
secondary O
outcome O
measurement O
was O
the B-Sec
precision I-Sec
of I-Sec
the I-Sec
secondary I-Sec
result I-Sec
set I-Sec
selected I-Sec
to I-Sec
answer I-Sec
the I-Sec
clinical I-Sec
question I-Sec
. O

Although O
patients O
, O
investigators O
, O
and O
therapists O
administering O
treatment O
will O
not O
be O
blinded O
, O
those O
assessing O
the O
patients O
for O
secondary O
and O
secondary O
endpoints O
will O
be O
blinded O
to O
patient O
treatment O
assignment O
. O

Power O
calculations O
In O
this O
study O
, O
the B-Sec
PHQ-9 I-Sec
will O
be O
used O
as O
the O
secondary O
outcome O
measure O
. O

no O
interim O
analyses O
are O
planned O
for O
the O
secondary O
parameters O
. O

Thus O
, O
the O
proposed O
sample O
is O
sufficiently O
powered O
to O
detect O
clinically O
meaningful O
changes O
in O
this O
secondary O
outcome O
of O
interest O
. O

The O
secondary O
outcome O
is O
the B-Sec
incidence I-Sec
of I-Sec
PTS I-Sec
during I-Sec
follow-up I-Sec
. O

These O
variable O
results O
suggest O
that O
methacholine O
reactivity O
post O
allergen O
challenge O
is O
not O
a O
robust O
secondary O
endpoint O
to O
evaluate O
drug O
effects O
. O

The O
secondary O
endpoint O
is O
cure B-Sec
at I-Sec
day I-Sec
28 I-Sec
with O
secondary O
endpoint O
at B-Sec
day I-Sec
210 I-Sec
( I-Sec
6 I-Sec
months I-Sec
) I-Sec
. O

secondary O
outcome O
measures O
after O
six O
weeks O
of O
treatment O
were O
Treatment B-Sec
Alliance I-Sec
Scale I-Sec
( I-Sec
TAS I-Sec
) I-Sec
40 I-Sec
and O
Client B-Sec
Satisfaction I-Sec
Questionnaire I-Sec
( I-Sec
CSQ I-Sec
) I-Sec
44 I-Sec
. O

Crossover O
is O
not O
allowed O
until O
after O
the O
outcome O
measures O
have O
been O
collected O
at O
the O
study O
secondary O
endpoint O
of O
6 O
weeks O
; O
therefore O
, O
the O
secondary O
results O
will O
reflect O
the O
treatment O
to O
which O
the O
participant O
was O
randomized O
. O

A O
secondary O
parameter O
investigated O
was O
the O
prevalence O
of O
Plasmodium O
falciparum O
in O
the O
target O
population O
, O
a O
factor O
that O
will O
determine O
the O
quantity O
of O
anti-malarial O
treatments O
used O
. O

The O
secondary O
outcome O
measure O
is O
the B-Sec
change I-Sec
in I-Sec
the I-Sec
subscale I-Sec
bodily I-Sec
pain I-Sec
of I-Sec
the I-Sec
SF36 I-Sec
from I-Sec
M1 I-Sec
to I-Sec
M2 I-Sec
. O

The O
baseline O
questionnaire O
was O
then O
re-administered O
at O
the O
end O
of O
the O
study O
to O
all O
subjects O
( O
control O
and O
intervention O
) O
with O
change B-Sec
in I-Sec
score I-Sec
as O
the O
secondary O
outcome O
, O
and O
difference B-Sec
in I-Sec
changes I-Sec
in I-Sec
score I-Sec
as O
the O
secondary O
outcome O
. O

Our O
aim O
is O
to O
assess O
whether O
UCR O
and O
/ O
or O
UTR O
are O
superior O
to O
conventional O
hemodialysis O
with O
respect O
to O
frequency B-Sec
of I-Sec
intra- I-Sec
and I-Sec
post-dialytic I-Sec
complications I-Sec
( O
secondary O
outcome O
) O
, O
and O
improvement O
of O
various O
secondary O
outcome O
parameters O
, O
possibly O
related O
to O
improved O
hemodialysis O
stability O
and O
volume O
status O
. O

This O
absence O
of O
a O
beneficial O
effect O
of O
selenium O
treatment O
could O
theoretically O
be O
related O
to O
the O
small O
size O
of O
the O
study O
allowing O
conclusions O
only O
on O
the O
secondary O
endpoint O
. O

length O
of O
hospital O
stay O
) O
and O
total O
hospital O
costs O
per O
patient O
, O
alongside O
the O
secondary O
clinical O
endpoint O
. O

secondary O
outcome O
measure O
is O
adherence B-Sec
to I-Sec
oral I-Sec
antidiabetics I-Sec
calculated I-Sec
from I-Sec
: I-Sec
1 I-Sec
) I-Sec
data I-Sec
collected I-Sec
with I-Sec
RTMM I-Sec
, I-Sec
as I-Sec
a I-Sec
percentage I-Sec
of I-Sec
medication I-Sec
taken I-Sec
as I-Sec
prescribed I-Sec
, I-Sec
and I-Sec
as I-Sec
percentage I-Sec
of I-Sec
medication I-Sec
taken I-Sec
within I-Sec
the I-Sec
correct I-Sec
time I-Sec
interval I-Sec
, O
2 B-Sec
) I-Sec
refill I-Sec
data I-Sec
, I-Sec
taking I-Sec
the I-Sec
number I-Sec
of I-Sec
days I-Sec
for I-Sec
which I-Sec
oral I-Sec
antidiabetics I-Sec
are I-Sec
dispensed I-Sec
during I-Sec
the I-Sec
study I-Sec
period I-Sec
divided I-Sec
by I-Sec
the I-Sec
total I-Sec
number I-Sec
of I-Sec
days I-Sec
of I-Sec
the I-Sec
study I-Sec
period I-Sec
. O

Measures O
secondary O
outcome O
measures O
The O
secondary O
outcome O
in O
the O
study O
is O
sick B-Sec
leave I-Sec
. O

Data O
analysis O
The O
secondary O
outcome O
will O
be O
compared O
between O
each O
of O
the O
study O
arms O
using O
methods O
appropriate O
for O
cluster O
randomized O
trials O
. O

Phase O
II O
secondary O
endpoint O
The O
secondary O
endpoint O
variable O
OS_12 B-Sec
m I-Sec
was O
planned O
to O
be O
analysed O
by O
a O
one O
sided O
logrank O
test O
of O
stratified O
by O
histology O
testing O
H O
0 O
: O
OS O
A O
-12 O
m O
= O
OS O
B O
-12 O
m O
versus O
H O
1 O
: O
OS O
A O
-12 O
m O
> O
OS O
B O
-12 O
m O
at O
the O
level O
of O
alpha O
= O
5 O
% O
. O

secondary O
outcome O
measure O
Alzheimer B-Sec
Disease I-Sec
Assessment I-Sec
Scale-Cognitive I-Sec
( I-Sec
ADAS-COG I-Sec
) I-Sec
13 I-Sec
is O
a O
frequently O
used O
measure O
of O
global O
cognitive O
functioning O
and O
assesses O
cognitive O
domains O
including O
orientation O
, O
memory O
, O
language O
, O
and O
praxis O
; O
common O
areas O
of O
impairment O
present O
in O
AD O
. O

The O
secondary O
outcome O
variable O
is O
the B-Sec
exclusive I-Sec
o I-Sec
predominant I-Sec
breastfeeding I-Sec
at I-Sec
6 I-Sec
moths I-Sec
of I-Sec
age I-Sec
. O
. O
secondary O
effectiveness O
will O
be O
analyzed O
by O
comparing O
the O
percentage O
of O
infants O
with O
exclusive O
or O
predominant O
breastfeeding O
at O
6 O
months O
between O
the O
intervention O
group O
and O
the O
control O
group O
. O

Outcome O
measures O
secondary O
outcome O
secondary O
outcome O
will O
be O
presented O
by O
the B-Sec
mean I-Sec
percentage I-Sec
change I-Sec
of I-Sec
inflammatory I-Sec
lesion I-Sec
counts I-Sec
from I-Sec
baseline I-Sec
to I-Sec
the I-Sec
end I-Sec
of I-Sec
the I-Sec
trial I-Sec
29 O
33 O
. O

The O
secondary O
outcome O
was O
the B-Sec
number I-Sec
of I-Sec
hospital I-Sec
days I-Sec
after I-Sec
surgery I-Sec
with O
cost-effectiveness B-Sec
as O
a O
secondary O
outcome O
. O

The O
secondary O
outcome O
is O
presence B-Sec
/ I-Sec
absence I-Sec
of I-Sec
incontinence I-Sec
at I-Sec
six I-Sec
weeks I-Sec
post-stroke I-Sec
. O

First O
of O
all O
, O
blinding O
is O
not O
feasible O
in O
such O
studies O
and O
therefore O
a O
bias O
in O
the O
assessment O
of O
secondary O
and O
further O
outcomes O
cannot O
be O
ruled O
out O
( O
especially O
with O
subjective O
outcomes O
) O
. O

secondary O
and O
secondary O
outcomes O
will O
be O
evaluated O
within O
and O
between O
groups O
by O
comparing O
data O
from O
baseline O
, O
after O
completion O
of O
the O
visits O
, O
and O
again O
after O
a O
6-month O
follow-up O
. O

The O
secondary O
study O
outcomes O
are O
muscle B-Sec
endurance I-Sec
and O
functional B-Sec
abilities I-Sec
, I-Sec
assessed I-Sec
with I-Sec
a I-Sec
Six-Minute I-Sec
Bicycle I-Sec
Test I-Sec
and I-Sec
the I-Sec
Motor I-Sec
Function I-Sec
Measure I-Sec
. O

The O
secondary O
efficacy O
variables O
were O
analyzed O
using O
the O
Wilcoxon O
signed O
rank O
test O
to O
compute O
the O
within-group O
differences O
and O
the O
Wilcoxon O
rank O
sum O
test O
for O
between-group O
differences O
. O

The O
proportion O
of O
individuals O
in O
the O
two O
groups O
requiring O
more O
than O
six O
emergency O
interventions O
, O
first O
criterion O
for O
heavy O
use O
of O
MHS O
, O
did O
not O
differ O
at O
T24 O
( O
n O
= O
5 O
/ O
16 O
in O
the O
STM O
group O
and O
n O
= O
3 O
/ O
18 O
in O
the O
SB-APP O
group O
; O
chi O
-square O
= O
.443 O
; O
p O
< O
.311 O
) O
. O

Program O
evaluation O
and O
satisfaction O
questions O
will O
also O
be O
asked O
of O
each O
participant O
near O
the O
end O
of O
this O
secondary O
assessment O
. O

The O
aim O
will O
be O
to O
recruit O
78 O
patients O
in O
each O
group O
as O
this O
will O
provide O
sufficient O
participants O
to O
obtain O
a O
power O
of O
90 O
% O
for O
both O
secondary O
outcome O
measures O
. O

Secondary O
outcome O
variables O
The B-Sec
change I-Sec
from I-Sec
baseline I-Sec
to I-Sec
secondary I-Sec
assessment I-Sec
of I-Sec
the I-Sec
study I-Sec
knee I-Sec
in I-Sec
self-reported I-Sec
knee I-Sec
pain I-Sec
and O
difficulty B-Sec
with I-Sec
physical I-Sec
function I-Sec
will O
be O
measured O
using O
the O
WOMAC O
Index O
32 O
. O

Outcomes O
The O
secondary O
outcome O
is O
whether B-Sec
or I-Sec
not I-Sec
headache I-Sec
is I-Sec
present I-Sec
at I-Sec
24 I-Sec
hours I-Sec
after I-Sec
the I-Sec
start I-Sec
of I-Sec
treatment I-Sec
. O

The O
secondary O
outcome O
is O
mortality B-Sec
at I-Sec
28 I-Sec
days I-Sec
after I-Sec
randomisation I-Sec
; O
secondary O
outcomes O
are O
mortality B-Sec
in I-Sec
ICU I-Sec
, O
mortality B-Sec
in I-Sec
hospital I-Sec
, O
number B-Sec
of I-Sec
ventilator-free I-Sec
days I-Sec
, O
number B-Sec
of I-Sec
non-pulmonary I-Sec
organ I-Sec
failure-free I-Sec
days I-Sec
, O
mortality B-Sec
at I-Sec
twelve I-Sec
months I-Sec
post-randomisation I-Sec
, O
quality B-Sec
of I-Sec
life I-Sec
at I-Sec
six I-Sec
and I-Sec
twelve I-Sec
months I-Sec
, O
length B-Sec
of I-Sec
stay I-Sec
in I-Sec
ICU I-Sec
, O
length B-Sec
of I-Sec
stay I-Sec
in I-Sec
hospital I-Sec
, O
adverse B-Sec
effects I-Sec
( O
e.g. O

Also O
, O
every O
effort O
will O
be O
made O
to O
ensure O
that O
the O
physician O
who O
is O
assessing O
the O
secondary O
outcome O
is O
blinded O
to O
the O
treatment O
allocation O
. O

Univariate O
, O
multivariate O
and O
descriptive O
techniques O
are O
applied O
to O
estimate O
the O
effect O
of O
the O
intervention O
by O
comparing O
the O
experimental O
with O
the O
control O
groups O
with O
regard O
to O
the O
secondary O
and O
secondary O
outcomes O
at O
the O
follow-up O
measurements O
and O
by O
comparing O
the O
pre-test O
( O
T1 O
) O
with O
post-tests O
( O
T3 O
and O
T4 O
) O
. O

Effect O
variables O
The O
secondary O
effect O
variable O
was O
u-AQP2 B-Sec
CR I-Sec
, O
and O
the O
secondary O
effect O
variables O
were O
urinary B-Sec
sodium I-Sec
excretion I-Sec
rate I-Sec
( I-Sec
U I-Sec
Na I-Sec
) I-Sec
, O
FE B-Sec
Na I-Sec
, O
u-ENaC B-Sec
β-CR I-Sec
, O
urine B-Sec
volume I-Sec
( I-Sec
V I-Sec
) I-Sec
, O
C B-Sec
H20 I-Sec
, O
serum B-Sec
osmolality I-Sec
( I-Sec
s-osm I-Sec
) I-Sec
, O
urine B-Sec
osmolality I-Sec
( I-Sec
u-osm I-Sec
) I-Sec
, O
u-cAMP B-Sec
and I-Sec
u-PGE I-Sec
2 I-Sec
, O
plasma B-Sec
concentrations I-Sec
of I-Sec
AVP I-Sec
, O
PRC B-Sec
, O
Ang B-Sec
II I-Sec
, O
Aldo B-Sec
, O
ANP B-Sec
, O
BNP B-Sec
, O
sodium B-Sec
( I-Sec
p-Na I-Sec
) I-Sec
, O
and O
albumin B-Sec
( I-Sec
p-albumin I-Sec
) I-Sec
, O
systolic B-Sec
and I-Sec
diastolic I-Sec
blood I-Sec
pressure I-Sec
, O
heart B-Sec
rate I-Sec
, O
body B-Sec
weight I-Sec
, O
and O
glomerular B-Sec
filtration I-Sec
rate I-Sec
( I-Sec
GFR I-Sec
) I-Sec
. O

At O
the O
secondary O
assessment O
, O
participants O
were O
required O
to O
fill-out O
a O
Completion O
Questionnaire O
without O
the O
assessor O
present O
. O

secondary O
outcome O
measure O
The B-Sec
median I-Sec
RTDI I-Sec
for O
the O
whole O
study O
population O
was O
95.5 O
% O
( O
CECOG O
88.8 O
% O
, O
Mamma-1 O
95.6 O
% O
, O
Mamma-3 O
99.6 O
% O
) O
, O
whereas O
the O
mean O
RTDI O
overall O
was O
85.7 O
% O
( O
CECOG O
81.2 O
% O
, O
Mamma-1 O
85.6 O
% O
, O
Mamma-3 O
93.0 O
% O
) O
. O

The O
effect O
of O
acetylcysteine O
versus O
placebo O
on O
the O
secondary O
endpoint O
, O
incidence B-Sec
of I-Sec
CIN I-Sec
between I-Sec
48 I-Sec
to I-Sec
96 I-Sec
hours I-Sec
, O
will O
be O
evaluated O
with O
a O
chi-square O
test O
. O

The O
secondary O
outcome O
will O
be O
the B-Sec
total I-Sec
( I-Sec
non-maternity I-Sec
) I-Sec
cost I-Sec
per I-Sec
member I-Sec
as I-Sec
reported I-Sec
to I-Sec
the I-Sec
private I-Sec
health I-Sec
insurer I-Sec
( O
i.e. O

Other O
than O
the O
secondary O
outcome O
, O
secondary O
outcomes O
and O
eligibility O
criteria O
agreed O
upon O
by O
the O
6 O
sites O
, O
each O
site O
was O
free O
to O
design O
a O
trial O
that O
was O
different O
in O
some O
way O
. O

Treatment O
effect O
was O
measured O
as O
the O
change O
on O
anthropometric O
and O
biochemical O
determinations O
within O
initial O
and O
secondary O
measures O
and O
mean O
change O
among O
groups O
comparison O
. O

Outcome O
measures O
The O
secondary O
outcome O
measure O
is O
( B-Sec
unassisted I-Sec
) I-Sec
patency I-Sec
of I-Sec
the I-Sec
AVF I-Sec
at I-Sec
three I-Sec
months I-Sec
after I-Sec
randomisation I-Sec
. O

Effect O
of O
the O
intervention O
on O
secondary O
outcome O
measures O
Lifestyle-related O
cardiovascular O
risk O
factors O
Table O
3 O
shows O
the O
effect O
of O
the O
intervention O
on O
lifestyle O
measures O
. O

If O
the O
differences O
between O
the O
centers O
are O
not O
significant O
, O
the O
subsequent O
comparison O
of O
the O
secondary O
outcome O
will O
be O
performed O
between O
the O
two O
treatment O
groups O
across O
the O
centers O
, O
otherwise O
it O
will O
be O
stratified O
on O
center O
. O

Families O
were O
notified O
by O
means O
of O
a O
letter O
of O
their O
child's O
allocation O
to O
the O
intervention O
group O
or O
the O
control O
group O
prior O
to O
the O
first O
baseline O
assessment O
. O

We O
discussed O
in O
detail O
whether O
death O
before O
nursing O
home O
placement O
should O
be O
included O
in O
the O
secondary O
endpoint O
or O
count O
as O
a O
censoring O
event O
. O

The O
secondary O
outcome O
measure O
was O
the B-Sec
Roland I-Sec
Morris I-Sec
Disability I-Sec
Questionnaire I-Sec
( I-Sec
RDQ I-Sec
) I-Sec
41 I-Sec
, O
an O
established O
outcome O
measure O
for O
community O
based O
back O
pain O
studies O
46 O
. O

Whilst O
this O
interactive O
learning O
tool O
did O
not O
improve O
knowledge O
over O
and O
above O
self-directed O
learning O
, O
an O
improved O
tool O
might O
be O
more O
effective O
and O
efficiency O
might O
be O
a O
more O
appropriate O
secondary O
outcome O
for O
further O
research O
. O

This O
outcome O
, O
compared O
with O
the O
secondary O
study O
outcomes O
, O
will O
provide O
insight O
into O
the O
accuracy O
with O
which O
physicians O
' O
discern O
their O
own O
prescribing O
practices O
. O

These O
studies O
have O
used O
the B-Sec
ORS I-Sec
scale I-Sec
as O
the O
secondary O
outcome O
measure O
. O

Generalized O
Estimating O
Equations O
( O
GEE O
) O
84 O
will O
be O
used O
to O
fit O
regression O
models O
to O
describe O
the O
effects O
of O
the O
intervention O
on O
key O
outcome O
variables O
among O
children O
. O

Outcome O
measures O
Our O
secondary O
outcome O
measure O
will O
be O
the B-Sec
IBS I-Sec
Symptom I-Sec
Severity I-Sec
Score I-Sec
( I-Sec
IBS I-Sec
SSS I-Sec
) I-Sec
. O

Since O
there O
was O
a O
lack O
of O
previous O
data O
to O
guide O
estimation O
of O
sample O
size O
based O
on O
our O
designated O
secondary O
outcome O
, O
one O
purpose O
of O
this O
study O
was O
to O
determine O
feasible O
sample O
size O
for O
future O
study O
. O

Since O
the O
sequential O
application O
of O
treatment O
regimens O
is O
evaluated O
, O
time B-Sec
to I-Sec
failure I-Sec
of I-Sec
strategy I-Sec
( I-Sec
TFS I-Sec
) I-Sec
was O
chosen O
as O
the O
secondary O
endpoint O
( O
Figure O
1 O
) O
. O

They O
will O
decide O
whether O
or O
not O
a O
secondary O
end-point O
has O
occurred O
and O
classify O
strokes O
as O
thrombo-embolic O
, O
haemorrhagic O
, O
or O
uncertain O
. O

Biomarkers B-Sec
associated I-Sec
with I-Sec
oesophageal I-Sec
AC I-Sec
development I-Sec
will O
be O
measured O
as O
secondary O
outcomes O
via O
blood O
samples O
. O

The O
secondary O
outcome O
is O
the B-Sec
combined I-Sec
incidence I-Sec
of I-Sec
all I-Sec
cause I-Sec
hospitalization I-Sec
and I-Sec
death I-Sec
. O

Outcome O
Measures O
The O
secondary O
outcome O
measure O
is O
depressive B-Sec
symptomology I-Sec
, I-Sec
which I-Sec
is I-Sec
being I-Sec
measured I-Sec
using I-Sec
the I-Sec
Edinburgh I-Sec
Postnatal I-Sec
Depression I-Sec
Scale I-Sec
32 I-Sec
. O

Statistical O
analyses O
The O
secondary O
outcome O
variable O
is O
the B-Sec
maximum I-Sec
SOFA I-Sec
score I-Sec
during I-Sec
ICU I-Sec
stay I-Sec
. O

secondary O
and O
secondary O
endpoint O
analysis O
The O
secondary O
endpoint O
of O
this O
trial O
is O
overall B-Sec
survival I-Sec
, O
i.e. O

Outcome O
measures O
: O
secondary O
outcome O
measure O
: O
Alteration B-Sec
of I-Sec
Pain I-Sec
intensity I-Sec
( I-Sec
VAS I-Sec
) I-Sec
; O
Secondary O
outcome O
measure O
: O
alteration B-Sec
of I-Sec
pain I-Sec
intensity I-Sec
/ I-Sec
frequency I-Sec
( I-Sec
evaluated I-Sec
by I-Sec
diary I-Sec
) I-Sec
; O
pain B-Sec
questionnaires I-Sec
( I-Sec
including I-Sec
: I-Sec
NPI I-Sec
, I-Sec
PDI I-Sec
, I-Sec
SES I-Sec
, I-Sec
please I-Sec
refer I-Sec
to I-Sec
Table I-Sec
3 I-Sec
) I-Sec
; O
quality B-Sec
of I-Sec
life I-Sec
( I-Sec
SF-36 I-Sec
) I-Sec
Sensoric B-Sec
perception I-Sec
evaluated I-Sec
through I-Sec
qualitative I-Sec
sensory I-Sec
testing I-Sec
( I-Sec
QST I-Sec
) I-Sec
; O
credibility B-Sec
assessment I-Sec
according I-Sec
to I-Sec
Vincent I-Sec
; O
cost B-Sec
effectiveness I-Sec
and O
safety B-Sec
aspects I-Sec
. O

The O
secondary O
outcome O
measures O
are O
changes B-Sec
in I-Sec
clinical I-Sec
practices I-Sec
that I-Sec
are I-Sec
recommended I-Sec
in I-Sec
RHL I-Sec
measured I-Sec
approximately I-Sec
a I-Sec
year I-Sec
after I-Sec
the I-Sec
first I-Sec
workshop I-Sec
. O

Sample O
size O
calculation O
The O
size O
of O
the O
study O
was O
based O
on O
the O
secondary O
outcome O
measure O
HbA1c B-Sec
. O

secondary O
outcomes O
include O
a B-Sec
) I-Sec
duration I-Sec
of I-Sec
breastfeeding I-Sec
measured I-Sec
at I-Sec
6 I-Sec
and I-Sec
12 I-Sec
months I-Sec
, O
b B-Sec
) I-Sec
introduction I-Sec
of I-Sec
solids I-Sec
measured I-Sec
at I-Sec
4 I-Sec
and I-Sec
6 I-Sec
months I-Sec
, O
c B-Sec
) I-Sec
nutrition I-Sec
, I-Sec
physical I-Sec
activity I-Sec
and I-Sec
television I-Sec
viewing I-Sec
measured I-Sec
at I-Sec
24 I-Sec
months I-Sec
, O
and O
d B-Sec
) I-Sec
overweight I-Sec
/ I-Sec
obesity I-Sec
status I-Sec
at I-Sec
age I-Sec
2 I-Sec
and I-Sec
5 I-Sec
years I-Sec
. O

The O
result O
of O
a O
sample O
size O
calculation O
with O
the O
secondary O
outcome O
( O
NRS B-Sec
changes I-Sec
) O
of O
this O
study O
, O
adopting O
0.05 O
for O
α O
, O
0.2 O
for O
β O
and O
20 O
% O
for O
drop-out O
rate O
, O
suggested O
that O
115 O
participants O
in O
each O
group O
are O
an O
adequate O
sample O
size O
. O

secondary O
outcome O
The O
patients O
were O
well O
matched O
for O
baseline O
characteristics O
( O
Table O
1 O
) O
. O

The O
secondary O
study O
outcome O
is O
the B-Sec
cumulative I-Sec
ongoing I-Sec
pregnancy I-Sec
rate I-Sec
resulting I-Sec
in I-Sec
live I-Sec
birth I-Sec
achieved I-Sec
within I-Sec
18 I-Sec
months I-Sec
after I-Sec
randomisation I-Sec
. O

The O
secondary O
outcome O
will O
be O
change B-Sec
in I-Sec
depressive I-Sec
symptoms I-Sec
at I-Sec
6 I-Sec
months I-Sec
on I-Sec
the I-Sec
90-item I-Sec
Symptoms I-Sec
Checklist I-Sec
( I-Sec
SCL-90 I-Sec
) I-Sec
. O

Study O
objectives O
and O
outcome O
measures O
The O
secondary O
objective O
is O
to O
ascertain O
whether O
there O
are O
equivalent O
changes O
in O
HbA1c B-Sec
( O
secondary O
outcome O
measure O
) O
in O
people O
with O
newly O
diagnosed O
T2DM O
allocated O
to O
either O
a O
urine O
or O
a O
blood O
glucose O
monitoring O
strategy O
over O
18 O
months O
when O
incorporated O
as O
an O
integral O
part O
of O
a O
comprehensive O
self-management O
structured O
education O
programme O
( O
DESMOND O
) O
. O

Subgroup O
analyses O
for O
the O
secondary O
outcome O
will O
be O
based O
on O
time O
from O
injury O
to O
randomization O
, O
the O
severity O
of O
TBI O
( O
moderate O
or O
severe O
) O
, O
the O
location O
of O
the O
intracranial O
bleeding O
, O
and O
baseline O
risk O
. O

The O
secondary O
outcome O
measure O
will O
be O
the B-Sec
Disabilities I-Sec
of I-Sec
the I-Sec
Arm I-Sec
, I-Sec
Shoulder I-Sec
and I-Sec
Hand I-Sec
( I-Sec
DASH I-Sec
) I-Sec
score I-Sec
and O
the O
secondary O
outcome O
measures O
will O
be O
the B-Sec
EuroQol-5D I-Sec
( I-Sec
EQ-5D I-Sec
) I-Sec
value I-Sec
, O
OSS B-Sec
, O
Constant-Murley B-Sec
Score I-Sec
, O
VAS B-Sec
, O
and O
15D B-Sec
. O

The O
secondary O
outcomes O
are O
depression B-Sec
and O
anxiety B-Sec
symptoms I-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
Beck I-Sec
Depression I-Sec
and I-Sec
Anxiety I-Sec
Inventories I-Sec
. O

secondary O
outcome O
measure O
The O
secondary O
outcome O
measure O
for O
the O
study O
is O
the B-Sec
score I-Sec
on I-Sec
the I-Sec
AUDIT I-Sec
screen I-Sec
at I-Sec
12 I-Sec
months I-Sec
post-consent I-Sec
. O

These O
data O
will O
be O
disclosed O
to O
the O
central O
office O
only O
after O
data O
on O
secondary O
outcome O
have O
been O
collected O
. O

As O
illustrated O
in O
Figure O
2 O
, O
the O
study O
is O
designed O
to O
include O
a O
secondary O
data O
assessment O
12 O
months O
after O
baseline O
; O
the O
secondary O
outcome O
assessment O
will O
be O
performed O
immediately O
after O
the O
intervention O
program O
4 O
months O
after O
baseline O
. O

A O
recent O
randomized O
controlled O
trial O
of O
an O
active O
video O
game O
( O
PlayStation O
EyeToy™ O
) O
intervention O
showed O
a O
statistically O
significant O
treatment O
effect O
on O
the O
secondary O
outcome O
, O
change B-Sec
from I-Sec
baseline I-Sec
in I-Sec
body I-Sec
mass I-Sec
index I-Sec
( I-Sec
BMI I-Sec
) I-Sec
, O
which O
favored O
the O
intervention O
group O
at O
24 O
weeks O
1 O
. O

If O
serum O
phosphate O
remains O
below O
this O
level O
after O
6 O
weeks O
and O
/ O
or O
a O
dose O
reduction O
subjects O
will O
be O
withdrawn O
from O
the O
study O
after O
a O
secondary O
set O
of O
measurements O
. O

In O
addition O
, O
the O
secondary O
outcome O
measure O
, O
reduction B-Sec
of I-Sec
depressive I-Sec
symptoms I-Sec
, O
is O
measured O
from O
three O
different O
perspectives O
. O

Sample O
Size O
Determination O
and O
Power O
Analysis O
The O
secondary O
response O
variable O
for O
sample O
size O
calculation O
is O
the B-Sec
proportion I-Sec
( I-Sec
% I-Sec
) I-Sec
of I-Sec
patients I-Sec
who I-Sec
respond I-Sec
to I-Sec
treatment I-Sec
. O

Outcomes O
Effectiveness O
measures O
The O
secondary O
effectiveness O
measures O
of O
the O
study O
consist O
of O
Roland B-Sec
Morris I-Sec
Disability I-Sec
Questionnaire I-Sec
( I-Sec
RDQ I-Sec
) I-Sec
31 I-Sec
32 I-Sec
( I-Sec
scale I-Sec
0-24 I-Sec
; I-Sec
lower I-Sec
score I-Sec
indicates I-Sec
lower I-Sec
disability I-Sec
) I-Sec
, O
Mc B-Sec
Gill I-Sec
Pain I-Sec
Questionnaire I-Sec
33 I-Sec
34 I-Sec
35 I-Sec
36 I-Sec
37 I-Sec
( I-Sec
including I-Sec
VAS I-Sec
1-10 I-Sec
; I-Sec
lower I-Sec
score I-Sec
indicates I-Sec
less I-Sec
pain I-Sec
) I-Sec
, O
and O
Goldberg B-Sec
questionnaire I-Sec
on I-Sec
anxiety I-Sec
and I-Sec
depression I-Sec
. O

The O
secondary O
outcome O
, O
change B-Sec
in I-Sec
systolic I-Sec
blood I-Sec
pressure I-Sec
at I-Sec
6 I-Sec
months I-Sec
, O
will O
be O
compared O
between O
the O
two O
groups O
using O
a O
simple O
t-test O
against O
the O
usual O
null O
hypothesis O
of O
no O
difference O
. O

Measures O
The O
secondary O
outcome O
is O
health-related B-Sec
quality I-Sec
of I-Sec
life I-Sec
for I-Sec
the I-Sec
carer I-Sec
. O

Assessments O
are O
re-reviewed O
by O
a O
second O
clinical O
investigator O
if O
the O
first O
assessment O
noted O
worsening O
HF O
as O
either O
' O
probably O
' O
or O
' O
probably O
not O
' O
a O
contributing O
factor O
to O
the O
admission O
or O
if O
it O
is O
marked O
' O
unsure O
' O
. O

Definition O
of O
endpoints O
The O
secondary O
endpoint O
is O
biochemical B-Sec
progression-free I-Sec
survival I-Sec
( I-Sec
bPFS I-Sec
) I-Sec
. O

The O
secondary O
measure O
for O
this O
task O
is O
the B-Sec
number I-Sec
of I-Sec
correct I-Sec
items I-Sec
. O

secondary O
outcome O
is O
the B-Sec
task I-Sec
performance I-Sec
measured I-Sec
with I-Sec
the I-Sec
Task I-Sec
Performance I-Sec
Scale I-Sec
six I-Sec
weeks I-Sec
post I-Sec
treatment I-Sec
. O

Outcome O
assessment O
Data O
collected O
at O
baseline O
, O
including O
secondary O
and O
secondary O
outcome O
measures O
, O
will O
be O
collected O
again O
at O
12 O
and O
18 O
months O
post-intervention O
for O
both O
the O
intervention O
and O
control O
groups O
. O

Outcome O
measures O
secondary O
objective O
The O
secondary O
outcome O
measured O
is O
adherence B-Sec
, O
means B-Sec
of I-Sec
increasing I-Sec
physical I-Sec
activity I-Sec
level I-Sec
assessed I-Sec
with I-Sec
short-version I-Sec
IPAQ I-Sec
questionnaire I-Sec
37 I-Sec
. O

The O
collection O
of O
the O
same O
data O
items O
at O
multiple O
data O
points O
should O
facilitate O
imputation O
of O
values O
for O
data O
points O
missed O
by O
individual O
participants O
and O
minimise O
the O
impact O
of O
lower O
participation O
, O
however O
, O
this O
will O
remain O
a O
limitation O
for O
measures O
analysed O
cross-sectionally O
. O

We O
elected O
to O
include O
a O
small O
number O
of O
key O
competence O
measures O
as O
we O
felt O
that O
we O
could O
not O
interpret O
confidence O
entirely O
isolated O
from O
competence O
. O

The O
patient O
follow-up O
has O
three O
distinct O
phases--from O
randomization O
and O
baseline O
injection O
to O
the O
secondary O
endpoint O
at O
six O
weeks O
, O
from O
optional O
crossover O
at O
six O
weeks O
until O
nine O
weeks O
, O
and O
the O
follow-up O
period O
from O
nine O
weeks O
to O
one O
year O
after O
randomization O
( O
see O
Figure O
1 O
) O
. O

In O
the O
all O
, O
mean O
total O
cholesterol O
, O
LDL O
, O
HDL O
, O
and O
triglyceride O
levels O
increased O
from O
baseline O
to O
the O
first O
assessment O
after O
tocilizumab O
infusion O
at O
week O
6 O
and O
remained O
at O
week O
6 O
levels O
with O
continued O
tocilizumab O
treatment O
( O
Table O
5 O
) O
. O

The O
secondary O
outcome O
measure O
was O
the B-Sec
prevalence I-Sec
of I-Sec
arm I-Sec
, I-Sec
shoulder I-Sec
and I-Sec
neck I-Sec
symptoms I-Sec
. O

Sub-group O
analysis O
of O
those O
with O
a O
recorded O
hospitalisation O
within O
12 O
months O
prior O
to O
enrolment O
of O
the O
trial O
will O
be O
undertaken O
with O
respect O
to O
secondary O
and O
secondary O
outcome O
measures O
. O

The O
structured O
adolescent O
questionnaire O
contained O
validated O
measures O
of O
the O
mental O
wellbeing O
and O
physical O
activity O
secondary O
outcomes O
: O
negative O
mental O
health O
symptoms O
were O
measured O
using O
the O
Strengths O
and O
Difficulties O
Questionnaire O
( O
SDQ O
) O
64 O
; O
positive O
mental O
wellbeing O
was O
measured O
using O
the O
Positive O
and O
Negative O
Affect O
Scale O
( O
PANAS O
) O
65 O
; O
physical O
activity O
was O
measured O
using O
the O
Adolescent O
Physical O
Activity O
Questionnaire O
( O
PAQ-A O
) O
66 O
. O

This O
figure O
assumes O
that O
the O
annual O
incidence O
of O
the O
secondary O
end-point O
on O
aspirin O
is O
9 O
% O
, O
6 O
16 O
the O
annual O
rate O
of O
secondary O
end-points O
or O
death O
will O
be O
14 O
% O
and O
that O
loss O
to O
follow O
up O
will O
be O
1 O
% O
. O

Co-Secary O
outcome O
measures O
are O
the B-Sec
duration I-Sec
of I-Sec
antibiotic I-Sec
therapy I-Sec
( I-Sec
superiority I-Sec
aspect I-Sec
of I-Sec
the I-Sec
trial I-Sec
) I-Sec
and O
the B-Sec
proportion I-Sec
of I-Sec
infants I-Sec
with I-Sec
a I-Sec
recurrence I-Sec
of I-Sec
infection I-Sec
requiring I-Sec
additional I-Sec
courses I-Sec
of I-Sec
antibiotic I-Sec
therapy I-Sec
and I-Sec
/ I-Sec
or I-Sec
death I-Sec
in I-Sec
the I-Sec
first I-Sec
month I-Sec
of I-Sec
life I-Sec
( I-Sec
safety I-Sec
of I-Sec
study I-Sec
intervention I-Sec
, I-Sec
non-inferiority I-Sec
aspect I-Sec
of I-Sec
the I-Sec
trial I-Sec
) I-Sec
. O

For O
intervention O
participants O
with O
an O
attrition O
of O
at O
least O
75 O
% O
a O
per-protocol O
analysis O
will O
be O
performed O
with O
data O
of O
the O
first O
measurement O
from O
baseline O
and O
, O
secondly O
. O

A O
per-protocol O
analysis O
will O
also O
be O
performed O
on O
the O
secondary O
outcomes O
using O
completers O
only O
, O
which O
we O
define O
as O
those O
patients O
who O
complete O
at O
least O
5 O
cCBT O
sessions O
. O

Instruments O
secondary O
outcome O
Depressive B-Sec
symptoms I-Sec
Symptoms O
of O
depression O
will O
be O
assessed O
with O
the O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
( O
CES-D O
) O
31 O
38 O
. O

The O
secondary O
outcome O
variable O
was O
the B-Sec
mean I-Sec
change I-Sec
in I-Sec
modified I-Sec
extrinsic I-Sec
tooth I-Sec
stain I-Sec
index I-Sec
( I-Sec
all I-Sec
sites I-Sec
) I-Sec
from I-Sec
baseline I-Sec
to I-Sec
week I-Sec
6 I-Sec
; O
this O
study O
duration O
was O
consistent O
with O
other O
tooth O
whitening O
studies O
in O
the O
literature O
3 O
10 O
11 O
12 O
13 O
and O
was O
also O
consistent O
with O
the O
FDA O
´ O
s O
definition O
of O
the O
secondary O
time-point O
for O
smoking O
cessation O
efficacy O
( O
6 O
weeks O
with O
complete O
abstinence O
for O
the O
last O
four O
weeks O
) O
.The O
full O
study O
ran O
for O
12 O
weeks O
according O
to O
the O
design O
of O
traditional O
smoking O
cessation O
studies O
. O

Outcome O
measurements O
The O
secondary O
endpoint O
shall O
be O
the B-Sec
change I-Sec
in I-Sec
the I-Sec
number I-Sec
of I-Sec
colorectal I-Sec
ACF I-Sec
after I-Sec
1-months’s I-Sec
intervention I-Sec
. O

secondary O
outcome O
measure O
Patient B-Sec
satisfaction I-Sec
As O
a O
surrogate O
of O
service O
quality O
, O
patient O
satisfaction O
will O
be O
assessed O
at O
baseline O
and O
at O
the O
end O
of O
12 O
months O
using O
the O
Short-Form O
Patient O
Satisfaction O
Questionnaire O
( O
PSQ-18 O
) O
14 O
. O

Discussion O
We O
have O
described O
the O
development O
of O
an O
outcome O
measure O
for O
quantifying O
patients' O
experiences O
of O
treatment O
for O
MS O
relapses O
, O
to O
be O
used O
as O
the O
secondary O
outcome O
measure O
in O
a O
randomised O
controlled O
trial O
of O
service O
delivery O
20 O
. O

The O
secondary O
outcome O
will O
be O
disability B-Sec
as I-Sec
measured I-Sec
by I-Sec
Roland-Morris I-Sec
Disability I-Sec
Questionnaire I-Sec
. O

This O
was O
the O
secondary O
outcome O
measure O
. O

secondary O
end O
point O
" O
Optimized O
ventilation O
" O
when O
compared O
to O
" O
standard O
ventilation O
" O
was O
associated O
with O
a O
higher O
rate O
of O
pH O
normalization O
at O
two O
hours O
( O
51 O
% O
vs O
. O

Moreover O
, O
all O
statisticians O
and O
experts O
that O
were O
consulted O
about O
the O
secondary O
outcome O
for O
this O
project O
advised O
us O
to O
move O
forward O
with O
the O
nonweighted O
score O
, O
as O
they O
agreed O
that O
weighted O
endpoints O
should O
be O
avoided O
when O
there O
is O
no O
clear O
evidence O
available O
to O
assign O
specific O
weights O
. O

The O
secondary O
outcome O
will O
be O
sunbathing B-Sec
at I-Sec
1- I-Sec
, I-Sec
and I-Sec
12-months I-Sec
follow-up I-Sec
and O
a O
questionnaire-only O
control O
group O
will O
be O
employed O
for O
comparison O
. O

For O
the O
IMPALA O
study O
, O
an O
innovative O
nurse-led O
implementation O
strategy O
was O
developed O
, O
comprising O
key O
elements O
of O
risk O
assessment O
, O
risk O
communication O
, O
a O
decision O
aid O
, O
and O
adapted O
motivational O
interviewing O
. O

The O
secondary O
endpoint O
of O
the O
study O
was O
the B-Sec
duration I-Sec
of I-Sec
the I-Sec
weaning I-Sec
process I-Sec
. O

The O
secondary O
outcomes O
were O
day-28 B-Sec
failure I-Sec
rates I-Sec
( I-Sec
uncorrected I-Sec
and I-Sec
PCR I-Sec
corrected I-Sec
) I-Sec
. O

Ongoing O
RCTs O
using O
decline O
in O
GFR O
as O
the O
secondary O
outcome O
measure O
include O
a O
European O
pediatric O
study O
and O
comparing O
ACEi O
vs. O
placebo O
18 O
, O
an O
Italian O
study O
comparing O
ACEi O
and O
prednisone O
to O
ACEi O
alone O
19 O
, O
and O
another O
Italian O
study O
examining O
intravenous O
and O
oral O
corticosteroids O
with O
and O
without O
azathioprine O
20 O
. O

The O
χ O
2 O
difference O
test O
indicated O
non O
– O
invariance O
for O
the O
first O
measure O
( O
p O
< O
.0001 O
) O
, O
and O
invariance O
for O
the O
second O
measure O
( O
p O
= O
.0889 O
) O
( O
Table O
6 O
) O
. O

Study O
researchers O
, O
screeners O
, O
research O
assistants O
and O
therapists O
are O
masked O
to O
treatment O
allocation O
during O
the O
screening O
period O
and O
the O
first O
assessment O
. O

The O
secondary O
efficacy O
endpoint O
was O
PCR-adjusted B-Sec
42-day I-Sec
cure I-Sec
rates I-Sec
after I-Sec
starting I-Sec
treatment I-Sec
. O

Results O
Table O
3 O
presents O
the O
baseline O
, O
3-month O
follow-up O
, O
and O
6-month O
follow-up O
data O
for O
each O
of O
the O
secondary O
study O
outcomes O
. O

In O
this O
trial O
the O
secondary O
outcome O
measurement O
and O
most O
of O
the O
secondary O
outcome O
measurements O
will O
be O
scored O
by O
the O
patients O
. O

The O
two O
secondary O
efficacy O
outcomes O
, O
FVC B-Sec
and O
mMRC B-Sec
, O
are O
combined O
in O
a O
responder O
analysis O
. O

We O
wished O
to O
reflect O
the O
population O
that O
present O
to O
secondary O
care O
for O
assessment O
and O
treatment O
and O
who O
in O
many O
cases O
will O
not O
have O
these O
investigative O
procedures O
performed O
. O

However O
, O
the O
aforementioned O
studies O
used O
development O
of O
" O
clinical O
vasospasm O
" O
as O
secondary O
endpoint O
whereas O
in O
the O
E O
ARLYDRAIN O
study O
the O
secondary O
endpoint O
is O
degree O
of O
disability O
after O
6 O
months O
assessed O
in O
a O
prospective O
blinded O
manner O
using O
the O
mRS-score O
. O

The O
secondary O
outcomes O
were O
comparison B-Sec
of I-Sec
the I-Sec
change I-Sec
from I-Sec
baseline I-Sec
to I-Sec
end I-Sec
of I-Sec
12 I-Sec
weeks I-Sec
between I-Sec
simvastatin I-Sec
and I-Sec
fenofibrate I-Sec
. O

The O
secondary O
outcome O
measure O
of O
the O
study O
is O
cognitive B-Sec
decline I-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
change I-Sec
from I-Sec
baseline I-Sec
in I-Sec
the I-Sec
total I-Sec
score I-Sec
on I-Sec
the I-Sec
Alzheimer's I-Sec
disease I-Sec
Assessment I-Sec
Scale-Cognitive I-Sec
section I-Sec
. O

The O
alternative O
hypothesis O
establishes O
a O
relationship O
between O
such O
consumption O
and O
the O
incidence O
of O
the O
secondary O
variable O
. O

The O
extended O
AUDIT-C O
is O
used O
to O
derive O
the O
secondary O
outcome O
measure O
for O
the O
study O
. O

The O
secondary O
outcome O
measure O
is O
apathy B-Sec
after I-Sec
12 I-Sec
months I-Sec
using I-Sec
the I-Sec
German I-Sec
version I-Sec
of I-Sec
the I-Sec
Apathy I-Sec
Evaluation I-Sec
Scale I-Sec
- I-Sec
AES I-Sec
16 O
17 O
. O

Therefore O
, O
a O
minimum O
total O
of O
152 O
participants O
are O
required O
in O
this O
cross-over O
study O
to O
achieve O
the O
desired O
level O
of O
probability O
in O
detecting O
a O
statistically O
significant O
difference O
across O
the O
two O
secondary O
outcome O
measures O
. O

Results O
of O
the O
effect O
of O
melatonin O
on O
secondary O
and O
secondary O
sleep O
measurements O
are O
shown O
in O
Table O
2 O
. O

Outcome O
variables O
Our O
four O
secondary O
outcome O
variables O
were O
force B-Sec
platform I-Sec
variables I-Sec
PVF I-Sec
and O
impulse B-Sec
, O
the B-Sec
validated I-Sec
HCPI I-Sec
and O
the B-Sec
use I-Sec
of I-Sec
rescue I-Sec
NSAIDs I-Sec
. O

Outcome O
measures O
secondary O
outcome O
At O
present O
, O
the O
goal O
of O
asthma O
care O
is O
to O
achieve O
and O
maintain O
control O
of O
clinical O
manifestation O
of O
the O
disease O
27 O
28 O
. O

alpha O
= O
0.0095 O
instead O
of O
alpha O
= O
0.01 O
) O
secondary O
outcomes O
Assessment B-Sec
of I-Sec
group I-Sec
differences I-Sec
at I-Sec
6 I-Sec
months I-Sec
for I-Sec
: I-Sec
• I-Sec
Harris I-Sec
Hip I-Sec
Score I-Sec
( I-Sec
HHS I-Sec
) I-Sec
18 I-Sec
: O
this O
score O
will O
be O
used O
as O
a O
self-administered O
questionnaire O
in O
accordance O
with O
the O
developers' O
instructions O
. O

Salivary O
cotinine O
validation O
of O
smoking O
abstinence O
The O
secondary O
endpoint O
of O
this O
study O
is O
biochemically B-Sec
verified I-Sec
7-day I-Sec
point I-Sec
prevalence I-Sec
smoking I-Sec
abstinence I-Sec
defined I-Sec
as I-Sec
no I-Sec
cigarettes I-Sec
( I-Sec
not I-Sec
even I-Sec
a I-Sec
puff I-Sec
) I-Sec
in I-Sec
the I-Sec
previous I-Sec
7 I-Sec
days I-Sec
at I-Sec
Week I-Sec
26 I-Sec
, I-Sec
validated I-Sec
using I-Sec
salivary I-Sec
cotinine I-Sec
collected I-Sec
at I-Sec
Week I-Sec
26. I-Sec

Only O
first O
consultations O
within O
the O
same O
episode O
will O
be O
evaluated O
for O
the O
secondary O
outcome O
, O
using O
a O
10 O
day O
time O
window O
. O

Study O
results O
will O
be O
obtained O
for O
the O
secondary O
variable O
MNA B-Sec
test I-Sec
, O
a O
validated O
screening O
test O
with O
a O
sensitivity O
of O
80 O
% O
and O
a O
specificity O
of O
90 O
% O
14 O
, O
and O
also O
using O
other O
outcomes O
measures O
like O
anthropometric O
measurements O
( O
estimated O
according O
to O
standard O
recommendations O
) O
, O
a O
validated O
food O
frequency O
questionnaire O
, O
and O
biochemical O
markers O
. O

Although O
a O
strict O
Bonferroni O
adjustment O
for O
multiple O
testing O
would O
suggest O
use O
of O
somewhat O
more O
conservative O
significance O
levels O
( O
1 O
% O
for O
secondary O
outcomes O
) O
, O
this O
adjustment O
is O
too O
conservative O
when O
outcomes O
are O
positively O
correlated O
, O
as O
they O
will O
be O
in O
this O
trial O
. O

The O
most O
efficacious O
combination O
of O
total O
daily O
dose O
and O
dosing O
interval O
for O
the O
secondary O
endpoint O
was O
HU O
300 O
mg O
twice O
daily O
( O
P O
= O
0.017 O
) O
. O

For O
a O
secondary O
outcome O
of O
CHD B-Sec
events I-Sec
( I-Sec
CHD I-Sec
death I-Sec
plus I-Sec
nonfatal I-Sec
MI I-Sec
) I-Sec
, O
it O
is O
projected O
that O
approximately O
500 O
CHD O
events O
will O
have O
occurred O
when O
5 O
years O
median O
follow-up O
has O
elapsed O
( O
during O
the O
first O
quarter O
of O
2005 O
) O
; O
by O
this O
time O
the O
trial O
will O
have O
80 O
% O
power O
to O
detect O
an O
observed O
22 O
% O
reduction O
in O
CHD O
events O
( O
based O
on O
the O
intention-to-treat O
method O
of O
analysis O
) O
. O

This O
secondary O
endpoint O
is O
assessed O
using O
a B-Sec
validated I-Sec
8-item I-Sec
multiple I-Sec
choice I-Sec
type I-Sec
questionnaire I-Sec
on I-Sec
cosmesis I-Sec
and I-Sec
body I-Sec
image I-Sec
. O

This O
decision O
was O
made O
because O
the O
secondary O
outcome O
of O
the O
trial O
is O
a B-Sec
dichotomous I-Sec
measure I-Sec
( I-Sec
occurrence I-Sec
of I-Sec
low I-Sec
back I-Sec
pain I-Sec
) I-Sec
and O
we O
wanted O
these O
analyses O
to O
be O
parallel O
. O

Outcome O
measurements O
secondary O
outcome O
measure O
Exacerbations B-Sec
Frequency O
, O
nature O
and O
severity O
of O
exacerbations O
of O
COPD O
will O
be O
evaluated O
in O
the O
first O
, O
the O
third O
and O
the O
sixth O
month O
during O
the O
follow-up O
period O
. O

End O
points O
The O
secondary O
end O
point O
was O
the B-Sec
recovery I-Sec
rate I-Sec
, I-Sec
defined I-Sec
as I-Sec
the I-Sec
percentage I-Sec
of I-Sec
patients I-Sec
who I-Sec
had I-Sec
an I-Sec
adequate I-Sec
clinical I-Sec
and I-Sec
parasitological I-Sec
response I-Sec
( I-Sec
ACPR I-Sec
) I-Sec
after I-Sec
follow-up I-Sec
for I-Sec
28 I-Sec
days I-Sec
. O

The O
secondary O
outcome O
will O
be O
a B-Sec
participant I-Sec
rating I-Sec
of I-Sec
global I-Sec
improvement I-Sec
, O
from O
which O
measures O
of O
success O
and O
recurrence O
will O
be O
derived O
. O

Endpoints O
The O
secondary O
outcome O
criterion O
used O
is O
the B-Sec
number I-Sec
of I-Sec
days I-Sec
spent I-Sec
outside I-Sec
the I-Sec
hospital I-Sec
in I-Sec
the I-Sec
first I-Sec
year I-Sec
following I-Sec
the I-Sec
trauma I-Sec
. O

Students O
who O
did O
not O
complete O
the O
protocol O
including O
post-test O
could O
not O
be O
analyzed O
on O
the O
secondary O
dependent O
variable O
. O

After O
6 O
months O
the O
nonunion O
rates O
can O
be O
calculated O
and O
therefore O
6 O
months O
is O
the O
first O
possible O
endpoint O
to O
determine O
the O
success O
rate O
of O
the O
surgery O
. O

Data O
analyses O
Difference O
between O
the O
groups O
in O
the O
secondary O
outcome O
will O
be O
analysed O
based O
on O
the O
basis O
of O
the O
" O
intention-to-treat O
" O
principle O
. O

Should O
baseline O
data O
differ O
between O
groups O
, O
regression O
will O
be O
used O
to O
check O
that O
the O
secondary O
outcomes O
are O
not O
affected O
by O
this O
chance O
finding O
. O

Three O
methods O
of O
patient O
accrual O
were O
used O
to O
ensure O
consecutive O
patient O
accrual O
for O
secondary O
outcomes O
– O
regular O
( O
weekly O
) O
phone O
calls O
to O
surgeons' O
offices O
, O
review O
of O
operating O
room O
booking O
logs O
, O
and O
hospital O
health O
records O
queries O
. O

The O
secondary O
variable O
will O
be O
the B-Sec
incidence I-Sec
of I-Sec
spontaneous I-Sec
falls I-Sec
. O

The O
secondary O
outcomes O
are O
the B-Sec
number I-Sec
of I-Sec
days I-Sec
from I-Sec
the I-Sec
initial I-Sec
visit I-Sec
to I-Sec
return I-Sec
to I-Sec
regular I-Sec
work I-Sec
activities I-Sec
, O
and O
the B-Sec
total I-Sec
number I-Sec
of I-Sec
sick I-Sec
leave I-Sec
days I-Sec
during I-Sec
12 I-Sec
and I-Sec
24 I-Sec
months I-Sec
of I-Sec
follow-up I-Sec
. O

secondary O
and O
secondary O
outcomes O
The O
secondary O
study O
endpoint O
of O
the O
EXCITE O
trial O
is O
the B-Sec
change I-Sec
in I-Sec
the I-Sec
coronary I-Sec
CBF I-Sec
index I-Sec
after I-Sec
4 I-Sec
weeks I-Sec
of I-Sec
therapy I-Sec
among I-Sec
the I-Sec
three I-Sec
treatment I-Sec
groups I-Sec
( O
Table O
1 O
) O
. O

The O
only O
variables O
assessed O
with O
the O
PP O
analysis O
set O
were O
the O
secondary O
efficacy O
endpoint O
and O
TOTPAR O
. O

Success O
The O
secondary O
outcome O
( O
' B-Sec
success I-Sec
' I-Sec
) O
, O
was O
detection B-Sec
of I-Sec
bilateral I-Sec
aerated I-Sec
middle I-Sec
ears I-Sec
( I-Sec
confirmed I-Sec
with I-Sec
tympanometry I-Sec
) I-Sec
at I-Sec
two I-Sec
consecutive I-Sec
monthly I-Sec
visits I-Sec
. O

Analysis O
Statistical O
analysis O
of O
clinical O
data O
We O
will O
analyse O
our O
secondary O
outcome O
of O
severity B-Sec
of I-Sec
depression I-Sec
on O
the O
PHQ-9 O
at O
four O
months O
using O
between O
groups O
analysis O
of O
covariance O
on O
individual O
baseline O
depression O
score O
. O

Results O
Phase O
2 O
recruitment O
A O
total O
of O
58 O
eligible O
patients O
were O
recruited O
to O
the O
trial O
( O
46 O
% O
of O
those O
initially O
planned O
) O
and O
42 O
( O
72 O
% O
) O
provided O
data O
on O
the O
secondary O
outcome O
at O
3 O
months O
. O

Figure O
1 O
Consort O
flowchart O
for O
secondary O
and O
secondary O
outcome O
measures O
Consort O
flowchart O
for O
secondary O
and O
secondary O
outcome O
measures O
. O

secondary O
outcome O
measures O
The B-Sec
Insomnia I-Sec
Severity I-Sec
Index I-Sec
( I-Sec
ISI I-Sec
) I-Sec
32 I-Sec
is O
a O
much O
used O
, O
7-item O
patient-reported O
outcome O
measure O
assessing O
the O
severity O
of O
initial O
, O
middle O
and O
late O
insomnia O
; O
sleep O
satisfaction O
; O
interference O
of O
insomnia O
with O
daytime O
functioning O
; O
noticeability O
of O
sleep O
problems O
by O
others O
; O
and O
distress O
about O
sleep O
difficulties O
. O

What O
should O
be O
the O
secondary O
efficacy O
outcome O
? O

The O
trial O
will O
measure O
effect O
of O
injection O
on O
the O
secondary O
outcome O
of O
pain B-Sec
, O
and O
secondary O
outcomes O
of O
function B-Sec
and O
quality B-Sec
of I-Sec
life I-Sec
. O

The O
secondary O
outcomes O
are O
medial B-Sec
knee I-Sec
load I-Sec
during I-Sec
walking I-Sec
( I-Sec
the I-Sec
peak I-Sec
external I-Sec
knee I-Sec
adduction I-Sec
moment I-Sec
from I-Sec
3D I-Sec
gait I-Sec
analysis I-Sec
) I-Sec
, O
pain B-Sec
, O
and O
self-reported B-Sec
physical I-Sec
function I-Sec
measured I-Sec
at I-Sec
baseline I-Sec
and I-Sec
immediately I-Sec
following I-Sec
the I-Sec
program I-Sec
. O

The O
secondary O
endpoint O
with O
respect O
to O
efficacy O
was O
change B-Sec
in I-Sec
BMD I-Sec
between I-Sec
pre-treatment I-Sec
and I-Sec
16 I-Sec
weeks I-Sec
. O

Anonymised O
and O
encrypted O
data O
pertaining O
to O
the O
computerised O
secondary O
and O
secondary O
outcomes O
measures O
are O
sent O
via O
the O
Internet O
to O
a O
secure O
computer O
at O
the O
University O
of O
Nottingham O
. O

Outcomes O
secondary O
outcome O
The O
secondary O
outcome O
is O
the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
attending I-Sec
facilities I-Sec
that I-Sec
report I-Sec
a I-Sec
fever I-Sec
or I-Sec
suspected I-Sec
malaria I-Sec
and I-Sec
receive I-Sec
treatment I-Sec
according I-Sec
to I-Sec
malaria I-Sec
guidelines I-Sec
. O

The O
secondary O
endpoint O
of O
this O
study O
is O
the B-Sec
differences I-Sec
in I-Sec
birth I-Sec
weight I-Sec
between I-Sec
the I-Sec
2 I-Sec
groups I-Sec
. O

The O
study O
is O
therefore O
substantially O
overpowered O
to O
address O
the O
secondary O
endpoint O
of O
hospitalisation B-Sec
. O

However O
, O
we O
do O
not O
include O
a O
proximal O
DVT O
in O
our O
secondary O
outcome O
which O
only O
comes O
to O
attention O
because O
of O
symptoms O
starting O
more O
than O
30 O
days O
after O
enrollment O
because O
this O
might O
introduce O
bias O
. O

Analysis O
secondary O
outcome O
will O
be O
examined O
in O
an O
intention-to-treat O
framework O
as O
pregnancy B-Sec
rate I-Sec
at I-Sec
one I-Sec
year I-Sec
among O
women O
randomized O
to O
immediate O
insertion O
compared O
to O
women O
randomized O
to O
a O
planned O
insertion O
at O
4 O
weeks O
( O
" O
delayed O
insertion O
" O
) O
for O
each O
of O
the O
two O
IUC O
devices O
. O

The O
inclusion O
of O
women O
at O
a O
lower O
risk O
of O
the O
secondary O
outcomes O
necessitated O
an O
increase O
in O
the O
sample O
size O
. O

Statistical O
analysis O
plan O
Analysis O
of O
efficacy O
PRP O
vs O
standard-of-care O
( O
parallel O
cannulated O
screws O
) O
The O
secondary O
outcome O
measure O
, O
the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
requiring I-Sec
re-operation I-Sec
for I-Sec
failure I-Sec
of I-Sec
fixation I-Sec
within I-Sec
one I-Sec
year I-Sec
of I-Sec
sustaining I-Sec
the I-Sec
fracture I-Sec
, O
will O
be O
analysed O
using O
a O
chi-squared O
test O
for O
differences O
between O
internal O
fixation O
alone O
( O
control O
) O
and O
internal O
fixation O
and O
PRP O
( O
PRP O
) O
on O
an O
intention-to-treat O
basis O
. O

The O
study O
subjects O
number O
calculation O
assumed O
a O
two-tailed O
alpha O
= O
0.05 O
and O
1-β O
= O
90 O
% O
to O
detect O
a O
10 O
% O
difference O
with O
a O
standard O
error O
of O
0.28 O
in O
the O
comet B-Sec
assay I-Sec
which O
is O
secondary O
outcome O
and O
an O
attrition O
rate O
( O
20 O
% O
) O
. O

Power O
calculation O
for O
the O
analysis O
of O
secondary O
endpoints O
For O
the O
power O
calculation O
we O
assume O
that O
788 O
patients O
are O
available O
for O
analysis O
with O
24 O
patients O
per O
practice O
( O
i.e. O

Outcomes O
Given O
this O
degree O
of O
complexity O
identifying O
a O
single O
secondary O
outcome O
measure O
to O
capture O
the O
impact O
of O
an O
OHC O
intervention O
is O
problematic O
6 O
. O

Our O
second O
secondary O
outcome O
measure O
was O
the B-Sec
number I-Sec
of I-Sec
ECT I-Sec
treatments I-Sec
given I-Sec
. O

secondary O
treatment O
outcome O
is O
the B-Sec
patient's I-Sec
global I-Sec
perceived I-Sec
effect I-Sec
concerning I-Sec
recovery I-Sec
from I-Sec
the I-Sec
complaint I-Sec
. O

For O
this O
evaluation O
, O
the O
secondary O
outcome O
measure O
, O
i.e. O

Accelerometry O
measures O
PA O
intensity O
over O
a O
period O
of O
six O
days O
, O
with O
the B-Sec
mean I-Sec
over I-Sec
six I-Sec
days I-Sec
used O
as O
the O
secondary O
outcome O
measure O
. O

Between-treatment O
differences O
on O
quality O
of O
life O
scales O
( O
FACT-B O
, O
RSCL O
, O
HADS O
, O
and O
MRS O
) O
at O
the O
secondary O
endpoint O
( O
3 O
weeks O
after O
completion O
of O
chemotherapy O
) O
were O
analysed O
using O
Analysis O
of O
Covariance O
( O
ANCOVA O
) O
( O
with O
pre-randomisation O
values O
as O
covariate O
) O
. O

The O
secondary O
outcome O
was O
self-reported B-Sec
MUVD I-Sec
, O
upon O
ruling O
out O
reproductive O
tract O
infections O
( O
RTIs O
) O
, O
through O
lab O
analysis O
. O

Statistical O
analysis O
Regression O
models O
will O
be O
used O
to O
assess O
the O
effect O
of O
group O
allocation O
on O
the O
secondary O
and O
secondary O
outcome O
measures O
after O
adjusting O
for O
baseline O
values O
. O

Table O
2 O
Comparison O
of O
secondary O
and O
secondary O
outcomes O
in O
both O
treatment O
groups O
. O

The O
secondary O
end O
points O
were O
defined O
as O
10-percentage B-Sec
point I-Sec
difference I-Sec
between I-Sec
arms I-Sec
in I-Sec
increase I-Sec
in I-Sec
the I-Sec
proportion I-Sec
of I-Sec
participants I-Sec
reaching I-Sec
the I-Sec
target I-Sec
level I-Sec
in I-Sec
five I-Sec
global I-Sec
and I-Sec
two I-Sec
patient-group I-Sec
specific I-Sec
clinical I-Sec
parameters I-Sec
at I-Sec
12 I-Sec
months I-Sec
( O
Table O
1 O
) O
. O

This O
trial O
attempts O
to O
enroll O
300 O
patients O
with O
lumbar O
disc O
herniations O
( O
150 O
patients O
in O
both O
treatment O
groups O
, O
including O
8 O
% O
loss O
to O
follow-up O
) O
which O
is O
regarded O
sufficient O
to O
detect O
a O
difference O
of O
20 O
% O
( O
α O
= O
0 O
, O
05 O
and O
a O
power O
of O
90 O
% O
) O
in O
the O
secondary O
outcome O
. O

Analyses O
of O
the O
secondary O
outcomes O
will O
include O
as O
covariates O
any O
patient O
or O
physician O
factors O
that O
differed O
significantly O
between O
study O
arms O
. O

All O
study O
personnel O
directly O
or O
indirectly O
involved O
in O
assessments O
of O
secondary O
or O
secondary O
outcomes O
were O
blinded O
to O
treatment O
assignment O
for O
the O
duration O
of O
the O
study O
. O

The O
secondary O
outcomes O
of O
this O
trial O
will O
assist O
clinicians O
in O
the O
development O
of O
effective O
and O
alternative O
treatment O
methods O
post O
proximal O
femoral O
fracture O
surgery O
which O
may O
ultimately O
result O
in O
a O
reduction O
in O
systemic O
inflammation O
, O
loss O
of O
weight O
and O
lean O
muscle O
and O
improvements O
in O
nutritional O
status O
, O
mobility O
, O
independence O
and O
quality O
of O
life O
among O
elderly O
patients O
. O

In O
order O
to O
allow O
for O
a O
90 O
% O
follow-up O
rate O
for O
the O
secondary O
outcome O
measure O
of O
antibiotic B-Sec
prescribing I-Sec
we O
intend O
to O
recruit O
400 O
patients O
( O
20 O
per O
practice O
and O
100 O
in O
each O
cell O
) O
. O

Sample O
Size O
and O
Power O
Calculation O
The O
sample O
size O
calculation O
was O
approximated O
with O
a O
3x3-factorial O
ANOVA-approach O
based O
on O
the O
secondary O
outcome O
and O
was O
done O
with O
the O
software O
" O
gpower O
3.1 O
" O
63 O
64 O
. O

Outcome O
measures O
The O
secondary O
outcome O
measure O
for O
self-perceived O
health O
was O
the B-Sec
generic I-Sec
instrument I-Sec
EuroQol-5D I-Sec
( I-Sec
EQ5D I-Sec
) I-Sec
17 O
18 O
. O

The O
secondary O
outcome O
will O
be O
walking B-Sec
, I-Sec
measured I-Sec
by I-Sec
pedometer I-Sec
. O

Endpoints O
The O
secondary O
trial O
endpoint O
will O
be O
tumor B-Sec
recurrence I-Sec
diagnosed I-Sec
by I-Sec
enhanced I-Sec
CT I-Sec
scan I-Sec
or I-Sec
serum I-Sec
alpha-fetoprotein I-Sec
level I-Sec
. O

Outcome O
Measures O
The O
two O
secondary O
outcomes O
of O
this O
trial O
were O
neonatal B-Sec
mortality I-Sec
and O
omphalitis B-Sec
among I-Sec
live I-Sec
born I-Sec
enrolled I-Sec
infants I-Sec
. O

secondary O
outcome O
The O
secondary O
outcome O
of O
the O
trial O
is O
represented O
by O
the B-Sec
clinical I-Sec
effectiveness I-Sec
of I-Sec
the I-Sec
SMATH I-Sec
® I-Sec
system I-Sec
versus I-Sec
sham I-Sec
therapy I-Sec
after I-Sec
4 I-Sec
weeks I-Sec
of I-Sec
treatment I-Sec
in I-Sec
patients I-Sec
with I-Sec
sub-acute I-Sec
and I-Sec
chronic I-Sec
non-specific I-Sec
LBP I-Sec
, I-Sec
determined I-Sec
by I-Sec
evaluating I-Sec
self I-Sec
perceived I-Sec
physical I-Sec
function I-Sec
with I-Sec
RMDQ I-Sec
scores I-Sec
. O

Outcomes O
The O
secondary O
study O
outcomes O
will O
be O
changes B-Sec
, I-Sec
from I-Sec
baseline I-Sec
measures I-Sec
, I-Sec
in I-Sec
serum I-Sec
cholesterol I-Sec
and O
systolic B-Sec
blood I-Sec
pressure I-Sec
and O
self-reported B-Sec
current I-Sec
use I-Sec
of I-Sec
aspirin I-Sec
, I-Sec
a I-Sec
statin I-Sec
and I-Sec
at I-Sec
least I-Sec
two I-Sec
blood I-Sec
pressure I-Sec
lowering I-Sec
drugs I-Sec
. O

In O
summary O
, O
multi-level O
regression O
modelling O
was O
used O
to O
evaluate O
differences O
in O
our O
secondary O
outcome O
, O
10-year B-Sec
CVD I-Sec
risk I-Sec
, O
between O
groups O
and O
over O
time O
, O
accounting O
for O
clustering O
at O
the O
practice O
level O
. O

The O
difference O
in O
recovery O
rates O
between O
groups O
in O
these O
trials O
ranged O
from O
27 O
% O
to O
55 O
% O
, O
with O
66 O
% O
to O
85 O
% O
of O
mothers O
in O
the O
intervention O
group O
classified O
as O
non-depressed O
at O
the O
secondary O
outcome O
time O
period O
. O

Outcome O
measures O
The O
secondary O
outcome O
is O
the B-Sec
child's I-Sec
psychosocial I-Sec
problems I-Sec
measured I-Sec
by I-Sec
the I-Sec
SDQ I-Sec
( I-Sec
parent I-Sec
and I-Sec
teacher I-Sec
versions I-Sec
) I-Sec
and I-Sec
the I-Sec
Eyberg I-Sec
Child I-Sec
Behaviour I-Sec
Inventory I-Sec
( I-Sec
ECBI I-Sec
) I-Sec
. O

Analysis O
The O
secondary O
outcome O
of O
interest O
was O
a B-Sec
change I-Sec
in I-Sec
the I-Sec
serum I-Sec
ALT I-Sec
activity I-Sec
or O
the B-Sec
INR I-Sec
. O

Type O
of O
economic O
evaluation O
The O
first O
planned O
analysis O
is O
a O
cost O
effectiveness O
analysis O
( O
CEA O
) O
with O
increase B-Sec
in I-Sec
survival I-Sec
without I-Sec
severe I-Sec
disability I-Sec
at I-Sec
six I-Sec
months I-Sec
( I-Sec
the I-Sec
secondary I-Sec
outcome I-Sec
in I-Sec
the I-Sec
CESAR I-Sec
trial I-Sec
) I-Sec
as O
the O
secondary O
outcome O
measure O
. O

Measurement O
secondary O
outcome O
for O
intervention O
trial O
The O
secondary O
outcome O
for O
the O
intervention O
is O
the B-Sec
percentage I-Sec
of I-Sec
days I-Sec
on I-Sec
which I-Sec
the I-Sec
prescribed I-Sec
dose I-Sec
of I-Sec
secondary I-Sec
hypoglycaemic I-Sec
medication I-Sec
is I-Sec
taken I-Sec
as I-Sec
prescribed I-Sec
, O
measured B-Sec
with I-Sec
the I-Sec
TrackCap I-Sec
electronic I-Sec
medication I-Sec
monitor I-Sec
over I-Sec
a I-Sec
12-week I-Sec
period I-Sec
from I-Sec
eight I-Sec
to I-Sec
twenty I-Sec
weeks I-Sec
. O

Pre-specified O
secondary O
outcomes O
included O
reduction B-Sec
in I-Sec
systolic I-Sec
blood I-Sec
pressure I-Sec
, O
total B-Sec
cholesterol I-Sec
and O
estimated B-Sec
10-year I-Sec
CVD I-Sec
risk I-Sec
. O

Data O
collection O
and O
outcome O
Data O
were O
collected O
both O
on O
cluster O
level O
as O
well O
as O
on O
individual O
level O
on O
three O
secondary O
domains O
; O
the O
intervention O
process O
( O
cluster O
level O
) O
, O
perinatal O
healthcare O
process O
indicators O
( O
cluster O
and O
individual O
level O
) O
, O
and O
the O
secondary O
outcome O
of O
the O
intervention O
, O
being O
neonatal B-Sec
mortality I-Sec
( I-Sec
individual I-Sec
level I-Sec
) I-Sec
( O
Table O
1 O
) O
. O

secondary O
endpoint O
The O
secondary O
endpoint O
is O
a B-Sec
composite I-Sec
of I-Sec
mortality I-Sec
or I-Sec
infections I-Sec
( O
i.e. O

Dexa-scan O
During O
the O
baseline O
and O
secondary O
assessment O
, O
a O
Dual O
Energy O
X-ray O
Absorptiometry O
( O
DEXA O
) O
scan O
will O
be O
used O
to O
make O
scans O
of O
the O
pelvis O
. O

During O
short-term O
assessment O
the O
following O
secondary O
outcome O
measurements O
were O
recorded O
: O
1. O

C O
. O
The O
composite O
secondary O
end O
point O
of O
death B-Sec
from I-Sec
any I-Sec
cause I-Sec
, I-Sec
recurrent I-Sec
infarction I-Sec
and I-Sec
unstable I-Sec
angina I-Sec
within I-Sec
one I-Sec
year I-Sec
( I-Sec
per I-Sec
protocol I-Sec
and I-Sec
adjusted I-Sec
for I-Sec
2 I-Sec
days I-Sec
PCI I-Sec
delay I-Sec
) I-Sec
. O

The O
secondary O
outcomes O
of O
the O
interventions O
in O
the O
Well O
London O
project O
are O
: O
- B-Sec
For I-Sec
healthy I-Sec
eating I-Sec
a I-Sec
50 I-Sec
% I-Sec
increase I-Sec
in I-Sec
the I-Sec
proportion I-Sec
of I-Sec
adults I-Sec
( I-Sec
base I-Sec
estimate I-Sec
27 I-Sec
% I-Sec
) I-Sec
and O
a B-Sec
30 I-Sec
% I-Sec
increase I-Sec
in I-Sec
the I-Sec
proportion I-Sec
of I-Sec
children I-Sec
( I-Sec
base I-Sec
estimate I-Sec
47 I-Sec
% I-Sec
) I-Sec
who I-Sec
eat I-Sec
five I-Sec
or I-Sec
more I-Sec
pieces I-Sec
of I-Sec
fruit I-Sec
and I-Sec
vegetables I-Sec
a I-Sec
day I-Sec
. O

The O
secondary O
outcome O
assessed O
at O
12 O
months O
is O
change B-Sec
in I-Sec
electrophysiological I-Sec
indices I-Sec
of I-Sec
peripheral I-Sec
and I-Sec
central I-Sec
neurosensory I-Sec
responses I-Sec
required I-Sec
for I-Sec
mobility I-Sec
and I-Sec
sensory I-Sec
function I-Sec
. O

Outcome O
Measures O
The O
goal O
of O
rehabilitation O
is O
to O
increase O
function O
and O
for O
this O
reason O
, O
we O
selected O
the B-Sec
shortened I-Sec
version I-Sec
of I-Sec
the I-Sec
Chedoke I-Sec
Arm I-Sec
& I-Sec
Hand I-Sec
Activity I-Sec
Inventory I-Sec
( I-Sec
CAHAI-7 I-Sec
) I-Sec
as O
the O
secondary O
outcome O
measure O
. O

Sample O
size O
calculation O
Sample O
size O
calculations O
are O
based O
on O
the O
expected O
effect O
of O
the O
intervention O
on O
the O
secondary O
outcome O
which O
is O
the B-Sec
adherence I-Sec
. O

However O
, O
as O
the O
number O
of O
patients O
injecting O
opioids O
at O
recruitment O
was O
low O
, O
the O
secondary O
outcome O
was O
changed O
as O
‘the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
abstinent I-Sec
from I-Sec
of I-Sec
street I-Sec
opioids I-Sec
after I-Sec
1 I-Sec
year’ I-Sec
, O
and O
the O
dimension O
of O
the O
study O
was O
re-computed O
. O

secondary O
outcome O
measure O
The B-Sec
severity I-Sec
of I-Sec
anxiety I-Sec
symptoms I-Sec
is O
measured O
with O
the O
Beck O
Anxiety O
Inventory O
( O
BAI O
) O
60 O
. O

Freeman O
and O
colleagues O
recently O
conducted O
two O
clinical O
trials O
41 O
42 O
of O
omega-3 O
fatty O
acid O
supplementation O
and O
perinatal O
depression O
, O
using O
the O
EPDS O
as O
their O
secondary O
measure O
of O
depressive O
symptomatology O
and O
reported O
a O
51 O
% O
and O
41 O
% O
reduction O
in O
EPDS O
score O
over O
an O
8 O
week O
study O
period O
. O

The O
prevalence O
of O
hyperglycaemia O
was O
based O
on O
initial O
PICU O
glucose O
measurement O
, O
highest O
value O
within O
24 O
hours O
, O
and O
highest O
value O
measured O
during O
PICU O
stay O
up O
to O
10 O
days O
after O
the O
first O
measurement O
. O

Sample O
size O
estimation O
The O
secondary O
outcome O
is O
re-consultation B-Sec
for I-Sec
the I-Sec
same I-Sec
illness I-Sec
episode I-Sec
. O

Using O
self-selected B-Sec
gait I-Sec
speed I-Sec
as O
the O
secondary O
outcome O
, O
this O
sample O
size O
has O
been O
estimated O
based O
on O
a O
range O
of O
change O
scores O
and O
standard O
deviation O
values O
reported O
in O
the O
literature O
. O

Outcome O
Measures O
The O
secondary O
outcome O
measure O
will O
be O
time B-Sec
to I-Sec
the I-Sec
first I-Sec
episode I-Sec
of I-Sec
CRB I-Sec
. O

For O
the O
secondary O
outcome O
only O
, O
the O
secondary O
and O
secondary O
analyses O
will O
be O
conducted O
( O
i O
) O
for O
all O
participants O
completing O
the O
7-DAY O
PAR O
and O
( O
ii O
) O
with O
the O
addition O
of O
multiply O
imputed O
values O
of O
the O
secondary O
outcome O
for O
those O
who O
did O
not O
complete O
the O
7-DAY O
PAR O
but O
who O
did O
complete O
either O
the O
Baecke O
or O
GPPAQ O
instruments O
at O
12-month O
follow-up O
. O

The O
intended O
secondary O
outcome O
analysis O
, O
time B-Sec
to I-Sec
catheter I-Sec
association I-Sec
blood I-Sec
stream I-Sec
infection I-Sec
, O
definite O
or O
probable O
is O
shown O
in O
Figure O
1 O
. O

The O
secondary O
end O
point O
was O
recurrence B-Sec
and O
the O
secondary O
end O
points O
were O
time B-Sec
off I-Sec
from I-Sec
work I-Sec
, O
postoperative B-Sec
pain I-Sec
, O
scrotal B-Sec
swelling I-Sec
and O
wound B-Sec
infections I-Sec
. O

The O
secondary O
outcomes O
will O
be O
sleep B-Sec
quality I-Sec
( I-Sec
self-report I-Sec
and I-Sec
objective I-Sec
measurement I-Sec
) I-Sec
, O
and O
self-reported B-Sec
functional I-Sec
disability I-Sec
, O
pain B-Sec
, O
quality B-Sec
of I-Sec
life I-Sec
, O
fear B-Sec
avoidance I-Sec
, O
anxiety B-Sec
and O
depression B-Sec
, O
physical B-Sec
activity I-Sec
, O
and O
patient B-Sec
satisfaction I-Sec
. O

In O
addition O
to O
practice O
level O
, O
patient O
level O
data O
will O
also O
be O
collected O
, O
and O
so O
the O
analysis O
is O
divided O
into O
practice O
level O
and O
patient O
level O
with O
the O
patient B-Sec
level I-Sec
analysis I-Sec
as O
the O
secondary O
outcome O
. O

The O
secondary O
outcomes O
to O
assess O
the O
effectiveness O
would O
be O
point B-Sec
abstinence I-Sec
at I-Sec
4 I-Sec
weeks I-Sec
and O
continuous B-Sec
abstinence I-Sec
up I-Sec
to I-Sec
6 I-Sec
months I-Sec
. O

To O
explore O
any O
longer O
term O
effects O
, O
a O
repeated O
measures O
mixed O
model O
analysis O
of O
the O
secondary O
and O
secondary O
outcomes O
will O
be O
undertaken O
, O
comparing O
groups O
across O
the O
6 O
and O
12 O
month O
time O
points O
. O

secondary O
outcome O
measure O
Body B-Sec
weight I-Sec
and O
body B-Sec
composition I-Sec
Patients O
will O
be O
weighed O
to O
the O
nearest O
0.05 O
kg O
and O
percentage O
body O
fat O
estimated O
using O
bio-electrical O
impedance O
( O
Bodystat O
1500 O
, O
Bodystat O
Ltd. O
, O
UK O
) O
. O

The O
secondary O
outcome O
of O
the O
WEAN O
study O
is O
to B-Sec
evaluate I-Sec
compliance I-Sec
with I-Sec
the I-Sec
proposed I-Sec
weaning I-Sec
and I-Sec
sedation I-Sec
protocols I-Sec
. O

The O
secondary O
outcome O
was O
self-rated B-Sec
overall I-Sec
effect I-Sec
of I-Sec
treatment I-Sec
, I-Sec
measured I-Sec
once I-Sec
; I-Sec
on I-Sec
the I-Sec
day I-Sec
treatment I-Sec
was I-Sec
completed I-Sec
. O

Data O
Collection O
The O
secondary O
outcome O
was O
the B-Sec
disclosure I-Sec
rate I-Sec
of I-Sec
abuse I-Sec
by I-Sec
women I-Sec
who I-Sec
were I-Sec
identified I-Sec
by I-Sec
the I-Sec
VAWS I-Sec
tool I-Sec
during I-Sec
the I-Sec
three I-Sec
screening I-Sec
sessions I-Sec
compared I-Sec
to I-Sec
those I-Sec
in I-Sec
the I-Sec
interview I-Sec
group I-Sec
. O

These O
analyses O
will O
be O
repeated O
but O
using O
the O
occurrence O
of O
our O
secondary O
outcome O
within O
14 O
days O
of O
randomisation O
( O
instead O
of O
30 O
days O
) O
. O

Post-intervention O
assessments O
are O
undertaken O
within O
two O
weeks O
of O
program O
completion O
and O
the O
secondary O
assessment O
is O
completed O
26 O
weeks O
after O
the O
baseline O
assessment O
( O
see O
Figure O
1 O
) O
. O

The O
secondary O
effectiveness O
outcome O
will O
be O
quality B-Sec
adjusted I-Sec
life I-Sec
years I-Sec
( I-Sec
QALYs I-Sec
) I-Sec
measured I-Sec
over I-Sec
a I-Sec
time I-Sec
horizon I-Sec
of I-Sec
1 I-Sec
year I-Sec
based I-Sec
on I-Sec
EQ-5D I-Sec
scores I-Sec
collected I-Sec
during I-Sec
the I-Sec
trial I-Sec
; O
secondary O
analysis O
will O
examine O
the B-Sec
IWQoL I-Sec
to O
inform O
non O
preference-based O
cost-effectiveness O
analyses O
. O

secondary O
outcome O
measurements O
Physical B-Sec
activity I-Sec
The O
volume O
( O
frequency O
, O
intensity O
, O
duration O
) O
of O
leisure O
time O
and O
way O
to O
work O
physical O
activity O
are O
assessed O
by O
a O
self-administered O
questionnaire O
based O
on O
International O
Physical O
Activity O
Questionnaire O
( O
IPAQ O
) O
. O

secondary O
outcomes O
measures O
will O
be O
: O
1 B-Sec
) I-Sec
the I-Sec
percentage I-Sec
of I-Sec
participants I-Sec
who I-Sec
drink I-Sec
within I-Sec
the I-Sec
normative I-Sec
limits I-Sec
of I-Sec
the I-Sec
Dutch I-Sec
National I-Sec
Health I-Sec
Council I-Sec
for I-Sec
low-risk I-Sec
drinking I-Sec
, O
2 B-Sec
) I-Sec
reductions I-Sec
in I-Sec
mean I-Sec
weekly I-Sec
alcohol I-Sec
consumption I-Sec
, O
and O
3 B-Sec
) I-Sec
frequency I-Sec
of I-Sec
binge I-Sec
drinking I-Sec
. O

Modulation O
of O
key O
biochemical O
parameters O
of O
fat O
metabolism O
Reduction O
in O
serum O
glucose O
( O
17.0 O
% O
) O
, O
triglycerides O
( O
16.43 O
% O
) O
and O
LDL O
/ O
HDL O
ratio O
( O
12.6 O
% O
) O
was O
observed O
in O
LI85008F O
treated O
group O
compared O
to O
baseline O
( O
Table O
4 O
) O
. O

The O
secondary O
end-point O
was O
disease-free B-Sec
survival I-Sec
( I-Sec
DFS I-Sec
) I-Sec
at I-Sec
three I-Sec
years I-Sec
. O

All O
secondary O
and O
secondary O
outcomes O
of O
the O
effect O
evaluation O
were O
assessed O
at O
baseline O
, O
and O
at O
5 O
and O
17 O
week O
follow-up O
, O
except O
for O
the O
outcomes O
regarding O
the O
use O
of O
the O
identification O
cane O
. O

The O
secondary O
end O
point O
was O
sustained B-Sec
remission I-Sec
, I-Sec
defined I-Sec
as I-Sec
freedom I-Sec
from I-Sec
relapse I-Sec
at I-Sec
the I-Sec
6 I-Sec
months I-Sec
follow-up I-Sec
visit I-Sec
. O

But O
the O
smaller O
than O
planned O
study O
sample O
could O
have O
influenced O
the O
results O
of O
the O
other O
outcomes O
who O
were O
in O
line O
with O
the O
secondary O
outcome O
but O
failed O
to O
reach O
statistical O
significance O
. O

Study O
outcomes O
secondary O
outcomes O
secondary O
outcomes O
include O
emergency B-Sec
health I-Sec
service I-Sec
use I-Sec
( I-Sec
ie I-Sec
unplanned I-Sec
readmissions I-Sec
, I-Sec
time I-Sec
to I-Sec
first I-Sec
unplanned I-Sec
readmission I-Sec
, I-Sec
unplanned I-Sec
Emergency I-Sec
Department I-Sec
, I-Sec
General I-Sec
Practitioner I-Sec
and I-Sec
other I-Sec
health I-Sec
service I-Sec
use I-Sec
) I-Sec
, O
and O
functional B-Sec
ability I-Sec
( I-Sec
Instrumental I-Sec
Activities I-Sec
of I-Sec
Daily I-Sec
Living I-Sec
23 I-Sec
, I-Sec
Index I-Sec
of I-Sec
Activities I-Sec
of I-Sec
Daily I-Sec
Living I-Sec
24 I-Sec
, I-Sec
Walking I-Sec
Impairment I-Sec
Questionnaire I-Sec
25 I-Sec
) I-Sec
. O

Statistical O
analysis O
Baseline O
characteristics O
of O
the O
two O
intervention O
groups O
and O
control O
group O
with O
regard O
to O
the O
most O
important O
prognostic O
indicators O
and O
secondary O
outcome O
measures O
will O
be O
compared O
to O
assess O
the O
adequacy O
of O
the O
randomization O
. O

The O
secondary O
endpoint O
of O
the O
study O
was O
the B-Sec
change I-Sec
from I-Sec
baseline I-Sec
to I-Sec
52 I-Sec
weeks I-Sec
of I-Sec
carotid I-Sec
arterial I-Sec
wall I-Sec
volume I-Sec
, I-Sec
reflecting I-Sec
plaque I-Sec
burden I-Sec
, I-Sec
as I-Sec
measured I-Sec
by I-Sec
carotid I-Sec
cardiovascular I-Sec
magnetic I-Sec
resonance I-Sec
. O

secondary O
and O
secondary O
endpoints O
secondary O
endpoint O
Binary B-Sec
functional I-Sec
outcome I-Sec
6 I-Sec
months I-Sec
( I-Sec
± I-Sec
14 I-Sec
days I-Sec
) I-Sec
after I-Sec
randomization I-Sec
( I-Sec
measured I-Sec
by I-Sec
the I-Sec
modified I-Sec
Rankin I-Sec
scale I-Sec
, I-Sec
a I-Sec
seven-point-scale I-Sec
from I-Sec
0 I-Sec
to I-Sec
6 I-Sec
points I-Sec
) I-Sec
. O

Study O
sample O
Sample O
size O
calculation O
in O
a O
cRCT O
was O
based O
on O
the O
expected O
improvement O
in O
the O
secondary O
outcome O
variables O
12 O
17 O
18 O
20 O
22 O
. O

We O
also O
discuss O
the O
advantages O
and O
disadvantages O
of O
testing O
the O
psychometric O
properties O
of O
the O
secondary O
outcome O
measures O
concurrently O
with O
the O
trial O
. O

Analysis O
secondary O
Outcome O
Measures O
• O
Control O
and O
intervention O
arms O
: O
Cumulative B-Sec
incident I-Sec
≥ I-Sec
CIN3 I-Sec
detected I-Sec
up I-Sec
to I-Sec
and I-Sec
including I-Sec
four I-Sec
years I-Sec
in I-Sec
both I-Sec
the I-Sec
control I-Sec
arm I-Sec
and I-Sec
the I-Sec
intervention I-Sec
arm I-Sec
• O
Control O
and O
safety O
check O
arms O
: O
Incident B-Sec
≥ I-Sec
CIN2 I-Sec
detected I-Sec
at I-Sec
two I-Sec
years I-Sec
. O

The O
secondary O
endpoint O
was O
the B-Sec
reduction I-Sec
in I-Sec
systolic I-Sec
blood I-Sec
pressure I-Sec
defined I-Sec
as I-Sec
the I-Sec
average I-Sec
of I-Sec
3 I-Sec
office I-Sec
readings I-Sec
with I-Sec
the I-Sec
patient I-Sec
in I-Sec
the I-Sec
sitting I-Sec
position I-Sec
. O

The O
following O
four O
secondary O
efficacy O
parameters O
were O
used O
: O
Early B-Sec
Treatment I-Sec
Failure I-Sec
( I-Sec
ETF I-Sec
) I-Sec
; O
Late B-Sec
Clinical I-Sec
Failure I-Sec
( I-Sec
LCF I-Sec
) I-Sec
; O
Late B-Sec
Parasitological I-Sec
Failure I-Sec
( I-Sec
LPF I-Sec
) I-Sec
; O
Adequate B-Sec
Clinical I-Sec
and I-Sec
Parasitological I-Sec
Response I-Sec
( I-Sec
ACPR I-Sec
) I-Sec
18 I-Sec
. O

Furthermore O
, O
the O
secondary O
and O
secondary O
endpoints O
are O
to O
be O
analyzed O
in O
pre-specified O
subgroups O
, O
which O
are O
defined O
as O
: O
1. O

secondary O
outcomes O
The B-Sec
CORE-OM I-Sec
23 I-Sec
is O
a O
34-item O
scale O
covering O
four O
subscales O
of O
subjective O
well-being O
. O

The O
secondary O
endpoint O
is O
the B-Sec
peak I-Sec
transaminase I-Sec
serum I-Sec
level I-Sec
( I-Sec
AST I-Sec
) I-Sec
during I-Sec
the I-Sec
first I-Sec
three I-Sec
days I-Sec
after I-Sec
transplantation I-Sec
as I-Sec
a I-Sec
surrogate I-Sec
readout I-Sec
for I-Sec
parenchymal I-Sec
liver I-Sec
injury I-Sec
. O

The O
two O
secondary O
outcome O
measures O
are O
the B-Sec
difference I-Sec
in I-Sec
occurrence I-Sec
of I-Sec
DRPs I-Sec
between I-Sec
intervention I-Sec
and I-Sec
control I-Sec
group I-Sec
and O
adherence B-Sec
with I-Sec
drug I-Sec
use I-Sec
. O

Regarding O
the O
secondary O
endpoint O
of O
neovessel O
formation O
at O
weeks O
10 O
and O
14 O
, O
all O
angiograms O
were O
reviewed O
in O
real O
time O
, O
with O
decision O
for O
further O
treatment O
based O
on O
real O
time O
assessments O
. O

: O
not O
significant O
; O
EASI-severity O
> O
= O
4 O
means O
that O
treatment O
is O
needed O
46 O
Adherence O
to O
treatment O
The O
secondary O
outcome O
measure O
for O
this O
study O
was O
treatment B-Sec
adherence I-Sec
at I-Sec
and I-Sec
beyond I-Sec
eight I-Sec
sessions I-Sec
. O

The O
secondary O
composite O
outcome O
of O
re-operation O
provides O
a O
patient-important O
estimate O
of O
effect O
superior O
to O
previously O
described O
measures O
such O
as O
radiographic O
fracture O
healing O
, O
delayed O
unions O
, O
and O
nonunions O
. O

The O
secondary O
outcome O
( O
difference B-Sec
on I-Sec
endothelium-dependent I-Sec
brachial I-Sec
artery I-Sec
FMD I-Sec
at I-Sec
baseline I-Sec
and I-Sec
three I-Sec
months I-Sec
after I-Sec
randomization I-Sec
) O
and O
the O
secondary O
outcome O
( O
hs-CRP B-Sec
, O
glucose B-Sec
, O
blood B-Sec
lipid I-Sec
profile I-Sec
, O
and O
HOMA B-Sec
index I-Sec
) O
will O
be O
analyzed O
using O
repeated O
measures O
ANOVA O
for O
continuous O
variables O
. O

Sample O
size O
calculation O
and O
statistical O
analysis O
The O
secondary O
endpoint O
for O
the O
study O
was O
the B-Sec
QTcF I-Sec
interval I-Sec
( I-Sec
QT I-Sec
interval I-Sec
corrected I-Sec
for I-Sec
heart I-Sec
rate I-Sec
using I-Sec
Fridericia's I-Sec
formula I-Sec
, I-Sec
QT I-Sec
/ I-Sec
RR I-Sec
0.33 I-Sec
) I-Sec
. O

The O
secondary O
outcome O
was O
morning B-Sec
peak I-Sec
expiratory I-Sec
flow I-Sec
after I-Sec
4 I-Sec
weeks I-Sec
treatment I-Sec
. O

The O
secondary O
outcome O
measure O
of O
this O
study O
is O
long B-Sec
term I-Sec
adherence I-Sec
to I-Sec
physical I-Sec
activity I-Sec
. O

Self-rating O
measures O
were O
used O
as O
a O
secondary O
outcome O
in O
many O
of O
the O
large O
collaborative O
care O
studies O
22 O
42 O
43 O
and O
have O
been O
shown O
to O
provide O
valid O
ratings O
in O
non-psychotic O
depressed O
outpatients O
44 O
. O

The O
secondary O
outcomes O
were O
back-related B-Sec
functional I-Sec
status I-Sec
and O
symptom B-Sec
bothersomeness I-Sec
. O

secondary O
end O
point O
will O
be O
the B-Sec
conversion I-Sec
of I-Sec
AF I-Sec
to I-Sec
sinus I-Sec
rhythm I-Sec
confirmed I-Sec
in I-Sec
an I-Sec
electrocardiogram I-Sec
( I-Sec
ECG I-Sec
) I-Sec
during I-Sec
the I-Sec
observation I-Sec
period I-Sec
. O

We O
chose O
GHbA1c B-Sec
as O
the O
secondary O
metabolic O
outcome O
measure O
because O
it O
is O
more O
reliable O
than O
the O
fasting O
glucose O
value O
, O
as O
it O
reflects O
the O
glycemic O
control O
during O
a O
8 O
– O
12 O
weeks O
time O
period O
. O

Figure O
3 O
POC O
Component O
: O
Key O
Efficacy O
Endpoints O
( O
A O
) O
Effect O
of O
maraviroc O
on O
ACR20 O
response O
rate O
over O
time O
POC O
Component O
: O
Key O
Efficacy O
Endpoints O
( O
A O
) O
Effect O
of O
maraviroc O
on O
ACR20 O
response O
rate O
over O
time O
. O

Outcome O
measures O
secondary O
outcome O
measure O
The O
secondary O
outcome O
measure O
is O
an B-Sec
uneventful I-Sec
decline I-Sec
of I-Sec
serum I-Sec
hCG I-Sec
to I-Sec
an I-Sec
undetectable I-Sec
level I-Sec
( I-Sec
< I-Sec
2 I-Sec
IU I-Sec
/ I-Sec
l I-Sec
) I-Sec
by O
the O
initial O
intervention O
strategy O
, O
ie O
expectant O
management O
or O
a O
single O
dose O
systemic O
MTX O
. O

secondary O
outcome O
measures O
1. O

The O
secondary O
outcome O
measure O
of O
remission B-Sec
of I-Sec
major I-Sec
depressive I-Sec
disorder I-Sec
at I-Sec
each I-Sec
and I-Sec
all I-Sec
of I-Sec
24 I-Sec
, I-Sec
36 I-Sec
and I-Sec
48 I-Sec
weeks I-Sec
will O
be O
analysed O
in O
the O
same O
way O
as O
the O
secondary O
outcome O
measure O
. O

The O
latter O
was O
our O
secondary O
dependent O
variable O
. O

Data O
handlers O
were O
not O
blinded O
to O
the O
intervention O
status O
of O
responders O
, O
but O
this O
was O
not O
considered O
to O
be O
a O
source O
of O
bias O
as O
response B-Sec
rates I-Sec
were O
the O
secondary O
outcome O
. O

secondary O
outcomes O
include O
objectively B-Sec
measured I-Sec
physical I-Sec
activity I-Sec
, O
fruit B-Sec
and I-Sec
vegetable I-Sec
intake I-Sec
, O
medication B-Sec
adherence I-Sec
, O
and O
smoking B-Sec
status I-Sec
. O

Results O
Postprandial O
metabolic O
parameters O
No O
significant O
differences O
were O
observed O
in O
any O
of O
the O
iAUCs O
of O
the O
secondary O
metabolic O
variables O
( O
glucose O
, O
insulin O
, O
non-sterified O
fatty O
acids O
, O
serum O
triglycerides O
and O
high O
density O
lipoprotein O
cholesterol O
) O
after O
intake O
of O
phenol-rich O
virgin O
olive O
oil O
compared O
with O
olive O
oil O
with O
lower O
content O
of O
these O
compounds O
( O
Table O
1 O
) O
. O

For O
the O
secondary O
analysis O
, O
the O
three O
hypotheses O
of O
the O
secondary O
endpoint O
are O
tested O
at O
a O
nominal O
significance O
level O
of O
α2 O
= O
0.045 O
in O
the O
hierarchical O
manner O
described O
above O
. O

secondary O
outcome O
measures O
will O
be O
: O
1 B-Sec
) I-Sec
physical I-Sec
activity I-Sec
level I-Sec
, I-Sec
which I-Sec
will I-Sec
be I-Sec
measured I-Sec
objectively I-Sec
with I-Sec
an I-Sec
accelerometry-based I-Sec
activity I-Sec
monitor I-Sec
during I-Sec
72 I-Sec
h I-Sec
and I-Sec
subjectively I-Sec
with I-Sec
the I-Sec
Physical I-Sec
Activity I-Sec
Scale I-Sec
for I-Sec
Individuals I-Sec
with I-Sec
Physical I-Sec
Disabilities I-Sec
; O
2 B-Sec
) I-Sec
aerobic I-Sec
fitness I-Sec
, I-Sec
which I-Sec
will I-Sec
be I-Sec
measured I-Sec
with I-Sec
a I-Sec
maximal I-Sec
ramp I-Sec
test I-Sec
on I-Sec
a I-Sec
bicycle I-Sec
or I-Sec
armcrank I-Sec
ergometer I-Sec
and I-Sec
a I-Sec
6-minute I-Sec
walking I-Sec
or I-Sec
wheelchair I-Sec
test I-Sec
; O
3 B-Sec
) I-Sec
neuromuscular I-Sec
fitness I-Sec
, I-Sec
which I-Sec
will I-Sec
be I-Sec
measured I-Sec
with I-Sec
handheld I-Sec
dynamometry I-Sec
; O
and O
4 B-Sec
body I-Sec
composition I-Sec
, I-Sec
which I-Sec
will I-Sec
be I-Sec
determined I-Sec
by I-Sec
measuring I-Sec
body I-Sec
mass I-Sec
, I-Sec
height I-Sec
, I-Sec
waist I-Sec
circumference I-Sec
, I-Sec
fat I-Sec
mass I-Sec
and I-Sec
lipid I-Sec
profile I-Sec
. O

The B-Sec
safety I-Sec
and O
efficacy B-Sec
of I-Sec
this I-Sec
drug I-Sec
are O
analyzed O
as O
secondary O
endpoints O
. O

Moreover O
the O
study O
seeks O
to O
identify O
individual O
and O
social O
factors O
that O
influence O
secondary O
and O
secondary O
outcomes O
. O

The O
second O
secondary O
outcome O
is O
pain B-Sec
from I-Sec
the I-Sec
donor I-Sec
site I-Sec
area I-Sec
. O

We O
used O
these O
findings O
as O
an O
estimate O
of O
the O
secondary O
outcome O
for O
the O
power O
calculation O
, O
Women O
and O
clinicians O
did O
not O
consider O
the O
ultrasound O
assessment O
to O
be O
intrusive O
. O

Outcomes O
The O
secondary O
outcomes O
were O
body B-Sec
weight I-Sec
( I-Sec
kg I-Sec
) I-Sec
and O
waist B-Sec
circumference I-Sec
( I-Sec
cm I-Sec
) I-Sec
. O

The O
secondary O
outcome O
variable O
is O
defined O
as O
the B-Sec
length I-Sec
of I-Sec
time I-Sec
patients I-Sec
remain I-Sec
in I-Sec
the I-Sec
study I-Sec
. O

secondary O
outcome O
measure O
is O
the B-Sec
children’s I-Sec
body I-Sec
composition I-Sec
, I-Sec
operationalized I-Sec
as I-Sec
BMI I-Sec
z-score I-Sec
, O
waist B-Sec
circumference I-Sec
, O
and O
fat B-Sec
mass I-Sec
( I-Sec
biceps I-Sec
and I-Sec
triceps I-Sec
skinfolds I-Sec
) I-Sec
. O

Outcomes O
The O
secondary O
outcome O
was O
the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
in I-Sec
each I-Sec
group I-Sec
with I-Sec
cardiovascular I-Sec
risk I-Sec
≥ I-Sec
10 I-Sec
% I-Sec
over I-Sec
five-years I-Sec
at I-Sec
12 I-Sec
months I-Sec
follow I-Sec
up I-Sec
. O

We O
conclude O
from O
our O
trial O
that O
overall O
, O
gabapentin O
did O
not O
relieve O
pain O
as O
compared O
to O
placebo O
on O
pain B-Sec
visual I-Sec
analogue I-Sec
scores I-Sec
, O
our O
secondary O
outcome O
measure O
. O

The O
impact O
of O
the O
intensive O
implementation O
program O
on O
the O
implementation O
process O
and O
on O
the O
secondary O
outcomes O
was O
examined O
in O
a O
random O
coefficient O
logistic O
regression O
model O
, O
which O
took O
into O
account O
that O
patients O
were O
grouped O
within O
pharmacy O
clusters O
. O

The O
subjective O
measurement O
of O
the O
secondary O
outcome O
in O
our O
study O
( O
patient B-Sec
reported I-Sec
pain I-Sec
) O
was O
recognised O
to O
be O
prone O
to O
bias O
in O
an O
open O
trial O
design O
( O
ie O
, O
when O
people O
would O
know O
which O
intervention O
they O
had O
been O
randomised O
to O
) O
26 O
, O
and O
it O
was O
considered O
impossible O
to O
maintain O
an O
open O
trial O
sufficiently O
long O
for O
any O
placebo O
effect O
to O
have O
dissipated O
, O
and O
as O
such O
the O
inclusion O
of O
a O
placebo O
control O
was O
deemed O
to O
maximise O
scientific O
rigour O
. O

We O
will O
use O
cost-consequences O
analysis O
as O
a O
first O
step O
to O
compare O
any O
incremental O
costs O
of O
the O
intervention O
( O
costs O
accrued O
in O
the O
intervention O
arm O
, O
from O
intervention O
and O
resource O
use O
over O
the O
period O
of O
follow-up O
, O
compared O
to O
costs O
accrued O
in O
the O
control O
arm O
) O
to O
all O
secondary O
and O
secondary O
outcomes O
, O
expressed O
in O
their O
natural O
units O
of O
measurement O
. O

Conclusions O
Fluticasone O
/ O
formoterol O
had O
a O
good O
safety O
and O
tolerability O
profile O
and O
showed O
statistically O
superior O
efficacy O
for O
the O
three O
co-Secary O
endpoints O
compared O
to O
fluticasone O
, O
formoterol O
, O
and O
placebo O
, O
in O
adolescents O
and O
adults O
with O
mild-to-moderate O
asthma O
. O

secondary O
variables O
Smoking B-Sec
cessation I-Sec
at I-Sec
12 I-Sec
months I-Sec
. O

secondary O
and O
secondary O
outcomes O
will O
be O
assessed O
by O
an O
external O
nurse O
who O
will O
be O
blinded O
to O
treatment O
assignment O
after O
12 O
months O
. O

secondary O
Study O
Endpoints O
Whole B-Sec
Body I-Sec
, I-Sec
Hip I-Sec
and I-Sec
Spine I-Sec
Bone I-Sec
Mineral I-Sec
Density I-Sec
, O
and O
Body B-Sec
Composition I-Sec
BMD O
( O
g O
/ O
cm O
2 O
) O
of O
the O
hip O
( O
total O
hip O
) O
and O
lumbar O
spine O
( O
L O
2 O
– O
4 O
) O
regions O
as O
well O
as O
whole O
body O
bone O
mineral O
content O
( O
BMC O
, O
g O
) O
will O
be O
assessed O
by O
dual-energy O
X-ray O
absorptiometry O
( O
DXA O
, O
Hologic O
Discovery O
A O
, O
Waltham O
, O
MA O
) O
. O

Conclusion O
These O
results O
provide O
assurance O
that O
dropout O
was O
not O
related O
to O
secondary O
study O
outcomes O
. O

A B-Sec
composite' I-Sec
axial I-Sec
score' I-Sec
including I-Sec
the I-Sec
major I-Sec
clinical I-Sec
and I-Sec
anamnestic I-Sec
items I-Sec
on I-Sec
gait I-Sec
, I-Sec
posture I-Sec
and I-Sec
balance I-Sec
function I-Sec
from I-Sec
UPDRSII I-Sec
( I-Sec
items I-Sec
13-15 I-Sec
) I-Sec
and I-Sec
UPDRS I-Sec
III I-Sec
( I-Sec
items I-Sec
27-31 I-Sec
) I-Sec
constitutes O
the O
secondary O
outcome O
measure O
. O

These O
surveys O
included O
measurement O
of O
secondary O
outcome O
variables O
as O
described O
above O
( O
ie O
, O
screen B-Sec
time I-Sec
and I-Sec
fruit I-Sec
/ I-Sec
vegetable I-Sec
consumption I-Sec
) O
. O

Planned O
statistical O
analysis O
For O
the O
secondary O
outcomes O
, O
we O
will O
use O
intention-to-treat O
analyses O
for O
all O
secondary O
outcomes O
. O

The O
per O
protocol O
population O
, O
consisting O
of O
all O
patients O
of O
the O
ITT O
population O
who O
completed O
at O
least O
one O
chemotherapy O
cycle O
, O
have O
at O
least O
2 O
post-baseline O
assessments O
regarding O
the O
secondary O
endpoint O
without O
pre-specified O
, O
selected O
major O
protocol O
deviations O
thought O
to O
impact O
on O
efficacy O
analysis O
. O

The O
secondary O
outcome O
for O
this O
study O
is O
the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
who I-Sec
consume I-Sec
alcohol I-Sec
within I-Sec
recommended I-Sec
levels I-Sec
at I-Sec
6 I-Sec
month I-Sec
follow I-Sec
up I-Sec
. O

Power O
analysis O
The O
secondary O
endpoint O
is O
the B-Sec
occurrence I-Sec
of I-Sec
delirium I-Sec
during I-Sec
the I-Sec
first I-Sec
eight I-Sec
days I-Sec
after I-Sec
the I-Sec
start I-Sec
of I-Sec
study I-Sec
medication I-Sec
. O

In O
addition O
to O
HIV B-Sec
incidence I-Sec
, O
all B-Sec
deaths I-Sec
and O
severe B-Sec
or I-Sec
life-threatening I-Sec
clinical I-Sec
and I-Sec
laboratory I-Sec
events I-Sec
confirmed I-Sec
on I-Sec
examination I-Sec
or I-Sec
repeat I-Sec
testing I-Sec
will O
be O
secondary O
safety O
endpoints O
. O

Analysis O
secondary O
outcome O
continuous O
variables O
were O
analyzed O
in O
SPSS O
19 O
using O
a O
linear O
mixed O
effects O
model O
fitted O
with O
full O
information O
maximum O
likelihood O
estimation O
( O
FIML O
) O
49 O
. O

Secondly O
, O
following O
publication O
of O
national O
guidance O
on O
the O
treatment O
of O
schizophrenia O
highlighting O
the O
importance O
of O
arts O
therapies O
in O
treating O
symptoms O
of O
schizophrenia O
19 O
, O
we O
promoted O
total B-Sec
symptom I-Sec
score I-Sec
as O
a O
co-Secary O
outcome O
measure O
. O

The O
baseline O
comparison O
will O
be O
made O
between O
the O
secondary O
variables O
that O
we O
expected O
to O
be O
related O
to O
the O
secondary O
outcome O
using O
the O
Chi-Square O
test O
or O
an O
analysis O
of O
variance O
( O
ANOVA O
) O
. O

Assessment O
of O
the O
secondary O
outcome O
was O
blind O
to O
group O
allocation O
. O

The O
secondary O
outcome O
is O
the B-Sec
last I-Sec
week's I-Sec
total I-Sec
alcohol I-Sec
consumption I-Sec
in I-Sec
units I-Sec
of I-Sec
alcohol I-Sec
. O

The O
effect O
size O
estimate O
of O
2000 B-Sec
steps I-Sec
per I-Sec
day I-Sec
change I-Sec
as O
the O
secondary O
outcome O
is O
based O
on O
published O
research O
and O
clinically O
meaningful O
difference O
35 O
. O

Sample O
size O
calculations O
were O
performed O
post O
hoc O
as O
this O
was O
a O
sub-group O
analysis O
of O
a O
clinical O
trial O
with O
diarrhoea B-Sec
as O
the O
secondary O
endpoint O
36 O
. O

Our O
secondary O
outcomes O
are O
cardiorespiratory B-Sec
capacity I-Sec
, O
abdominal B-Sec
obesity I-Sec
, O
and O
lipid B-Sec
and I-Sec
glycemic I-Sec
control I-Sec
, O
while O
secondary O
outcomes O
include O
self-reported B-Sec
physical I-Sec
activity I-Sec
, O
quality B-Sec
of I-Sec
life I-Sec
and O
psychological B-Sec
distress I-Sec
. O

The O
secondary O
outcome O
and O
some O
of O
the O
secondary O
outcomes O
, O
involve O
self-reported O
questionnaires O
being O
completed O
by O
participants O
thus O
precluding O
blinding O
of O
assessment O
. O

Sample O
size O
A O
power O
calculation O
was O
carried O
out O
for O
the O
secondary O
outcome O
variable O
ankle B-Sec
sprain I-Sec
recurrences I-Sec
. O

Our O
secondary O
outcomes O
of O
maternal B-Sec
and I-Sec
perinatal I-Sec
mortality I-Sec
( I-Sec
within I-Sec
medical I-Sec
facilities I-Sec
) I-Sec
in O
a O
country O
like O
Malawi O
are O
influenced O
by O
many O
factors O
other O
than O
our O
intervention O
. O

The O
secondary O
endpoint O
was O
analysed O
to O
determine O
whether O
the O
ID O
vaccine O
was O
non-inferior O
to O
IM O
vaccination O
. O

The O
secondary O
composite O
outcome O
of O
re-operation B-Sec
provides O
a O
patient-important O
estimate O
of O
effect O
superior O
to O
previously O
described O
measures O
such O
as O
radiographic O
fracture O
healing O
, O
delayed O
unions O
, O
and O
nonunions O
. O

The O
secondary O
analysis O
will O
investigate O
differences O
in O
the O
secondary O
outcome O
measure O
, O
the B-Sec
WOMAC I-Sec
score I-Sec
, O
between O
the O
two O
treatment O
groups O
on O
an O
intention-to-treat O
basis O
at O
12 O
months O
post-operation O
. O

The O
statistical O
power O
in O
the O
two O
trials O
is O
calculated O
with O
the O
prospect O
of O
using O
a O
log O
rank O
test-statistic O
to O
test O
the O
null-hypothesis O
of O
no O
difference O
in O
time O
from O
randomisation O
to O
the O
secondary O
outcome O
. O

The O
secondary O
outcome O
is O
the B-Sec
incidence I-Sec
of I-Sec
perioperative I-Sec
bleeding I-Sec
episodes I-Sec
and O
clinically B-Sec
apparent I-Sec
thromboembolic I-Sec
events I-Sec
within I-Sec
30 I-Sec
days I-Sec
after I-Sec
surgery I-Sec
. O

It O
was O
not O
deemed O
likely O
, O
however O
, O
that O
the O
non-blinded O
nature O
of O
this O
study O
had O
a O
detrimental O
effect O
on O
the O
results O
, O
because O
the O
secondary O
efficacy O
measure O
was O
a O
physical O
rather O
than O
a O
subjective O
endpoint O
and O
analysis O
of O
the O
data O
was O
blinded O
until O
its O
completion O
. O

A O
decrease O
of O
the O
secondary O
endpoint O
from O
28.3 O
% O
( O
PC O
group O
) O
to O
14.6 O
% O
( O
LC O
group O
) O
with O
power O
80 O
% O
, O
alpha O
two-sided O
5 O
% O
, O
Fisher O
exact O
, O
two O
proportions O
, O
1 O
: O
1 O
randomization O
can O
be O
demonstrated O
by O
randomizing O
2 O
× O
140 O
patients O
( O
PS O
Power O
and O
Sample O
Size O
Calculations O
, O
version O
2.1.30 O
, O
February O
2003 O
) O
. O

It O
is O
not O
powered O
to O
detect O
a O
clinically O
or O
economically O
meaningful O
difference O
in O
the O
secondary O
outcome O
between O
the O
surgical O
and O
active O
monitoring O
groups O
. O

Lastly O
, O
the O
secondary O
outcome O
is O
defined O
by O
absence B-Sec
of I-Sec
PD I-Sec
at I-Sec
3-yr I-Sec
follow-up I-Sec
, I-Sec
operationalized I-Sec
by I-Sec
not I-Sec
meeting I-Sec
criteria I-Sec
for I-Sec
a I-Sec
PD I-Sec
on I-Sec
the I-Sec
SCID-II I-Sec
. O

Only O
secondary O
and O
secondary O
outcome O
measures O
will O
be O
analyzed O
. O

secondary O
and O
secondary O
endpoints O
The O
secondary O
endpoints O
of O
the O
LIR O
! O
C O
trial O
are O
the B-Sec
disease-specific I-Sec
quality I-Sec
of I-Sec
life I-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
IBDQ I-Sec
16 I-Sec
17 I-Sec
and O
the B-Sec
costs I-Sec
per I-Sec
QALY I-Sec
. O

Participants O
were O
seated O
for O
five O
minutes O
before O
the O
first O
blood O
pressure O
measurement O
and O
a O
rest O
period O
of O
two O
minutes O
between O
measures O
was O
used O
. O

The O
secondary O
efficacy O
endpoint O
was O
the B-Sec
American I-Sec
College I-Sec
of I-Sec
Rheumatology I-Sec
20 I-Sec
% I-Sec
improvement I-Sec
criteria I-Sec
( I-Sec
ACR20 I-Sec
) I-Sec
response I-Sec
at I-Sec
week I-Sec
24 I-Sec
19 I-Sec
20 I-Sec
. O

Application O
of O
this O
testing O
strategy O
with O
local O
type O
I O
error O
rate O
α O
1 O
= O
0.0299 O
in O
the O
interim O
analysis O
guarantees O
control O
of O
the O
multiple O
type O
I O
error O
rate O
α O
= O
0.05 O
for O
the O
confirmatory O
test O
problem O
for O
the O
secondary O
variable O
29 O
. O

We O
aim O
to O
show O
non-inferiority O
of O
the O
expectant O
management O
arm O
and O
therefore O
this O
secondary O
assessment O
day O
was O
chosen O
: O
if O
there O
would O
be O
any O
difference O
between O
randomized O
groups O
, O
this O
difference O
is O
expected O
to O
be O
the O
largest O
three O
days O
postpartum O
5 O
. O

2 O
: O
Following O
the O
IYP O
, O
participants O
will O
show O
significant O
improvement O
on O
the O
secondary O
outcomes O
of O
general B-Sec
functioning I-Sec
, O
arthritis B-Sec
functioning I-Sec
and O
HRQOL B-Sec
relative O
to O
controls O
. O

Statistical O
analysis O
secondary O
outcomes O
are O
psychological B-Sec
distress I-Sec
as I-Sec
measured I-Sec
with I-Sec
the I-Sec
HADS I-Sec
and O
physical B-Sec
role I-Sec
function I-Sec
as I-Sec
measured I-Sec
with I-Sec
the I-Sec
EORTC-QLQ-C30 I-Sec
. O

Loss O
to O
follow-up O
is O
expected O
to O
be O
marginal O
: O
during O
the O
period O
that O
the O
secondary O
endpoint O
( O
POPF B-Sec
grade I-Sec
B I-Sec
or I-Sec
C I-Sec
) O
has O
to O
be O
assessed O
( O
until O
postoperative O
day O
30 O
) O
, O
all O
patients O
are O
under O
continuous O
in-hospital O
observation O
in O
the O
perioperative O
period O
, O
followed O
by O
in-hospital O
rehabilitation O
for O
the O
great O
majority O
and O
close O
ambulatory O
observation O
in O
every O
case O
. O

The O
secondary O
endpoint O
for O
analysis O
will O
be O
data O
collected O
at O
week O
24. O

The O
secondary O
outcome O
will O
be O
the B-Sec
ability I-Sec
of I-Sec
the I-Sec
intervention I-Sec
( I-Sec
Project I-Sec
Tomato I-Sec
) I-Sec
to I-Sec
maintain I-Sec
consumption I-Sec
of I-Sec
fruit I-Sec
and I-Sec
vegetable I-Sec
portions I-Sec
compared I-Sec
to I-Sec
the I-Sec
control I-Sec
group I-Sec
. O

secondary O
outcomes O
were O
analysed O
on O
an O
intention-to-treat O
basis O
: O
if O
the O
person O
did O
not O
finish O
the O
course O
of O
detoxification O
or O
did O
not O
give O
a O
urine O
sample O
then O
this O
was O
considered O
as O
a O
positive O
urine O
test O
for O
opiates O
. O

The O
secondary O
outcome O
measure O
is O
change B-Sec
in I-Sec
body I-Sec
mass I-Sec
index I-Sec
and O
the O
secondary O
outcome O
measures O
are O
changes B-Sec
in I-Sec
body I-Sec
composition I-Sec
, O
risk B-Sec
factors I-Sec
for I-Sec
type I-Sec
2 I-Sec
diabetes I-Sec
and I-Sec
cardiovascular I-Sec
disease I-Sec
, O
changes B-Sec
in I-Sec
diet I-Sec
, O
physical B-Sec
activity I-Sec
, O
and O
psychosocial B-Sec
well-being I-Sec
( I-Sec
eg I-Sec
, I-Sec
quality I-Sec
of I-Sec
life I-Sec
) I-Sec
. O

Surprisingly O
, O
even O
though O
all O
these O
programs O
aimed O
at O
reducing O
the O
fragmentation O
of O
care O
, O
consolidating O
the O
range O
of O
services O
, O
and O
promoting O
a O
better O
match O
of O
resources O
to O
the O
older O
person's O
needs O
, O
only O
the O
Wisconsin O
Partnership O
Program O
( O
WPP O
) O
( O
a O
variation O
of O
the O
PACE O
Program O
) O
, O
12 O
, O
has O
investigated O
unmet O
needs O
for O
ADL O
/ O
IADL O
disabilities O
as O
a O
secondary O
outcome O
of O
an O
ISD O
network O
, O
but O
failed O
to O
achieve O
an O
impact O
. O

The O
expected O
secondary O
endpoint O
was O
a B-Sec
decrease I-Sec
in I-Sec
carer I-Sec
burden I-Sec
in I-Sec
the I-Sec
intervention I-Sec
group I-Sec
three I-Sec
months I-Sec
after I-Sec
receiving I-Sec
the I-Sec
DA I-Sec
. O

The O
secondary O
endpoint O
is O
the B-Sec
change I-Sec
from I-Sec
the I-Sec
baseline I-Sec
value I-Sec
of I-Sec
HbA1c I-Sec
at I-Sec
6 I-Sec
months I-Sec
. O

Only O
87 O
of O
the O
102 O
remaining O
patients O
( O
57 O
% O
of O
those O
randomised O
) O
reached O
the O
secondary O
endpoint O
. O

Outcome O
Measures O
The O
first O
secondary O
outcome O
measure O
, O
assessed O
at O
6 O
and O
26 O
weeks O
after O
randomisation O
, O
was O
patient-perceived B-Sec
recovery I-Sec
( I-Sec
PPR I-Sec
) I-Sec
10 I-Sec
. O

Sensitivity O
analysis O
A O
sensitivity O
analysis O
is O
an O
important O
feature O
in O
economic O
evaluations O
, O
since O
study O
results O
can O
be O
sensitive O
to O
the O
values O
assumed O
for O
by O
key O
parameters O
22 O
. O

Outcome O
measurements O
secondary O
outcomes O
Adequate B-Sec
relief I-Sec
( I-Sec
AR I-Sec
) I-Sec
will O
be O
used O
as O
a O
secondary O
outcome O
to O
evaluate O
IBS O
symptom O
improvement O
. O

secondary O
endpoints O
are O
the B-Sec
local I-Sec
radiation I-Sec
dose I-Sec
leading I-Sec
to I-Sec
tumor I-Sec
infiltrating I-Sec
T4 I-Sec
cells I-Sec
as I-Sec
a I-Sec
surrogate I-Sec
parameter I-Sec
for I-Sec
antitumor I-Sec
activity I-Sec
. O

The O
secondary O
study O
endpoint O
is O
progression-free B-Sec
survival I-Sec
. O

secondary O
outcome O
Overall O
, O
63 O
men O
( O
70 O
% O
) O
gave O
a O
urine O
sample O
at O
5 O
days O
post O
detoxification O
( O
Table O
4 O
) O
, O
between O
the O
two O
allocated O
regimens O
for O
provision O
of O
urine O
sample O
( O
RR O
1.18 O
, O
CI O
0.90 O
– O
1.54 O
, O
z O
= O
1.20 O
, O
p O
= O
0.43 O
) O
. O

Key O
messages O
• O
This O
study O
, O
the O
first O
to O
measure O
the O
response O
of O
individual O
delirium O
symptoms O
to O
antipsychotic O
therapy O
in O
the O
ICU O
, O
demonstrates O
that O
quetiapine O
use O
may O
be O
associated O
with O
more O
rapid O
resolution O
of O
many O
common O
ICU O
delirium O
symptoms O
compared O
to O
placebo O
, O
resulting O
in O
less O
time O
affected O
by O
hallucinations O
, O
inattention O
, O
symptom O
fluctuation O
and O
an O
undesirable O
level O
of O
consciousness O
. O

Analyses O
of O
covariance O
were O
used O
to O
examine O
the O
effects O
of O
the O
intervention O
( O
study O
arm O
allocation O
) O
on O
the O
secondary O
outcomes O
( O
log B-Sec
HbA I-Sec
1c I-Sec
and O
HRQL B-Sec
) O
, O
with O
the O
inclusion O
of O
baseline O
values O
of O
the O
outcomes O
as O
covariates O
. O

The O
secondary O
outcome O
will O
be O
the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
who I-Sec
are I-Sec
adherent I-Sec
to I-Sec
a I-Sec
complete I-Sec
, I-Sec
guideline-based I-Sec
medication I-Sec
regimen I-Sec
. O

secondary O
outcome O
measures O
are O
time B-Sec
to I-Sec
establish I-Sec
full I-Sec
enteral I-Sec
feeding I-Sec
and O
necrotising B-Sec
enterocolitis I-Sec
; O
secondary O
outcomes O
include O
sepsis B-Sec
and O
growth B-Sec
. O

Our O
secondary O
endpoint O
is O
the B-Sec
reduction I-Sec
in I-Sec
the I-Sec
number I-Sec
of I-Sec
exacerbations I-Sec
of I-Sec
COPD I-Sec
in I-Sec
the I-Sec
year I-Sec
of I-Sec
treatment I-Sec
. O

The O
tests O
of O
the O
secondary O
hypotheses O
were O
performed O
in O
the O
following O
order O
if O
the O
secondary O
endpoint O
was O
significant O
at O
level O
0.05 O
: O
( O
1 O
) O
percentage O
of O
subjects O
reaching O
LDL-C O
goal O
of O
< O
1.81 O
mmol O
/ O
L O
( O
70 O
mg O
/ O
dL O
) O
, O
( O
2 O
) O
percentage O
of O
subjects O
reaching O
LDL-C O
goal O
of O
< O
2.00 O
mmol O
/ O
L O
( O
77 O
mg O
/ O
dL O
) O
, O
( O
3 O
) O
percentage O
of O
subjects O
reaching O
LDL-C O
goal O
of O
< O
2.59 O
mmol O
/ O
L O
( O
100 O
mg O
/ O
dL O
) O
. O

Outcome O
measures O
secondary O
outcome O
• B-Sec
The I-Sec
incidence I-Sec
of I-Sec
AF I-Sec
according I-Sec
to I-Sec
a I-Sec
variety I-Sec
of I-Sec
screening I-Sec
strategies I-Sec
• I-Sec
The I-Sec
associated I-Sec
costs I-Sec
providing I-Sec
an I-Sec
incremental I-Sec
cost I-Sec
per I-Sec
case I-Sec
detected I-Sec
. O

Our O
hypothesis O
is O
that O
in O
uncomplicated O
( O
mild O
) O
acute O
diverticulitis O
, O
a O
liberal O
strategy O
treatment O
without O
antibiotics O
is O
a O
more O
cost-effective O
approach O
than O
conservative O
treatment O
strategy O
with O
hospital O
admission O
and O
antibiotics O
, O
outcome O
is O
measured O
by O
time-to-full B-Sec
recovery I-Sec
as O
secondary O
outcome O
and O
diverticulitis-associated B-Sec
complication I-Sec
rates I-Sec
and O
patient B-Sec
well-being I-Sec
as O
secondary O
outcome O
. O

These O
effects O
are O
manifested O
at O
the O
secondary O
assessments O
( O
see O
Table O
2 O
: O
t4 O
, O
t6 O
, O
t8 O
) O
a O
cross O
the O
trial O
. O

Minimisation O
cut-offs O
were O
derived O
from O
an O
analysis O
of O
mean O
and O
median O
values O
in O
the O
first O
1000 O
Fenland O
participants O
measured O
. O

secondary O
outcome O
is O
severity B-Sec
of I-Sec
hip I-Sec
pain I-Sec
reported I-Sec
by I-Sec
the I-Sec
patients I-Sec
at I-Sec
2-week I-Sec
follow-up I-Sec
. O

To O
check O
the O
secondary O
hypothesis O
all O
variables O
will O
be O
compared O
( O
t0-tk O
) O
by O
means O
of O
the O
ANOVA O
test O
with O
adequate O
post-hoc O
contrasts O
for O
normally O
distributed O
variables O
or O
the O
Kruskal-Wallis O
H O
test O
. O

Separate O
mixed O
group O
( O
yoga O
vs. O
control O
) O
by O
time O
( O
baseline O
vs. O
post-treatment O
/ O
post-control O
) O
repeated O
measure O
analysis O
of O
variance O
( O
ANOVA O
) O
will O
be O
conducted O
on O
the O
secondary O
outcomes O
, O
or O
the O
non-parametric O
equivalent O
( O
Friedman O
procedure O
) O
, O
in O
the O
event O
the O
assumptions O
for O
parametric O
analyses O
are O
not O
met O
. O

The O
secondary O
outcome O
of O
interest O
is O
the B-Sec
proportion I-Sec
of I-Sec
subjects I-Sec
who I-Sec
self-report I-Sec
smoking I-Sec
cessation I-Sec
with I-Sec
urinary I-Sec
cotinine I-Sec
validation I-Sec
at I-Sec
12 I-Sec
months I-Sec
. O

The O
secondary O
outcome O
measure O
for O
residents O
in O
the O
model O
is O
quality B-Sec
of I-Sec
life I-Sec
. O

The O
secondary O
outcome O
measure O
for O
this O
study O
is O
the B-Sec
sustained I-Sec
reversion I-Sec
to I-Sec
sinus I-Sec
rhythm I-Sec
with I-Sec
a I-Sec
heart I-Sec
rate I-Sec
greater I-Sec
than I-Sec
50 I-Sec
/ I-Sec
min I-Sec
within I-Sec
2 I-Sec
hours I-Sec
of I-Sec
completion I-Sec
of I-Sec
FDP I-Sec
/ I-Sec
placebo I-Sec
bolus I-Sec
. O

Subgroup O
analyses O
will O
be O
performed O
by O
assessing O
interactions O
of O
the O
secondary O
outcome O
with O
a O
maximum O
of O
three O
pre-determined O
factors O
( O
education O
, O
gender O
, O
and O
baseline O
alcohol O
consumption O
) O
. O

secondary O
outcome O
measure O
is O
the B-Sec
change I-Sec
of I-Sec
tinnitus I-Sec
distress I-Sec
as I-Sec
quantified I-Sec
by I-Sec
the I-Sec
Tinnitus I-Sec
Questionnaire I-Sec
( I-Sec
TQ I-Sec
) I-Sec
. O

Results O
Among O
274 O
patients O
with O
evaluable O
efficacy O
data O
, O
the B-Sec
percentage I-Sec
of I-Sec
responders I-Sec
according I-Sec
to I-Sec
American I-Sec
College I-Sec
of I-Sec
Rheumatology I-Sec
50 I-Sec
criteria I-Sec
( O
the O
secondary O
endpoint O
, O
based O
on O
a O
28-joint O
count O
) O
was O
significantly O
higher O
with O
canakinumab O
150 O
mg O
SC O
q4wk O
than O
with O
placebo O
( O
26.5 O
% O
vs. O
11.4 O
% O
, O
respectively O
; O
p O
= O
0.028 O
) O
. O

In O
this O
UK O
study O
of O
74 O
male O
prisoners O
with O
opiate O
addiction O
, O
lofexidine O
was O
compared O
with O
methadone O
with O
the O
secondary O
outcome O
being O
self-reported B-Sec
withdrawal I-Sec
symptom I-Sec
severity I-Sec
during I-Sec
the I-Sec
detoxification I-Sec
period I-Sec
. O

The O
secondary O
outcome O
measure O
was O
the B-Sec
intra-individual I-Sec
change I-Sec
in I-Sec
the I-Sec
total I-Sec
score I-Sec
of I-Sec
the I-Sec
Hamilton I-Sec
Rating I-Sec
Scale I-Sec
for I-Sec
Depression I-Sec
( I-Sec
HAM-D I-Sec
, I-Sec
17-item I-Sec
version I-Sec
) I-Sec
between I-Sec
baseline I-Sec
and I-Sec
the I-Sec
end I-Sec
of I-Sec
the I-Sec
6-week I-Sec
acute I-Sec
phase I-Sec
. O

The O
purpose O
of O
the O
additional O
combing O
immediately O
following O
the O
first O
treatment O
( O
ie O
a O
combing O
on O
days O
1 O
and O
2 O
rather O
than O
on O
day O
1 O
or O
day O
2 O
as O
have O
been O
used O
in O
other O
studies O
) O
was O
to O
enable O
the O
investigators O
a O
better O
opportunity O
to O
find O
any O
newly O
hatched O
nymphs O
in O
relation O
to O
evaluation O
of O
the O
first O
secondary O
outcome O
measure O
, O
the B-Sec
ovicidal I-Sec
effect I-Sec
of I-Sec
the I-Sec
treatments I-Sec
, I-Sec
defined I-Sec
as I-Sec
no I-Sec
nymphal I-Sec
lice I-Sec
emerging I-Sec
from I-Sec
eggs I-Sec
between I-Sec
treatments I-Sec
. O

The O
secondary O
outcome O
of O
interest O
will O
be O
biochemically B-Sec
verified I-Sec
continuous I-Sec
abstinence I-Sec
at I-Sec
1 I-Sec
year I-Sec
. O

The O
secondary O
outcome O
is O
the B-Sec
proportion I-Sec
of I-Sec
risky I-Sec
sexual I-Sec
practices I-Sec
. O

secondary O
and O
secondary O
outcomes O
Our O
first O
objective O
is O
to O
compare O
the O
effectiveness O
of O
the O
two O
different O
strategies O
for O
changing O
lifestyle O
with O
each O
other O
as O
well O
as O
with O
a O
control O
group O
. O

The B-Sec
mean I-Sec
decrease I-Sec
in I-Sec
Young I-Sec
Mania I-Sec
Rating I-Sec
Scale I-Sec
score I-Sec
from I-Sec
baseline I-Sec
was O
used O
as O
the O
secondary O
outcome O
measure O
of O
response O
of O
mania O
to O
treatment O
. O

Mean O
differences O
secondary O
measures O
WOMAC B-Sec
Pain I-Sec
, O
Physical B-Sec
Function I-Sec
and O
Total B-Sec
scores I-Sec
improved O
more O
significantly O
in O
the O
OAK O
group O
than O
in O
the O
control O
group O
( O
Table O
4 O
) O
. O

The O
secondary O
outcomes O
are O
physical B-Sec
activity I-Sec
, I-Sec
measured I-Sec
with I-Sec
the I-Sec
StepWatch I-Sec
activity I-Sec
monitor I-Sec
, O
and O
self-reported B-Sec
physical I-Sec
activity I-Sec
. O

The O
secondary O
outcome O
of O
patient B-Sec
intention I-Sec
to I-Sec
visit I-Sec
a I-Sec
psychosocial I-Sec
counselor I-Sec
was O
measured O
by O
a O
single O
item O
( O
yes O
/ O
no O
) O
. O

Click O
here O
for O
file O
Sample O
size O
calculation O
( O
a O
) O
Sample O
size O
calculation O
for O
Theme O
1 O
The O
secondary O
outcome O
measure O
was O
taken O
as O
the B-Sec
proportion I-Sec
admitted I-Sec
to I-Sec
hospital I-Sec
, O
with O
the O
secondary O
outcome O
measure O
being O
number B-Sec
of I-Sec
bed I-Sec
days I-Sec
. O

Outcomes O
The O
secondary O
outcome O
was O
28-day B-Sec
all-cause I-Sec
mortality I-Sec
. O

An O
interim O
analysis O
on O
the O
secondary O
end O
point O
( O
ie O
, O
efficacy B-Sec
) O
will O
be O
performed O
after O
50 O
% O
of O
patients O
have O
completed O
their O
follow-up O
. O

The O
secondary O
outcome O
is O
adherence B-Sec
to I-Sec
medication I-Sec
. O

With O
16 O
clusters O
( O
8 O
pairs O
) O
this O
would O
give O
the O
study O
95 O
% O
power O
to O
detect O
a O
20 O
% O
reduction O
in O
secondary O
outcome O
from O
75 O
% O
to O
55 O
% O
( O
as O
seen O
in O
the O
trial O
by O
Kettle O
et O
al O
2002 O
7 O
) O
or O
alternatively O
a O
small-to-moderate O
difference O
of O
one O
third O
of O
a O
standard O
deviation O
on O
continuous O
scales O
, O
such O
as O
VAS O
scores O
for O
pain O
) O
. O

Quantitative O
assessments O
For O
the O
secondary O
outcome O
assessments O
, O
we O
will O
record O
the B-Sec
symptoms I-Sec
of I-Sec
schizophrenia I-Sec
at I-Sec
baseline I-Sec
and I-Sec
at I-Sec
12 I-Sec
months I-Sec
, I-Sec
with I-Sec
the I-Sec
Positive I-Sec
and I-Sec
Negative I-Sec
Syndrome I-Sec
Scale I-Sec
( I-Sec
PANSS I-Sec
) I-Sec
17 I-Sec
. O

At O
6 O
and O
12 O
months O
patients O
will O
be O
followed O
up O
by O
a O
research O
nurse O
( O
RN O
) O
where O
details O
of O
secondary O
and O
secondary O
outcomes O
will O
be O
collected O
. O

The O
secondary O
endpoint O
is O
to B-Sec
assess I-Sec
quality I-Sec
of I-Sec
life I-Sec
at I-Sec
6 I-Sec
months I-Sec
on I-Sec
the I-Sec
Minnesota I-Sec
questionnaire I-Sec
. O

End O
points O
The O
secondary O
end O
point O
was O
time B-Sec
to I-Sec
death I-Sec
from I-Sec
all I-Sec
causes I-Sec
, O
non-fatal B-Sec
myocardial I-Sec
infarction I-Sec
( I-Sec
MI I-Sec
) I-Sec
, O
non-fatal B-Sec
stroke I-Sec
, O
or O
heart B-Sec
failure I-Sec
requiring I-Sec
hospitalization I-Sec
or I-Sec
emergency I-Sec
service I-Sec
intervention I-Sec
. O

The O
secondary O
outcome O
measure O
is O
sedentary B-Sec
time I-Sec
defined I-Sec
as I-Sec
time I-Sec
< I-Sec
100 I-Sec
counts I-Sec
per I-Sec
minute I-Sec
29 I-Sec
. O

Outcome O
measures O
To O
determine O
the O
effects O
of O
tadalafil O
on O
the O
microcirculation O
, O
the O
secondary O
outcome O
measure O
was O
the B-Sec
temperature I-Sec
difference I-Sec
between I-Sec
the I-Sec
CRPS I-Sec
affected I-Sec
and I-Sec
the I-Sec
contralateral I-Sec
limbs I-Sec
. O

The O
secondary O
outcome O
measures O
used O
to O
assess O
women's O
health O
and O
well-being O
at O
six O
months O
were O
the B-Sec
EPDS I-Sec
( I-Sec
a I-Sec
10-item I-Sec
scale I-Sec
developed I-Sec
for I-Sec
use I-Sec
in I-Sec
the I-Sec
postnatal I-Sec
period I-Sec
, I-Sec
in I-Sec
which I-Sec
a I-Sec
score I-Sec
≥ I-Sec
13 I-Sec
identifies I-Sec
probable I-Sec
depression I-Sec
33 I-Sec
, O
and O
the B-Sec
physical I-Sec
and I-Sec
mental I-Sec
component I-Sec
scores I-Sec
( I-Sec
PCS I-Sec
and I-Sec
MCS I-Sec
) I-Sec
of I-Sec
the I-Sec
Short I-Sec
Form I-Sec
36 I-Sec
( I-Sec
SF-36 I-Sec
) I-Sec
, I-Sec
a I-Sec
widely I-Sec
used I-Sec
general I-Sec
health I-Sec
status I-Sec
measure I-Sec
34 I-Sec
. O

Descriptive O
statistics O
The O
secondary O
outcome O
parameter O
of O
time B-Sec
to I-Sec
functional I-Sec
recovery I-Sec
and O
the O
secondary O
parameter O
of O
LOS B-Sec
in I-Sec
hospital I-Sec
will O
be O
given O
in O
days O
, O
with O
a O
median O
and O
range O
. O

To O
analyze O
the O
secondary O
outcome O
( O
ie O
, O
RRI B-Sec
) O
, O
the O
Kaplan-Meier O
method O
will O
be O
used O
. O

The O
secondary O
and O
secondary O
endpoints O
will O
be O
analyzed O
on O
modified O
intention-to-treat O
analysis O
. O

The O
secondary O
efficacy O
variable O
was O
trough B-Sec
forced I-Sec
expiratory I-Sec
volume I-Sec
in I-Sec
one I-Sec
second I-Sec
( I-Sec
FEV I-Sec
1 I-Sec
) I-Sec
at I-Sec
24 I-Sec
h I-Sec
post-dose I-Sec
after I-Sec
14 I-Sec
days I-Sec
. O

The O
secondary O
outcome O
measure O
was O
the B-Sec
PHQ-9 I-Sec
. O

The O
aim O
of O
this O
randomised O
, O
controlled O
, O
single-blind O
, O
cross-over O
study O
in O
single-use O
dialyser O
bicarbonate O
haemodialysis O
was O
to O
detail O
the O
consequences O
on O
systemic B-Sec
haemodynamics I-Sec
( O
secondary O
outcome O
) O
and O
on O
coagulation B-Sec
activation I-Sec
, O
acid-base B-Sec
status I-Sec
, O
calcium B-Sec
balance I-Sec
and O
dialysis B-Sec
efficiency I-Sec
( O
secondary O
outcomes O
) O
of O
using O
citric O
instead O
of O
acetic O
acid O
in O
haemodialysis O
fluids O
. O

The O
co-administration O
of O
formoterol O
and O
fluticasone O
shows O
superiority O
to O
the O
individual O
components O
administered O
separately O
and O
placebo O
for O
all O
three O
co-Secary O
endpoints O
and O
confers O
significant O
benefits O
in O
terms O
of O
lung O
function O
, O
disease O
control O
, O
and O
asthma O
symptoms O
. O

The O
secondary O
outcome O
measures O
were O
SHBG B-Sec
and O
sex B-Sec
hormones I-Sec
[ I-Sec
ie I-Sec
, I-Sec
testosterone I-Sec
, I-Sec
estradiol I-Sec
, I-Sec
dehydroepiandrosterone I-Sec
sulfate I-Sec
] I-Sec
. O

Overall O
study O
design O
and O
participants O
secondary O
outcomes O
and O
subjects O
The O
core O
portion O
of O
the O
study O
was O
a O
randomized O
post-test O
only O
control O
group O
design O
, O
for O
the O
secondary O
outcomes O
: O
attitudes B-Sec
, O
knowledge B-Sec
and O
skills B-Sec
in I-Sec
EBM I-Sec
. O

Assessing O
feasibility O
for O
a O
larger O
phase O
III O
trial O
According O
to O
the O
Medical O
Research O
Council's O
guidance O
for O
developing O
and O
evaluating O
complex O
interventions O
24 O
the O
piloting O
stage O
includes O
: O
testing O
procedures O
for O
delivering O
the O
intervention O
, O
estimating O
the O
likely O
rates O
of O
recruitment O
and O
retention O
of O
participants O
, O
and O
estimating O
the O
effect O
size O
of O
the O
secondary O
outcome O
measure O
in O
preparation O
for O
a O
sample O
size O
calculation O
. O

The O
secondary O
outcomes O
will O
be O
based O
on O
three O
validated O
QoL O
questionnaires O
, O
St O
Georges O
Respiratory O
Questionnaire O
( O
SGRQ O
) O
, O
Short O
Form O
Health O
Survey O
( O
SF-36 O
) O
and O
the O
COPD O
Assessment O
Test O
( O
CAT O
) O
. O

Statistical O
analyses O
Based O
on O
the O
secondary O
outcome O
measures O
, O
a O
sample O
size O
of O
130 O
participants O
would O
provide O
80 O
% O
power O
to O
detect O
a O
difference O
of O
eight O
units O
on O
the O
LBPRS O
( O
SD O
= O
13 O
) O
between O
the O
secondary O
and O
each O
of O
the O
comparator O
groups O
, O
assuming O
alpha O
of O
0.05 O
using O
a O
two-sided O
test O
. O

Sensitivity O
analyses O
will O
examine O
the O
impact O
of O
altering O
key O
assumptions O
and O
parameter O
values O
. O

Statistical O
analysis O
The O
secondary O
endpoints O
of O
the O
study O
were O
clinical B-Sec
response I-Sec
at I-Sec
the I-Sec
test-of-cure I-Sec
visit I-Sec
( I-Sec
14 I-Sec
– I-Sec
35 I-Sec
days I-Sec
after I-Sec
therapy I-Sec
) I-Sec
for I-Sec
the I-Sec
m-mITT I-Sec
and I-Sec
ME I-Sec
populations I-Sec
. O

secondary O
endpoint O
is O
the B-Sec
incidence I-Sec
of I-Sec
clinically I-Sec
relevant I-Sec
VTE I-Sec
( I-Sec
symptomatic I-Sec
deep I-Sec
venous I-Sec
thrombosis I-Sec
( I-Sec
DVT I-Sec
) I-Sec
of I-Sec
the I-Sec
leg I-Sec
and I-Sec
/ I-Sec
or I-Sec
pelvic I-Sec
and I-Sec
/ I-Sec
or I-Sec
pulmonary I-Sec
embolism I-Sec
( I-Sec
PE I-Sec
) I-Sec
) I-Sec
within I-Sec
the I-Sec
first I-Sec
3 I-Sec
months I-Sec
. O

The O
secondary O
outcome O
comparison O
will O
be O
of O
the B-Sec
proportion I-Sec
of I-Sec
infants I-Sec
with I-Sec
sleep I-Sec
and I-Sec
cry I-Sec
problems I-Sec
at I-Sec
4 I-Sec
months I-Sec
between O
the O
two O
trial O
arms O
. O

The O
secondary O
outcome O
measure O
of O
the O
trial O
will O
be O
the B-Sec
healing I-Sec
rate I-Sec
, I-Sec
defined I-Sec
as I-Sec
lesion I-Sec
disappearance I-Sec
in I-Sec
the I-Sec
affected I-Sec
zones I-Sec
after I-Sec
the I-Sec
topic I-Sec
application I-Sec
of I-Sec
the I-Sec
experimental I-Sec
treatment I-Sec
. O

For O
patients O
of O
the O
WLC O
group O
this O
is O
the O
secondary O
assessment O
. O

The O
secondary O
outcome O
is O
patient-perceived B-Sec
recovery I-Sec
at I-Sec
52 I-Sec
weeks I-Sec
, I-Sec
using I-Sec
the I-Sec
Global I-Sec
Perceived I-Sec
Effect I-Sec
questionnaire I-Sec
. O

Neither O
the O
secondary O
test O
variables O
nor O
the O
functional O
performance O
parameters O
showed O
that O
external O
focus O
instruction O
was O
beneficiary O
to O
internal O
focus O
instruction O
whilst O
learning O
to O
balance O
on O
a O
stable O
or O
unstable O
platform O
with O
concurrent O
feedback O
on O
a O
video O
screen O
. O

The O
secondary O
outcomes O
will O
be O
the B-Sec
percentage I-Sec
reduction I-Sec
in I-Sec
binge I-Sec
drinking I-Sec
, O
weekly B-Sec
drinking I-Sec
and O
drinking-related B-Sec
problems I-Sec
after I-Sec
three I-Sec
specified I-Sec
time I-Sec
periods I-Sec
. O

ANOVA O
testing O
for O
secondary O
outcome O
demonstrated O
a O
significant O
interaction O
effect O
time O
by O
group O
( O
F O
= O
7.4 O
; O
df O
= O
1 O
, O
33 O
; O
p O
= O
0.010 O
; O
η O
2 O
= O
0.183 O
) O
. O

The O
secondary O
endpoint O
will O
be O
analysed O
using O
a O
time O
to O
event O
approach O
. O

The O
secondary O
outcomes O
include O
the B-Sec
Extended I-Sec
Glasgow I-Sec
Outcome I-Sec
Scale I-Sec
and O
the B-Sec
Modified I-Sec
Rankin I-Sec
Scale I-Sec
. O

The O
reason O
for O
choosing O
pulmonary B-Sec
exacerbations I-Sec
as O
our O
secondary O
outcome O
is O
two-fold O
. O

As O
reported O
in O
the O
GAIT O
clinical O
trial O
investigating O
glucosamine O
hydrochloride O
and O
chondroitin O
sulfate O
in O
osteoarthritis O
subjects O
11 O
, O
we O
used O
response B-Sec
rate I-Sec
to I-Sec
treatment I-Sec
as O
a O
secondary O
efficacy O
variable O
based O
on O
the O
WOMAC O
A O
or O
pain O
criteria O
. O

Safety O
and O
efficacy O
monitoring O
The O
role O
of O
the O
DSMB O
is O
to O
perform O
an O
interim O
review O
of O
the O
trial's O
progress O
including O
updated O
figures O
on O
secondary O
outcomes O
and O
safety O
data O
. O

Study O
variables O
In O
addition O
to O
the O
inclusion O
and O
exclusion O
criteria O
, O
four O
types O
of O
variables O
will O
be O
collected O
: O
psychosocial O
, O
biomedical O
, O
treatment O
prescribed O
, O
and O
intermediate O
and O
secondary O
outcome O
variables O
( O
table O
2 O
) O
. O

Confidence O
intervals O
( O
95 O
% O
) O
will O
be O
computed O
for O
all O
secondary O
and O
secondary O
outcomes O
. O

Outcome O
Measure O
Details O
The O
supplementary O
four O
items O
contributing O
to O
the O
21-item O
version O
of O
the O
HRSD O
17 O
will O
also O
be O
assessed O
, O
but O
not O
used O
as O
part O
of O
the O
secondary O
outcome O
score O
. O

secondary O
outcome O
measure O
Participants O
are O
asked O
to O
rate O
their B-Sec
typical I-Sec
level I-Sec
of I-Sec
neck I-Sec
or I-Sec
back I-Sec
pain I-Sec
over I-Sec
the I-Sec
last I-Sec
week I-Sec
, I-Sec
using I-Sec
an I-Sec
ordinal I-Sec
11-box I-Sec
scale I-Sec
( I-Sec
0 I-Sec
= I-Sec
no I-Sec
pain I-Sec
, I-Sec
10 I-Sec
= I-Sec
the I-Sec
worst I-Sec
pain I-Sec
possible I-Sec
) I-Sec
31 I-Sec
. O

The O
secondary O
effectiveness O
outcomes O
are O
pain B-Sec
and O
dysfunction B-Sec
assessed I-Sec
at I-Sec
the I-Sec
10-week I-Sec
telephone I-Sec
interview I-Sec
. O

Methods O
The O
VERTOS O
IV O
study O
is O
a O
prospective O
, O
multicenter O
RCT O
with O
pain B-Sec
relief I-Sec
as O
secondary O
endpoint O
. O

secondary O
outcome O
measures O
are O
pulse B-Sec
wave I-Sec
velocity I-Sec
and O
carotid B-Sec
intima-media I-Sec
thickness I-Sec
. O

Analyses O
of O
covariance O
( O
with O
" O
other O
relevant O
variables O
" O
from O
above O
as O
covariates O
) O
will O
test O
the O
between O
group O
differences O
in O
the O
secondary O
and O
secondary O
outcomes O
at O
each O
assessment O
time O
point O
and O
across O
time O
points O
for O
the O
parents O
and O
children O
. O

The O
secondary O
outcome O
was O
trial B-Sec
feasibility I-Sec
, I-Sec
defined I-Sec
by I-Sec
randomization I-Sec
of I-Sec
> I-Sec
25 I-Sec
% I-Sec
of I-Sec
eligible I-Sec
patients I-Sec
, I-Sec
delivery I-Sec
of I-Sec
> I-Sec
75 I-Sec
% I-Sec
of I-Sec
the I-Sec
prescribed I-Sec
CRRT I-Sec
dose I-Sec
, I-Sec
and I-Sec
follow-up I-Sec
of I-Sec
> I-Sec
95 I-Sec
% I-Sec
of I-Sec
patients I-Sec
to I-Sec
60 I-Sec
days I-Sec
. O

Effect O
variables O
secondary O
effect O
variables O
were O
u-AQP2 B-Sec
and O
u-ENaC B-Sec
. O

This O
was O
a O
24-week O
placebo-controlled O
and O
randomized O
intervention O
trial O
to O
investigate O
the O
effects O
of O
GTP O
and O
TC O
on O
relevant O
secondary O
and O
secondary O
endpoints O
in O
postmenopausal O
women O
with O
osteopenia O
. O

Sample O
Size O
Considerations O
Gait B-Sec
speed I-Sec
at I-Sec
six I-Sec
months I-Sec
was O
chosen O
as O
the O
secondary O
outcome O
because O
safe O
, O
independent O
walking O
is O
a O
high O
priority O
amongst O
patients O
participating O
in O
rehabilitation O
, O
and O
gait O
speed O
is O
often O
recommended O
as O
a O
measure O
of O
status O
and O
outcome O
46 O
47 O
. O

At O
6 O
and O
14 O
weeks O
after O
the O
start O
of O
treatment O
, O
the O
secondary O
outcome O
and O
three O
potential O
mediators O
— O
self-efficacy O
, O
causal O
attributions O
and O
present-centred O
attention-awareness O
— O
will O
be O
measured O
. O

secondary O
outcome O
measures O
are O
measures B-Sec
of I-Sec
cognitive I-Sec
function I-Sec
. O

For O
our O
secondary O
outcome O
, O
the O
slope O
of O
quality O
score O
change O
was O
also O
similar O
: O
-0.229 O
( O
95 O
% O
CI O
−0.644 O
to O
−0.185 O
) O
for O
controls O
and O
−0.549 O
( O
−0.831 O
to O
−0.267 O
) O
for O
mentees O
. O

The O
secondary O
pharmacokinetic O
parameter O
was O
AUC O
τ O
. O

While O
the O
study's O
secondary O
assessment O
protocol O
was O
administered O
approximately O
eight O
months O
after O
baseline O
, O
one O
might O
still O
question O
whether O
the O
medical O
students' O
communication O
skills O
learning O
was O
maintained O
over O
a O
greater O
length O
of O
time O
. O

To O
circumvent O
this O
dilemma O
, O
we O
proposed O
that O
control O
participants O
should O
not O
receive O
a O
welfare O
rights O
assessment O
until O
the O
end O
of O
the O
trial O
period O
( O
ie O
following O
secondary O
outcome O
measurement O
) O
. O

The O
secondary O
outcomes O
are O
: O
serum B-Sec
levels I-Sec
of I-Sec
sTNFR-1 I-Sec
, I-Sec
sTNFR-2 I-Sec
, I-Sec
interleukin I-Sec
( I-Sec
IL I-Sec
) I-Sec
-6 I-Sec
, I-Sec
IL-10 I-Sec
, I-Sec
measured I-Sec
by I-Sec
the I-Sec
ELISA I-Sec
method I-Sec
; O
genotyping B-Sec
of I-Sec
tumor I-Sec
necrosis I-Sec
factor- I-Sec
( I-Sec
TNF I-Sec
) I-Sec
-alpha I-Sec
( I-Sec
rs1800629 I-Sec
) I-Sec
, I-Sec
IL6 I-Sec
( I-Sec
rs1800795 I-Sec
) I-Sec
, I-Sec
IL10 I-Sec
( I-Sec
rs1800896 I-Sec
) I-Sec
by I-Sec
the I-Sec
TaqMan I-Sec
Method I-Sec
( I-Sec
Applied I-Sec
Biosystems I-Sec
, I-Sec
Foster I-Sec
City I-Sec
, I-Sec
CA I-Sec
, I-Sec
USA I-Sec
) I-Sec
; O
and O
physical B-Sec
performance I-Sec
assessed I-Sec
by I-Sec
Timed I-Sec
Up I-Sec
and I-Sec
Go I-Sec
and I-Sec
10-Meter I-Sec
Walk I-Sec
Tests I-Sec
. O

Outcomes O
The O
secondary O
outcome O
will O
be O
the B-Sec
ability I-Sec
of I-Sec
the I-Sec
Internet I-Sec
package I-Sec
to I-Sec
promote I-Sec
change I-Sec
in I-Sec
BMI I-Sec
over I-Sec
6 I-Sec
and I-Sec
12 I-Sec
months I-Sec
compared I-Sec
with I-Sec
traditional I-Sec
treatment I-Sec
. O

The O
secondary O
outcome O
is O
pain-related B-Sec
disability I-Sec
and O
functional B-Sec
interference I-Sec
. O

Efficacy O
results O
In O
the O
double-blind O
part O
of O
the O
study O
, O
more O
patients O
on O
adalimumab O
achieved O
an B-Sec
ASAS40 I-Sec
, O
the O
secondary O
outcome O
parameter O
, O
at O
week O
4 O
( O
41 O
% O
) O
, O
week O
8 O
( O
53 O
% O
) O
and O
week O
12 O
( O
53 O
% O
) O
than O
on O
placebo O
( O
20 O
% O
, O
33 O
% O
, O
33 O
% O
) O
, O
while O
differences O
at O
week O
8 O
only O
reached O
the O
border O
significance O
( O
P O
= O
0.05 O
) O
. O

The O
secondary O
outcome O
measure O
is O
the B-Sec
patient-reported I-Sec
Disabilities I-Sec
of I-Sec
the I-Sec
Arm I-Sec
, I-Sec
Hand I-Sec
and I-Sec
Shoulder I-Sec
Questionnaire I-Sec
( I-Sec
DASH I-Sec
) I-Sec
. O

The O
secondary O
outcome O
measures O
are O
the B-Sec
quality I-Sec
of I-Sec
life I-Sec
of I-Sec
people I-Sec
with I-Sec
dementia I-Sec
, I-Sec
as I-Sec
assessed I-Sec
by I-Sec
QoL-AD I-Sec
, O
and O
their B-Sec
care-givers' I-Sec
mental I-Sec
health I-Sec
as I-Sec
assessed I-Sec
by I-Sec
the I-Sec
GHQ-28 I-Sec
. O

secondary O
outcome O
measures O
will O
be O
the B-Sec
Nottingham I-Sec
Extended I-Sec
Activities I-Sec
of I-Sec
Daily I-Sec
Living I-Sec
Scale I-Sec
( I-Sec
NEADL I-Sec
) I-Sec
and O
the B-Sec
Late I-Sec
Life I-Sec
Disability I-Sec
Index I-Sec
( I-Sec
LLDI I-Sec
) I-Sec
which I-Sec
will I-Sec
measure I-Sec
functional I-Sec
independence I-Sec
, O
and O
participation B-Sec
and I-Sec
limitation I-Sec
in I-Sec
daily I-Sec
life I-Sec
activities I-Sec
. O

However O
, O
additional O
research O
is O
needed O
to O
assess O
the O
long-term O
efficacy O
of O
walnut O
consumption O
on O
PSA O
and O
other O
secondary O
measures O
of O
prostate O
health O
. O

In O
order O
to O
adapt O
to O
the O
differences O
in O
populations O
, O
a O
pilot O
study O
comprising O
36 O
patients O
was O
conducted O
to O
determine O
the O
population O
size O
, O
inclusion O
and O
exclusion O
criteria O
, O
questionnaires O
, O
logistics O
and O
the O
secondary O
outcome O
measures O
in O
the O
RCT O
. O

Our O
co-Secary O
outcomes O
are O
the B-Sec
modified I-Sec
Roland I-Sec
score I-Sec
and O
pain B-Sec
numerical I-Sec
rating I-Sec
scale I-Sec
at I-Sec
1 I-Sec
month I-Sec
. O

We O
will O
also O
investigate O
the O
following O
areas O
: O
• O
differences O
in O
health O
care O
resources O
consumption O
• O
differences O
in O
comparing O
the O
costs O
of O
the O
study O
with O
the O
benefits O
resulting O
by O
the O
intervention O
( O
see O
Economic O
evaluation O
paragraph O
) O
A O
list O
of O
categories O
of O
the O
study O
outcomes O
, O
with O
the O
secondary O
outcome O
of O
each O
category O
, O
is O
reported O
in O
table O
1 O
. O

secondary O
endpoint O
is O
the B-Sec
comparison I-Sec
of I-Sec
the I-Sec
‘weaning I-Sec
time’ I-Sec
defined I-Sec
as I-Sec
the I-Sec
time I-Sec
required I-Sec
from I-Sec
discontinuation I-Sec
of I-Sec
the I-Sec
sedating I-Sec
agent I-Sec
until I-Sec
sufficient I-Sec
spontaneous I-Sec
breathing I-Sec
occurs I-Sec
. O

Sample O
size O
Our O
sample O
size O
calculation O
is O
based O
on O
the O
combined O
secondary O
endpoints O
( B-Sec
a I-Sec
) I-Sec
number I-Sec
of I-Sec
patients I-Sec
that I-Sec
resume I-Sec
and I-Sec
maintain I-Sec
sports I-Sec
during I-Sec
12 I-Sec
months I-Sec
follow-up I-Sec
, O
and O
( B-Sec
b I-Sec
) I-Sec
the I-Sec
time I-Sec
to I-Sec
resumption I-Sec
of I-Sec
sport I-Sec
. O

The O
secondary O
and O
secondary O
outcomes O
between O
the O
two O
intervention O
groups O
will O
be O
compared O
using O
the O
Chi-square O
test O
. O

secondary O
outcomes O
were O
changes B-Sec
between I-Sec
baseline I-Sec
and I-Sec
nine I-Sec
months I-Sec
of I-Sec
bone I-Sec
mineral I-Sec
density I-Sec
( I-Sec
BMD I-Sec
) I-Sec
of I-Sec
the I-Sec
proximal I-Sec
femur I-Sec
and I-Sec
lumbar I-Sec
spine I-Sec
( I-Sec
dual-energy I-Sec
X-ray I-Sec
absorptiometry I-Sec
) I-Sec
and O
serum B-Sec
markers I-Sec
of I-Sec
bone I-Sec
resorption I-Sec
and I-Sec
formation I-Sec
. O

The O
secondary O
outcome O
was O
health-related B-Sec
quality I-Sec
of I-Sec
life I-Sec
( I-Sec
HRQoL I-Sec
) I-Sec
; O
secondary O
outcomes O
were O
mood B-Sec
state I-Sec
, O
dyspnea B-Sec
, O
gas B-Sec
exchange I-Sec
, O
functional B-Sec
status I-Sec
, O
pulmonary B-Sec
function I-Sec
, O
and O
exacerbation B-Sec
frequency I-Sec
. O

The B-Sec
LSAS-SR I-Sec
was O
the O
secondary O
outcome O
measure O
. O

The O
secondary O
outcome O
for O
the O
analyses O
in O
this O
manuscript O
was O
perinatal B-Sec
mortality I-Sec
( I-Sec
stillbirth I-Sec
or I-Sec
death I-Sec
during I-Sec
the I-Sec
first I-Sec
seven I-Sec
days I-Sec
after I-Sec
birth I-Sec
) I-Sec
. O

The O
patients O
were O
informed O
of O
the O
study O
before O
the O
first O
assessment O
and O
signed O
a O
written O
, O
informed O
consent O
statement O
. O

Two O
CEAs O
will O
be O
performed O
from O
the O
company O
perspective O
: O
1 O
) O
intervention O
costs O
together O
with O
savings O
as O
a O
result O
of O
reduced O
sick O
leave O
( O
absenteeism O
) O
and O
loss O
of O
productivity O
( O
presenteeism O
) O
will O
be O
compared O
to O
the O
obtained O
effects O
on O
the O
secondary O
outcome O
measures O
lifestyle B-Sec
and O
vitality B-Sec
2 O
) O
intervention O
costs O
will O
be O
compared O
to O
the O
obtained O
benefits O
due O
to O
reduced O
sick O
leave O
and O
increased O
productivity O
. O

The O
secondary O
endpoint O
was O
change B-Sec
in I-Sec
urinary I-Sec
HRQOL I-Sec
at I-Sec
3 I-Sec
months I-Sec
. O

Sample O
size O
and O
power O
The O
study O
will O
be O
powered O
on O
the O
secondary O
outcome O
measure O
, O
namely O
( B-Sec
change I-Sec
in I-Sec
) I-Sec
risk I-Sec
perception I-Sec
. O

The O
secondary O
outcome O
of O
this O
study O
was O
the B-Sec
change I-Sec
in I-Sec
postbronchodilator I-Sec
FEV I-Sec
1 I-Sec
, O
which O
has O
been O
noted O
to O
improve O
in O
some O
, O
but O
not O
all O
, O
previous O
trials O
of O
ICS O
in O
COPD O
8 O
9 O
23 O
25 O
26 O
. O

In O
addition O
, O
participants O
with O
missing O
or O
inconsistent O
data O
on O
the O
secondary O
variables O
( O
n O
= O
1 O
, O
286 O
) O
or O
confounders O
( O
n O
= O
381 O
) O
were O
excluded O
, O
leaving O
19 O
, O
096 O
participants O
for O
statistical O
analyses O
. O

Analytic O
Methods O
The O
secondary O
analysis O
will O
compare O
the O
secondary O
outcome O
between O
the O
two O
treatments O
taking O
into O
account O
possible O
variability O
in O
the O
overall O
level O
of O
abstinence O
between O
sites O
. O

Study O
outcomes O
secondary O
outcome O
The O
secondary O
outcome O
is O
the B-Sec
difference I-Sec
between I-Sec
the I-Sec
two I-Sec
groups I-Sec
in I-Sec
achieving I-Sec
a I-Sec
50 I-Sec
% I-Sec
increase I-Sec
in I-Sec
breast I-Sec
milk I-Sec
volume I-Sec
at I-Sec
the I-Sec
end I-Sec
of I-Sec
the I-Sec
first I-Sec
2-week I-Sec
period I-Sec
( I-Sec
mean I-Sec
day I-Sec
14 I-Sec
volume- I-Sec
mean I-Sec
day I-Sec
0 I-Sec
volume I-Sec
at I-Sec
entry I-Sec
) I-Sec
. O

secondary O
outcomes O
include O
obesity B-Sec
( I-Sec
BMI I-Sec
≥95 I-Sec
th I-Sec
percentile I-Sec
) I-Sec
and O
overweight B-Sec
( I-Sec
BMI I-Sec
≥85 I-Sec
th I-Sec
percentile I-Sec
) I-Sec
based I-Sec
on I-Sec
the I-Sec
1988 I-Sec
BMI I-Sec
tables I-Sec
of I-Sec
Hernandez I-Sec
19 I-Sec
. O

Nevertheless O
, O
multiple O
outcome O
measures O
can O
lead O
to O
false O
positive O
conclusions O
about O
the O
effectiveness O
of O
a O
treatment O
so O
a O
secondary O
outcome O
variable O
( O
change B-Sec
in I-Sec
depressive I-Sec
symptoms I-Sec
) O
is O
specified O
. O

The O
secondary O
endpoints O
of O
our O
study O
will O
be O
: O
A B-Sec
) I-Sec
To I-Sec
evaluate I-Sec
the I-Sec
conversion I-Sec
rate I-Sec
B B-Sec
) I-Sec
To I-Sec
evaluate I-Sec
morbidity I-Sec
, I-Sec
mortality I-Sec
, I-Sec
operation I-Sec
time I-Sec
C B-Sec
) I-Sec
To I-Sec
evaluate I-Sec
hospital I-Sec
stay I-Sec
, I-Sec
postoperative I-Sec
pain I-Sec
, I-Sec
return I-Sec
to I-Sec
normal I-Sec
activity I-Sec
The O
onset O
of O
any O
other O
complications O
will O
be O
recorded O
intraoperatively O
, O
postoperatively O
, O
at O
discharge O
, O
at O
7-days O
, O
1-month O
and O
6-months O
. O

The O
secondary O
outcome O
was O
change B-Sec
in I-Sec
body I-Sec
weight I-Sec
and O
waist B-Sec
circumference I-Sec
. O

A O
post-hoc O
design O
that O
samples O
based O
on O
secondary O
trial O
outcomes O
would O
avoid O
this O
risk O
, O
but O
at O
the O
cost O
of O
being O
designed O
after O
trial O
effectiveness O
is O
known O
, O
and O
conducted O
long O
after O
the O
trial O
completes O
. O

Unless O
clinically O
necessary O
, O
there O
will O
be O
no O
angiographic O
follow-up O
until O
12 O
months O
post O
PCI O
, O
the O
timepoint O
for O
the O
secondary O
endpoint O
of O
the O
stent O
comparison O
. O

Sample O
size O
To O
detect O
a O
true O
difference O
in O
the O
secondary O
outcome O
measures O
of O
maximal B-Sec
exercise I-Sec
capacity I-Sec
and O
HRQoL B-Sec
, O
a O
total O
of O
36 O
subjects O
( O
18 O
per O
group O
) O
will O
be O
required O
. O

Study O
outcomes O
The O
secondary O
outcomes O
in O
this O
trial O
are O
: O
( B-Sec
1 I-Sec
) I-Sec
immune I-Sec
reconstitution I-Sec
, I-Sec
defined I-Sec
as I-Sec
change I-Sec
in I-Sec
CD4 I-Sec
cell I-Sec
count I-Sec
; O
( B-Sec
2 I-Sec
) I-Sec
weight I-Sec
gain I-Sec
; O
and O
( B-Sec
3 I-Sec
) I-Sec
change I-Sec
in I-Sec
quality I-Sec
of I-Sec
life I-Sec
, I-Sec
defined I-Sec
as I-Sec
overall I-Sec
score I-Sec
on I-Sec
the I-Sec
Medical I-Sec
Outcomes I-Sec
Survey-HIV I-Sec
( I-Sec
MOS-HIV I-Sec
) I-Sec
14 I-Sec
, I-Sec
and I-Sec
individual I-Sec
scores I-Sec
for I-Sec
general I-Sec
health I-Sec
perceptions I-Sec
, I-Sec
physical I-Sec
functioning I-Sec
, I-Sec
pain I-Sec
, I-Sec
energy I-Sec
, I-Sec
role I-Sec
functioning I-Sec
, I-Sec
social I-Sec
functioning I-Sec
, I-Sec
and I-Sec
mental I-Sec
health I-Sec
. O

Finally O
, O
information O
on O
participant O
disposition O
was O
collected O
to O
document O
the O
recruitment O
of O
participants O
and O
their O
progression O
through O
the O
trial O
, O
numbers O
receiving O
intended O
treatment O
, O
those O
completing O
the O
study O
protocol O
and O
analysed O
for O
the O
secondary O
outcome O
14 O
24 O
. O

The O
secondary O
outcome O
measure O
is O
sick B-Sec
leave I-Sec
duration I-Sec
until I-Sec
full I-Sec
RTW I-Sec
. O

secondary O
outcome O
criterium O
Mobilization B-Sec
status I-Sec
as I-Sec
assessed I-Sec
by I-Sec
the I-Sec
4-item I-Sec
abbreviation I-Sec
of I-Sec
the I-Sec
Barthel I-Sec
index I-Sec
, I-Sec
focusing I-Sec
on I-Sec
lower I-Sec
extremity I-Sec
motoric I-Sec
function I-Sec
. O

secondary O
outcomes O
We O
are O
using O
the B-Sec
function I-Sec
component I-Sec
of I-Sec
the I-Sec
Late I-Sec
Life I-Sec
Function I-Sec
and I-Sec
Disability I-Sec
Instrument I-Sec
( I-Sec
LLFDI I-Sec
) I-Sec
to O
measure O
the O
functional O
ability O
constructs O
25 O
. O

Power O
analysis O
of O
project O
A1 O
Analysis O
is O
based O
on O
a O
statistical O
power O
of O
80 O
% O
with O
an O
alpha O
of O
5 O
% O
for O
detecting O
a B-Sec
meaningful I-Sec
difference I-Sec
of I-Sec
6 I-Sec
points I-Sec
ie I-Sec
10 I-Sec
% I-Sec
on I-Sec
the I-Sec
Action I-Sec
Research I-Sec
Arm I-Sec
Test I-Sec
, I-Sec
ARAT I-Sec
sum I-Sec
score I-Sec
as O
the O
secondary O
outcome O
measure O
35 O
. O

secondary O
endpoint O
is O
number B-Sec
of I-Sec
scaphoid I-Sec
unions I-Sec
at I-Sec
six I-Sec
weeks I-Sec
, O
secondary O
endpoints O
are O
time B-Sec
interval I-Sec
to I-Sec
clinical I-Sec
and I-Sec
radiological I-Sec
consolidation I-Sec
, O
number B-Sec
of I-Sec
non-unions I-Sec
, O
functional B-Sec
status I-Sec
at I-Sec
52 I-Sec
weeks I-Sec
and O
non-adherence B-Sec
to I-Sec
the I-Sec
treatment I-Sec
protocol I-Sec
. O

Differences O
between O
treatment O
groups O
concerning O
the O
secondary O
outcome O
measures O
will O
be O
expressed O
as O
relative O
risks O
and O
95 O
% O
confidence O
intervals O
or O
as O
central O
estimators O
and O
variance O
measures O
where O
appropriate O
. O

The O
time O
of O
recording O
for O
each O
participant O
was O
kept O
constant O
for O
the O
initial O
and O
secondary O
assessment O
. O

The O
secondary O
outcome O
measure O
will O
be O
the B-Sec
rates I-Sec
of I-Sec
decline I-Sec
in I-Sec
eGFR I-Sec
( I-Sec
ml I-Sec
/ I-Sec
min I-Sec
/ I-Sec
1.73 I-Sec
m I-Sec
2 I-Sec
/ I-Sec
month I-Sec
) I-Sec
measured I-Sec
by I-Sec
MDRD I-Sec
and I-Sec
Cockcroft I-Sec
Gault I-Sec
equations I-Sec
. O

Table O
1 O
Subject O
characteristics O
and O
secondary O
outcome O
. O

The O
secondary O
outcome O
for O
this O
trial O
was O
incidence B-Sec
of I-Sec
low I-Sec
back I-Sec
pain I-Sec
resulting I-Sec
in I-Sec
the I-Sec
seeking I-Sec
of I-Sec
health I-Sec
care I-Sec
. O

Outcome O
A O
secondary O
outcome O
measure O
is O
change B-Sec
in I-Sec
AD I-Sec
patients’ I-Sec
weights I-Sec
. O

The O
secondary O
endpoint O
of O
this O
study O
is O
26 O
weeks O
, O
whilst O
the O
52 O
week O
questionnaire O
will O
provide O
data O
on O
the O
longer O
term O
effectiveness O
of O
the O
interventions O
. O

The O
secondary O
outcome O
was O
gingival B-Sec
bleeding I-Sec
with O
the O
hypothesis O
that O
6-monthly O
scale O
and O
polish O
would O
result O
in O
lower O
prevalence O
than O
12-month O
or O
24-month O
frequency O
. O

It O
also O
should O
be O
pointed O
out O
that O
an O
in O
vivo O
scenario O
is O
quite O
complex O
and O
the O
secondary O
outcome O
of O
an O
infectious O
process O
depends O
on O
the O
concerted O
action O
of O
several O
cells O
, O
including O
epithelial O
, O
endothelial O
, O
neutrophils O
, O
macrophages O
and O
lymphocytes O
, O
and O
therefore O
, O
we O
cannot O
rule O
out O
that O
glutamine O
may O
exert O
a O
positive O
effect O
on O
other O
cell O
types O
or O
even O
at O
the O
level O
of O
cross-talk O
between O
cells O
of O
the O
innate O
immune O
system O
. O

The O
secondary O
outcome O
of O
this O
project O
will O
be O
the B-Sec
determination I-Sec
of I-Sec
the I-Sec
strength I-Sec
of I-Sec
effect I-Sec
of I-Sec
exercise I-Sec
on I-Sec
the I-Sec
well I-Sec
established I-Sec
musculoskeletal I-Sec
, I-Sec
cardiovascular I-Sec
and I-Sec
insulin I-Sec
metabolism I-Sec
side I-Sec
effects I-Sec
of I-Sec
ADT I-Sec
in I-Sec
prostate I-Sec
cancer I-Sec
patients I-Sec
. O

Outcomes O
secondary O
outcome O
The O
secondary O
outcome O
was O
the B-Sec
duration I-Sec
of I-Sec
fluid I-Sec
fast I-Sec
prior I-Sec
to I-Sec
induction I-Sec
of I-Sec
anaesthesia I-Sec
. O

Figure O
2 O
illustrates O
the O
median O
and O
inter-quartile O
ranges O
for O
the O
secondary O
outcome O
measure O
at O
the O
secondary O
outcome O
point O
( O
9 O
months O
) O
. O

High-dose O
supplementation O
had O
no O
effect O
on O
several O
key O
measures O
that O
reveal O
HIV O
disease O
progression O
— O
CD4 O
count O
, O
plasma O
viral O
load O
, O
body O
mass O
index O
, O
or O
hemoglobin O
level O
concentration O
— O
and O
did O
not O
reduce O
death O
or O
disease O
progression O
risks O
for O
HIV-infected O
patients O
. O

The O
secondary O
endpoint O
is O
the B-Sec
mortality I-Sec
rate I-Sec
within I-Sec
hospitalization I-Sec
. O

We O
assumed O
the O
ICC O
for O
secondary O
care O
outcomes O
was O
0.02 O
50 O
. O

Participants O
reach O
the O
secondary O
endpoint O
if O
at O
least O
one O
of O
the O
following O
occurs O
: O
( B-Sec
1 I-Sec
) I-Sec
death I-Sec
, O
( B-Sec
2 I-Sec
) I-Sec
acute I-Sec
myocardial I-Sec
infarction I-Sec
, O
( B-Sec
3 I-Sec
) I-Sec
cerebral I-Sec
thrombosis I-Sec
, O
( B-Sec
4 I-Sec
) I-Sec
cerebral I-Sec
hemorrhage I-Sec
, O
( B-Sec
5 I-Sec
) I-Sec
peripheral I-Sec
arterial I-Sec
occlusive I-Sec
disease I-Sec
. O

The O
secondary O
outcomes O
are O
symptoms B-Sec
of I-Sec
depression I-Sec
and O
anxiety B-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
PHQ-9 I-Sec
and I-Sec
GAD-7 I-Sec
31 I-Sec
32 I-Sec
. O

The O
overall O
acceptance O
of O
the O
tool O
and O
its O
ability O
to O
alter O
antibiotic O
prescribing O
for O
suspected O
strep O
or O
pneumonia O
will O
be O
determined O
by O
the O
secondary O
outcomes O
of O
the O
trial O
. O

The O
secondary O
outcome O
measure O
, O
the B-Sec
Stanford I-Sec
Health I-Sec
Assessment I-Sec
Questionnaire I-Sec
Disability I-Sec
Index I-Sec
( I-Sec
HAQ-DI I-Sec
) I-Sec
which I-Sec
measures I-Sec
functional I-Sec
ability I-Sec
, O
and O
secondary O
measures O
of O
pain B-Sec
, O
fatigue B-Sec
and O
quality B-Sec
of I-Sec
life I-Sec
, O
will O
be O
assessed O
at O
baseline O
, O
eight O
and O
24 O
weeks O
by O
an O
independent O
assessor O
unaware O
of O
group O
allocation O
. O

Statistical O
issues O
Sample O
size O
calculations O
The O
study O
is O
designed O
as O
an O
equivalence O
study O
, O
whereby O
both O
treatments O
will O
have O
the O
same O
incidence O
of O
the O
secondary O
outcome O
measure O
of O
combined B-Sec
bad I-Sec
neonatal I-Sec
outcome I-Sec
. O

The O
secondary O
outcome O
will O
combine O
pain B-Sec
and O
function B-Sec
subscales I-Sec
of I-Sec
the I-Sec
AUSCAN I-Sec
31 I-Sec
40 I-Sec
and O
global B-Sec
assessment I-Sec
of I-Sec
improvement I-Sec
41 I-Sec
to I-Sec
determine I-Sec
a I-Sec
' I-Sec
responder' I-Sec
using I-Sec
the I-Sec
OARSI-OMERACT I-Sec
criteria I-Sec
42 I-Sec
at I-Sec
6 I-Sec
months I-Sec
post I-Sec
randomisation I-Sec
. O

Outcome O
measures O
secondary O
outcome O
measure O
The O
secondary O
outcome O
measure O
is O
the B-Sec
time I-Sec
to I-Sec
the I-Sec
occurrence I-Sec
of I-Sec
a I-Sec
spontaneous I-Sec
viable I-Sec
IUP I-Sec
. O

secondary O
Outcome O
measure O
: O
Depression B-Sec
using I-Sec
the I-Sec
Children's I-Sec
Depression I-Sec
Inventory I-Sec
2 I-Sec
( I-Sec
CDI-2 I-Sec
) I-Sec
. O

The O
secondary O
outcome O
measure O
( O
QPR B-Sec
) O
and O
the O
secondary O
outcome O
measures O
are O
listed O
in O
Section O
13. O

Authors' O
contributions O
DW O
is O
the O
secondary O
investigator O
; O
she O
led O
the O
conception O
and O
design O
of O
the O
study O
, O
development O
of O
the O
intervention O
, O
selection O
of O
secondary O
and O
secondary O
measures O
, O
and O
development O
of O
the O
manuscript O
. O

secondary O
outcome O
measures O
are O
symptoms B-Sec
of I-Sec
depression I-Sec
and O
anxiety B-Sec
. O

The O
secondary O
outcome O
will O
not O
simply O
be O
antibiotic O
prescribing O
in O
a O
single O
consultation O
as O
in O
individually O
randomized O
trials O
57 O
, O
but O
rather O
, O
antibiotic B-Sec
prescribing I-Sec
for I-Sec
a I-Sec
whole I-Sec
year I-Sec
. O

If O
they O
did O
not O
attend O
the O
day O
42 O
visit O
, O
the O
secondary O
outcome O
of O
the O
malaria O
episode O
was O
determined O
where O
possible O
. O

We O
recommend O
that O
randomised O
controlled O
trials O
of O
sufficient O
power O
are O
carried O
out O
using O
secondary O
outcomes O
of O
reduction O
in O
outward O
directed O
aggression O
, O
improvement O
in O
quality O
of O
life O
and O
cost O
efficacy O
as O
measured O
by O
standardised O
scales O
" O
27 O
. O

Study O
parameters O
secondary O
study O
outcome O
The O
secondary O
outcome O
of O
the O
study O
will O
be O
the B-Sec
capability I-Sec
of I-Sec
functional I-Sec
skills I-Sec
in I-Sec
mobility I-Sec
and I-Sec
self-care I-Sec
using I-Sec
the I-Sec
Functional I-Sec
Skills I-Sec
Scale I-Sec
of I-Sec
the I-Sec
PEDI I-Sec
( I-Sec
PEDI-FSS I-Sec
; I-Sec
37 I-Sec
) I-Sec
. O

Outcomes O
The O
secondary O
outcome O
measure O
is O
‘recurrence’ B-Sec
, I-Sec
defined I-Sec
as I-Sec
the I-Sec
proportion I-Sec
of I-Sec
patients I-Sec
with I-Sec
recurrent I-Sec
haemorrhoids I-Sec
at I-Sec
12 I-Sec
months I-Sec
, I-Sec
as I-Sec
derived I-Sec
from I-Sec
a I-Sec
telephone I-Sec
assessment I-Sec
in I-Sec
combination I-Sec
with I-Sec
GP I-Sec
and I-Sec
hospital I-Sec
records I-Sec
. O

The O
secondary O
outcome O
measures O
assessed O
in O
the O
pilot O
were O
success B-Sec
at I-Sec
quitting I-Sec
( I-Sec
expired I-Sec
CO I-Sec
≤ I-Sec
9 I-Sec
ppm I-Sec
) I-Sec
, O
the B-Sec
dose I-Sec
of I-Sec
NRT I-Sec
used I-Sec
, O
and O
the B-Sec
rating I-Sec
of I-Sec
withdrawal I-Sec
symptoms I-Sec
using I-Sec
the I-Sec
Mood I-Sec
and I-Sec
Symptoms I-Sec
Scale I-Sec
. O

Measurement O
of O
cardiac O
output O
Monitoring O
of O
the O
key O
cardiovascular O
variables O
of O
blood O
pressure O
and O
cardiac O
output O
( O
volume O
of O
blood O
pumped O
by O
the O
heart O
per O
minute O
) O
is O
common O
in O
patients O
at O
high O
risk O
of O
intra-operative O
and O
postoperative O
complications O
. O

The B-Sec
Shoulder I-Sec
Pain I-Sec
and I-Sec
Disability I-Sec
Index I-Sec
( I-Sec
SPADI I-Sec
) I-Sec
at I-Sec
1 I-Sec
year I-Sec
follow-up I-Sec
was O
used O
as O
the O
secondary O
outcome O
25 O
26 O
. O

Discussion O
In O
this O
paper O
, O
we O
have O
reported O
the O
background O
, O
the O
rationale O
, O
and O
the O
study O
protocol O
for O
a O
unique O
multi-center O
randomized O
controlled O
trial O
whose O
secondary O
outcome O
is O
a B-Sec
biochemical I-Sec
measurement I-Sec
( I-Sec
ie I-Sec
CRP I-Sec
) I-Sec
. O

The O
secondary O
endpoint O
will O
be O
assessed O
in O
Q3 O
2016. O

secondary O
end-points O
of O
the O
study O
were O
peak B-Sec
systolic I-Sec
and I-Sec
end-diastolic I-Sec
blood I-Sec
flow I-Sec
velocities I-Sec
in I-Sec
the I-Sec
short I-Sec
posterior I-Sec
ciliary I-Sec
artery I-Sec
( I-Sec
SPCA I-Sec
) I-Sec
under I-Sec
the I-Sec
new I-Sec
therapy I-Sec
. O

b O
secondary O
efficacy O
outcome O
. O

The O
secondary O
outcome O
for O
the O
initial O
trial O
was O
the B-Sec
time I-Sec
until I-Sec
shock I-Sec
reversal I-Sec
with O
a O
secondary O
outcome O
of O
attenuation B-Sec
of I-Sec
the I-Sec
inflammatory I-Sec
cascade I-Sec
following I-Sec
intervention I-Sec
. O

Intra O
class O
correlations O
will O
be O
assessed O
for O
all O
the O
secondary O
outcome O
measures O
and O
multilevel O
modelling O
used O
to O
take O
into O
account O
any O
design O
effects O
as O
well O
as O
the O
non O
independence O
of O
data O
from O
multiple O
children O
in O
one O
family O
. O

For O
the O
secondary O
endpoint O
( O
HAQ-DI B-Sec
at I-Sec
8 I-Sec
and I-Sec
24 I-Sec
weeks I-Sec
) O
an O
analysis O
of O
covariance O
( O
ANCOVA O
) O
will O
be O
used O
to O
explore O
between O
group O
differences O
in O
terms O
of O
the O
continuous O
variables O
thereby O
accounting O
for O
baseline O
scores O
. O

Sample O
size O
calculation O
As O
our O
secondary O
outcome O
measure O
is O
gene B-Sec
expression I-Sec
in I-Sec
whole I-Sec
blood I-Sec
, O
a O
priori O
sample O
size O
calculations O
are O
not O
possible O
. O

Sample O
size O
consideration O
The O
sample O
size O
and O
power O
calculations O
have O
been O
estimated O
for O
the O
secondary O
outcome O
of O
this O
study O
, O
ie O
, O
the B-Sec
rate I-Sec
of I-Sec
falls I-Sec
. O

There O
was O
no O
effect O
on O
length B-Sec
of I-Sec
stay I-Sec
( O
the O
secondary O
endpoint O
) O
, O
but O
a O
pronounced O
effect O
upon O
postoperative O
complications O
, O
mainly O
delirium O
( O
34 O
% O
versus O
44 O
% O
) O
and O
pressure O
sores O
( O
5 O
% O
versus O
17 O
% O
) O
21 O
. O

The O
secondary O
outcome O
is O
the B-Sec
proportion I-Sec
of I-Sec
participants I-Sec
who I-Sec
self-report I-Sec
seven-day I-Sec
point I-Sec
prevalence I-Sec
abstinence I-Sec
at I-Sec
six I-Sec
months I-Sec
since I-Sec
Quit I-Sec
date I-Sec
. O

We O
hope O
to O
assess O
long O
term O
maintenance O
of O
exercise O
participation O
in O
a O
full O
trial O
and O
to O
obtain O
information O
about O
the O
influence O
specific O
elements O
of O
the O
program O
have O
on O
the O
secondary O
outcome O
. O

The O
analysis O
will O
determine O
the O
size O
of O
the O
effect O
, O
if O
any O
, O
of O
physical O
activity O
on O
secondary O
and O
secondary O
outcome O
variables O
. O

secondary O
Outcome O
The O
secondary O
outcome O
is O
mean B-Sec
change I-Sec
difference I-Sec
in I-Sec
child I-Sec
percent I-Sec
body I-Sec
fat I-Sec
between I-Sec
baseline I-Sec
and I-Sec
post-intervention I-Sec
. O

Prognostic O
outcome O
measure O
Psychosocial O
workload O
is O
considered O
to O
be O
a O
potentially O
prognostic O
factor O
for O
the O
secondary O
outcome O
measure O
, O
' B-Sec
need I-Sec
for I-Sec
recovery I-Sec
after I-Sec
work' I-Sec
. O

secondary O
outcome O
variable O
will O
be O
the B-Sec
Action I-Sec
Research I-Sec
Arm I-Sec
Test I-Sec
( I-Sec
ARAT I-Sec
) I-Sec
, I-Sec
assessed I-Sec
at I-Sec
1 I-Sec
, I-Sec
2 I-Sec
, I-Sec
3 I-Sec
, I-Sec
4 I-Sec
, I-Sec
5 I-Sec
, I-Sec
8 I-Sec
, I-Sec
12 I-Sec
and I-Sec
26 I-Sec
weeks I-Sec
post I-Sec
stroke I-Sec
. O

Endpoints O
The O
secondary O
outcome O
was O
the B-Sec
mean I-Sec
time I-Sec
to I-Sec
onset I-Sec
of I-Sec
the I-Sec
first I-Sec
24-h I-Sec
heartburn-free I-Sec
period I-Sec
after I-Sec
initial I-Sec
dosing I-Sec
. O

Both O
budesonide O
/ O
formoterol O
( O
160 O
/ O
4.5 O
μg O
one O
inhalation O
) O
and O
salbutamol O
( O
100 O
μg O
two O
inhalations O
) O
were O
superior O
to O
placebo O
for O
the O
secondary O
efficacy O
variable O
– O
the B-Sec
onset I-Sec
of I-Sec
relief I-Sec
of I-Sec
dyspnoea I-Sec
, I-Sec
expressed I-Sec
as I-Sec
the I-Sec
change I-Sec
in I-Sec
Borg I-Sec
score I-Sec
1 I-Sec
minute I-Sec
after I-Sec
study I-Sec
drug I-Sec
administration I-Sec
. O

The O
secondary O
outcome O
measure O
is O
' B-Sec
distress I-Sec
due I-Sec
to I-Sec
breathlessness' I-Sec
measured I-Sec
using I-Sec
a I-Sec
Numerical I-Sec
Rating I-Sec
Scale I-Sec
( I-Sec
NRS I-Sec
; I-Sec
0-10 I-Sec
) I-Sec
. O

By O
day O
8 O
( O
the O
first O
assessment O
) O
, O
physicians O
assessed O
disease O
activity O
as O
absent O
or O
minimal O
in O
31 O
( O
88.6 O
% O
) O
patients O
, O
and O
this O
response O
was O
maintained O
at O
the O
end O
of O
part O
1 O
( O
Figure O
1a O
) O
. O

Methods O
/ O
Design O
The O
PROUD O
trial O
is O
designed O
as O
a O
randomised O
, O
controlled O
, O
observer O
, O
surgeon O
and O
patient O
blinded O
multicenter O
superiority O
trial O
with O
two O
parallel O
groups O
and O
a O
secondary O
endpoint O
of O
wound B-Sec
infection I-Sec
during I-Sec
30 I-Sec
days I-Sec
after I-Sec
surgery I-Sec
. O

Thus O
, O
the O
only O
effect O
on O
the O
secondary O
endpoint O
was O
the O
drugs O
used O
and O
not O
the O
variation O
in O
sedation O
/ O
analgesic O
levels O
. O

secondary O
outcome O
measures O
The B-Sec
objectively I-Sec
and I-Sec
subjectively I-Sec
measured I-Sec
difference I-Sec
in I-Sec
nocturnal I-Sec
restlessness I-Sec
between I-Sec
T0-T1-T2 I-Sec
. O

There O
will O
be O
two O
secondary O
outcome O
measures O
obtained O
at O
one O
, O
six O
, O
and O
12 O
month O
follow-up O
: O
1 B-Sec
) I-Sec
24-hour I-Sec
expired I-Sec
air I-Sec
CO I-Sec
validated I-Sec
self-reported I-Sec
smoking I-Sec
cessation I-Sec
and O
2 B-Sec
) I-Sec
7-day I-Sec
self-reported I-Sec
smoking I-Sec
cessation I-Sec
. O

Statistical O
analysis O
On O
the O
basis O
of O
the O
nature O
of O
the O
secondary O
outcome O
measure O
, O
patients O
with O
protocol O
violations O
and O
/ O
or O
missing O
data O
were O
excluded O
from O
the O
secondary O
analysis O
. O

This O
score O
is O
also O
secondary O
endpoint O
in O
the O
similar O
RCT O
going O
on O
in O
Trondheim O
, O
Norway O
53 O
. O

Involuntary B-Sec
termination I-Sec
of I-Sec
a I-Sec
woman's I-Sec
pregnancy I-Sec
( I-Sec
miscarriage I-Sec
) I-Sec
and O
other B-Sec
fetal I-Sec
loss I-Sec
( I-Sec
eg I-Sec
stillbirth I-Sec
) I-Sec
, I-Sec
( O
secondary O
outcomes O
of O
importance O
to O
the O
secondary O
study O
) O
were O
reported O
as O
adverse O
events O
, O
although O
participation O
in O
the O
intervention O
study O
was O
never O
considered O
to O
be O
a O
causal O
factor O
by O
the O
Data O
Safety O
Monitoring O
Board O
. O

In O
case O
of O
potential O
unilateral O
treatment O
, O
the O
secondary O
outcome O
measure O
will O
only O
be O
measured O
for O
the O
participant's O
potentially O
treated O
leg O
. O

With O
the O
proposed O
sample O
size O
of O
247 O
and O
247 O
for O
the O
two O
groups O
( O
ie O
assuming O
a O
1 O
: O
1 O
allocation O
ratio O
) O
, O
the O
study O
will O
have O
power O
of O
80 O
% O
to O
yield O
a O
statistically O
significant O
result O
using O
a O
chi-squared O
test O
( O
assuming O
an O
intention-to-treat O
principle O
for O
the O
analysis O
) O
at O
alpha O
= O
0.05 O
/ O
2 O
( O
ie O
using O
the O
Bonferroni O
correction O
factor O
for O
the O
two O
secondary O
outcomes O
) O
. O

Statistical O
and O
Health O
Economic O
analyses O
Differences O
in O
the O
secondary O
outcome O
, O
recurrence B-Sec
of I-Sec
haemorrhoids I-Sec
between I-Sec
the I-Sec
two I-Sec
treatment I-Sec
groups I-Sec
, O
will O
be O
analysed O
using O
logistic O
regression O
adjusting O
for O
sex O
, O
age O
at O
surgery O
and O
history O
of O
previous O
intervention O
as O
fixed O
effect O
covariates O
and O
surgeon O
as O
a O
random O
effect O
. O

The O
secondary O
endpoints O
were O
the B-Sec
proportion I-Sec
of I-Sec
children I-Sec
achieving I-Sec
a I-Sec
well I-Sec
clinical I-Sec
response I-Sec
and O
time B-Sec
to I-Sec
a I-Sec
well I-Sec
clinical I-Sec
response I-Sec
. O

Statistical O
design O
The O
secondary O
endpoint O
was O
change B-Sec
in I-Sec
EPIC I-Sec
urinary I-Sec
HRQOL I-Sec
domain I-Sec
summary I-Sec
score I-Sec
at I-Sec
3 I-Sec
months I-Sec
after I-Sec
the I-Sec
completion I-Sec
of I-Sec
RT I-Sec
( I-Sec
ΔEPIC-U I-Sec
3mo I-Sec
) I-Sec
. O

We O
want O
to O
be O
able O
to O
demonstrate O
moderate O
effects O
( O
d O
= O
0.5 O
) O
on O
the O
secondary O
outcome O
measure O
, O
while O
using O
a O
power O
0.80 O
, O
with O
alpha O
set O
at O
.05 O
( O
two-tailed O
) O
. O

It O
was O
calculated O
that O
a O
sample O
size O
of O
90 O
evaluable O
subjects O
per O
group O
would O
provide O
an O
overall O
power O
of O
92 O
% O
to O
meet O
the O
non-inferiority O
criteria O
for O
both O
the O
secondary O
endpoints O
assuming O
the O
groups O
elicited O
identical O
immune O
responses O
. O

Although O
the O
magnitude O
of O
the O
improvement O
was O
small O
, O
significance O
in O
the O
secondary O
outcome O
and O
many O
secondary O
outcomes O
was O
achieved O
. O

secondary O
end-points O
( O
baseline O
T0 O
and O
post-intervention O
T1 O
) O
and O
all O
follow-up O
measures O
( O
T2-T3 O
) O
are O
expected O
to O
be O
completed O
in O
January O
2013. O

Statistical O
analysis O
The O
secondary O
aim O
of O
the O
statistical O
analysis O
is O
to O
compare O
the O
two O
arms O
, O
with O
respect O
to O
the O
secondary O
and O
secondary O
outcomes O
, O
ie O
the O
time O
to O
virological O
treatment O
failure O
and O
adherence O
. O

secondary O
analysis O
used O
repeated O
measures O
analysis O
of O
variance O
( O
ANOVA O
) O
with O
the O
3 O
, O
6 O
and O
12 O
month O
data O
as O
outcomes O
and O
the O
appropriate O
baseline O
measurement O
as O
a O
covariate O
to O
test O
for O
the O
secondary O
effect O
of O
group O
( O
LI O
versus O
UC O
, O
intention-to-treat O
analyses O
) O
on O
QOL O
outcome O
measures O
( O
FACT-G O
; O
physical O
, O
functional O
, O
social O
, O
emotional O
well-being O
, O
fatigue O
and O
endometrial O
subscales O
) O
and O
self-efficacy O
( O
WEL O
; O
negative O
emotions O
, O
food O
availability O
, O
social O
pressure O
, O
positive O
activities O
, O
physical O
discomfort O
) O
. O

Minimum O
data O
collection O
at O
each O
follow-up O
data O
collection O
stage O
will O
attempt O
to O
capture O
the O
secondary O
outcomes O
, O
AUSCAN B-Sec
and O
global B-Sec
change I-Sec
scores I-Sec
, O
in O
the O
event O
of O
non-response O
to O
the O
mailed O
follow-up O
questionnaire O
. O

The O
secondary O
outcome O
of O
this O
study O
is O
be O
the B-Sec
number I-Sec
of I-Sec
new I-Sec
falls I-Sec
and I-Sec
fallers I-Sec
. O

Outcomes O
secondary O
endpoints O
are O
the B-Sec
number I-Sec
and I-Sec
stage I-Sec
of I-Sec
detected I-Sec
breast I-Sec
cancers I-Sec
, I-Sec
both I-Sec
DCIS I-Sec
and I-Sec
invasive I-Sec
, I-Sec
in I-Sec
each I-Sec
arm I-Sec
. O

Clinical O
efficacy O
measures O
As O
the O
secondary O
aim O
of O
this O
pedalling O
intervention O
is O
to O
enhance O
ability O
to O
voluntarily O
contract O
paretic O
muscle O
, O
the O
secondary O
measure O
enables O
assessment O
of O
impairment O
level O
change O
. O

The O
secondary O
outcome O
measures O
were O
time B-Sec
from I-Sec
induction I-Sec
to I-Sec
delivery I-Sec
and O
incidence B-Sec
of I-Sec
vaginal I-Sec
delivery I-Sec
within I-Sec
12 I-Sec
and I-Sec
24 I-Sec
hours I-Sec
. O

Parents O
receive O
€ O
15 O
, O
- O
after O
completing O
the O
first O
assessment O
, O
€ O
25 O
, O
- O
after O
participating O
in O
the O
program O
and O
completing O
the O
second O
assessment O
and O
€ O
40 O
, O
- O
after O
completing O
the O
follow O
up O
assessment O
. O

Outcome O
measures O
The O
secondary O
outcome O
measure O
was O
the B-Sec
incidence I-Sec
of I-Sec
AEs I-Sec
( I-Sec
sum I-Sec
of I-Sec
the I-Sec
incidence I-Sec
of I-Sec
pressure I-Sec
ulcers I-Sec
, I-Sec
urinary I-Sec
tract I-Sec
infections I-Sec
and I-Sec
falls I-Sec
) I-Sec
. O

Conclusions O
Formoterol O
4.5 O
μg O
and O
9 O
μg O
bid O
was O
effective O
and O
well O
tolerated O
in O
patients O
with O
COPD O
; O
there O
was O
no O
difference O
between O
formoterol O
doses O
for O
the O
secondary O
endpoint O
; O
however O
, O
an O
added O
value O
of O
formoterol O
9 O
μg O
over O
4.5 O
μg O
bid O
was O
observed O
for O
some O
secondary O
endpoints O
. O

On O
the O
basis O
of O
this O
trial O
, O
it O
was O
initially O
hypothesised O
a B-Sec
withdrawal I-Sec
proportion I-Sec
from I-Sec
allocated I-Sec
treatment I-Sec
within I-Sec
3 I-Sec
months I-Sec
( O
secondary O
study O
endpoint O
) O
of O
25 O
% O
in O
the O
group O
treated O
with O
clozapine O
plus O
haloperidol O
( O
control O
group O
) O
. O

secondary O
efficacy O
parameter O
The O
secondary O
efficacy O
instrument O
was O
the B-Sec
11-point I-Sec
NRS I-Sec
in I-Sec
patients' I-Sec
daily I-Sec
pain I-Sec
diaries I-Sec
. O

The O
secondary O
end-point O
variable O
was O
to B-Sec
decrease I-Sec
reintubation I-Sec
rates I-Sec
, I-Sec
defined I-Sec
by I-Sec
the I-Sec
necessity I-Sec
of I-Sec
mechanical I-Sec
positive-pressure I-Sec
ventilation I-Sec
through I-Sec
orotracheal I-Sec
intubation I-Sec
in I-Sec
the I-Sec
first I-Sec
48 I-Sec
hours I-Sec
after I-Sec
extubation I-Sec
, I-Sec
in I-Sec
the I-Sec
treatment I-Sec
group I-Sec
. O

The O
secondary O
outcomes O
in O
this O
trial O
will O
include O
differences B-Sec
in I-Sec
Nepean I-Sec
Dyspepsia I-Sec
Index I-Sec
scores I-Sec
and O
differences B-Sec
in I-Sec
the I-Sec
Symptom I-Sec
Index I-Sec
of I-Sec
Dyspepsia I-Sec
before I-Sec
randomization I-Sec
, I-Sec
2 I-Sec
weeks I-Sec
and I-Sec
4 I-Sec
weeks I-Sec
after I-Sec
randomization I-Sec
, I-Sec
and I-Sec
1 I-Sec
month I-Sec
and I-Sec
3 I-Sec
months I-Sec
after I-Sec
completing I-Sec
treatment I-Sec
. O

The O
secondary O
endpoint O
is O
a B-Sec
composite I-Sec
endpoint I-Sec
of I-Sec
mortality I-Sec
and I-Sec
re-admissions I-Sec
for I-Sec
biliary I-Sec
events I-Sec
. O

The O
former O
leads O
to O
, O
where O
t O
1 O
> O
0 O
is O
the O
time O
at O
which O
the O
first O
set O
of O
measurements O
are O
taken O
. O

Outcome O
measures O
include O
: O
weight B-Sec
( O
secondary O
outcome O
) O
, O
% O
body O
fat O
, O
waist O
circumference O
, O
blood O
pressure O
, O
resting O
heart O
rate O
, O
objectively O
measured O
physical O
activity O
, O
self-reported O
dietary O
intake O
, O
sedentary O
behaviour O
, O
physical O
activity O
and O
dietary O
cognitions O
, O
sleepiness O
, O
quality O
of O
life O
, O
and O
perceived O
sexual O
health O
. O

secondary O
analysis O
of O
the O
data O
is O
not O
yet O
available O
for O
comparing O
the O
two O
intervention O
groups O
in O
terms O
of O
protocol O
credibility O
, O
satisfaction O
, O
or O
the O
secondary O
and O
secondary O
outcomes O
. O

Four O
secondary O
assessments O
encompass O
the O
treatment O
phase O
and O
follow-up O
. O

The O
secondary O
outcome O
measure O
is O
ADHD B-Sec
symptoms I-Sec
. O

The O
secondary O
outcome O
will O
be O
uptake B-Sec
of I-Sec
the I-Sec
1 I-Sec
st I-Sec
and I-Sec
3 I-Sec
rd I-Sec
vaccinations I-Sec
. O

The O
data O
analysis O
of O
the O
secondary O
and O
secondary O
outcomes O
is O
mainly O
based O
on O
the O
ITT O
population O
. O

The O
secondary O
secondary O
set O
of O
outcome O
measures O
describes O
patient B-Sec
adherence I-Sec
. O

Study O
endpoints O
The O
secondary O
endpoint O
is O
6-month B-Sec
in-stent I-Sec
neointimal I-Sec
hyperplasia I-Sec
area I-Sec
assessed I-Sec
by I-Sec
OCT. I-Sec

Statistical O
analysis O
secondary O
efficacy O
variable O
The O
secondary O
efficacy O
variable O
was O
the B-Sec
p27 I-Sec
antigen I-Sec
analysis I-Sec
of I-Sec
serum I-Sec
samples I-Sec
. O

secondary O
outcome O
: O
Timed B-Sec
" I-Sec
up I-Sec
and I-Sec
go I-Sec
" I-Sec
test I-Sec
, O
secondary O
outcomes O
: O
peak B-Sec
surface I-Sec
EMG I-Sec
of I-Sec
gluteus I-Sec
maximus I-Sec
and I-Sec
gluteus I-Sec
medius I-Sec
, O
activation B-Sec
patterns I-Sec
of I-Sec
hemiplegic I-Sec
leg I-Sec
musculature I-Sec
, O
temporo-spatial B-Sec
gait I-Sec
parameters I-Sec
, O
hemiplegic B-Sec
hip I-Sec
kinematics I-Sec
in I-Sec
the I-Sec
frontal I-Sec
and I-Sec
sagittal I-Sec
planes I-Sec
, O
dynamic B-Sec
balance I-Sec
, O
daily B-Sec
activity I-Sec
measured I-Sec
by I-Sec
accelerometry I-Sec
, O
Stroke B-Sec
Impact I-Sec
Scale I-Sec
. O

This O
sample O
size O
would O
yield O
95 O
% O
statistical O
power O
with O
a O
true O
difference O
in O
the O
secondary O
endpoint O
of O
2. O

Sample O
size O
secondary O
study O
The O
secondary O
outcome O
is O
the B-Sec
Process I-Sec
of I-Sec
Recovery I-Sec
Questionnaire I-Sec
( I-Sec
QPR I-Sec
) I-Sec
26 I-Sec
. O

Protocol O
outcome O
measures O
The O
secondary O
outcome O
was O
the B-Sec
change I-Sec
in I-Sec
morning I-Sec
peak I-Sec
expiratory I-Sec
flow I-Sec
( I-Sec
PEF I-Sec
) I-Sec
rate I-Sec
from I-Sec
baseline I-Sec
to I-Sec
the I-Sec
end I-Sec
of I-Sec
the I-Sec
treatment I-Sec
period I-Sec
( I-Sec
mean I-Sec
of I-Sec
weeks I-Sec
23 I-Sec
– I-Sec
24 I-Sec
) I-Sec
. O

Calculations O
performed O
at O
80 O
% O
power O
with O
an O
alpha O
level O
of O
0.05 O
suggested O
that O
35 O
participants O
per O
group O
were O
needed O
to O
detect O
a O
difference O
in O
the O
secondary O
outcome O
measure O
of O
violent B-Sec
attitudes I-Sec
using I-Sec
the I-Sec
Total I-Sec
MVQ I-Sec
score I-Sec
with O
an O
effect O
size O
of O
.42 O
[ O
pre-treatment O
mean O
15.95 O
( O
S.D. O

The O
secondary O
outcome O
variable O
( O
POV O
) O
will O
be O
taken O
as O
the B-Sec
change I-Sec
in I-Sec
the I-Sec
global I-Sec
score I-Sec
on I-Sec
the I-Sec
Yale I-Sec
Scale I-Sec
, O
adjusted O
for O
the O
baseline O
values O
. O

While O
the O
study O
was O
open-label O
after O
concealed O
allocation O
, O
the O
secondary O
end O
point O
was O
measured O
by O
staff O
blinded O
to O
treatment O
group O
. O

The O
secondary O
objective O
is O
to O
estimate O
the O
precise O
sample O
size O
and O
secondary O
endpoint O
required O
for O
the O
large O
scale O
RCT O
. O

In O
order O
to O
test O
the O
hypothesis O
that O
the O
change O
in O
head O
circumference O
differs O
between O
the O
two O
groups O
while O
taking O
account O
of O
the O
clustering O
arising O
from O
multiple O
pregnancies O
, O
the O
secondary O
outcome O
will O
be O
assessed O
using O
a O
general O
linear O
model O
. O

Sample O
size O
and O
power O
We O
will O
randomize O
n O
= O
32 O
participants O
to O
each O
treatment O
group O
and O
assume O
6 O
% O
of O
participants O
will O
drop O
out O
by O
the O
end O
of O
the O
study O
so O
that O
there O
will O
be O
n O
= O
30 O
participants O
in O
each O
group O
at O
the O
secondary O
endpoint O
. O

Specifically O
, O
we O
aim O
to O
investigate O
the O
effects O
of O
a O
12-month O
exercise O
program O
designed O
to O
load O
the O
musculoskeletal O
system O
and O
reduce O
cardiovascular O
and O
diabetes O
disease O
progression O
on O
the O
following O
secondary O
endpoints O
: O
1 B-Sec
) I-Sec
bone I-Sec
mineral I-Sec
density I-Sec
; O
2 B-Sec
) I-Sec
cardiorespiratory I-Sec
function I-Sec
and I-Sec
maximal I-Sec
oxygen I-Sec
capacity I-Sec
; O
3 B-Sec
) I-Sec
body I-Sec
composition I-Sec
( I-Sec
lean I-Sec
mass I-Sec
and I-Sec
fat I-Sec
mass I-Sec
) I-Sec
; O
4 B-Sec
) I-Sec
blood I-Sec
pressure I-Sec
and I-Sec
cardiovascular I-Sec
function I-Sec
; O
5 B-Sec
) I-Sec
lipids I-Sec
and I-Sec
glycemic I-Sec
control I-Sec
; O
and O
6 B-Sec
) I-Sec
quality I-Sec
of I-Sec
life I-Sec
and I-Sec
psychological I-Sec
distress I-Sec
. O

We O
have O
chosen O
this O
secondary O
outcome O
because O
delirium O
is O
extremely O
common O
in O
hip O
fracture O
patients O
7 O
, O
there O
is O
increasing O
evidence O
that O
delirium O
may O
have O
long-term O
negative O
consequences O
upon O
cognition O
9 O
10 O
, O
and O
such O
consequences O
are O
devastating O
. O

The O
secondary O
end-point O
of O
MR-IMPACT O
II O
was O
the B-Sec
comparison I-Sec
of I-Sec
sensitivity I-Sec
and O
specificity B-Sec
of I-Sec
perfusion-CMR I-Sec
to I-Sec
detect I-Sec
CAD I-Sec
on I-Sec
CXA I-Sec
vs I-Sec
SPECT I-Sec
based I-Sec
on I-Sec
a I-Sec
single-point I-Sec
threshold I-Sec
reading I-Sec
. O

secondary O
outcome O
measurement O
for O
patients' B-Sec
QoL I-Sec
is O
the B-Sec
scale I-Sec
physical I-Sec
functioning I-Sec
of I-Sec
the I-Sec
SF-36 I-Sec
health I-Sec
questionnaire I-Sec
in I-Sec
a I-Sec
12-month I-Sec
follow-up I-Sec
. O

Our O
power O
calculation O
is O
based O
on O
our O
secondary O
outcome O
of O
weight B-Sec
, O
under O
the O
null O
hypothesis O
that O
there O
will O
be O
no O
between-group O
difference O
in O
weight O
at O
the O
3-month O
time O
point O
. O

Secondary O
analyses O
A O
sensitivity O
analysis O
will O
be O
performed O
on O
the O
secondary O
variable O
to O
assess O
the O
impact O
of O
protocol O
deviations O
using O
the O
per O
protocol O
analysis O
set O
. O

The O
secondary O
endpoint O
is O
overall B-Sec
survival I-Sec
that I-Sec
is I-Sec
assessed I-Sec
with I-Sec
a I-Sec
minimum I-Sec
follow-up I-Sec
of I-Sec
36 I-Sec
months I-Sec
. O

In O
the O
cost-effectiveness O
study O
, O
the O
secondary O
outcome O
is O
the B-Sec
level I-Sec
of I-Sec
functional I-Sec
abilities I-Sec
as I-Sec
measured I-Sec
with I-Sec
the I-Sec
Katz-15 I-Sec
index I-Sec
. O

This O
simple O
size O
gives O
a O
statistical O
power O
of O
higher O
than O
80 O
% O
, O
to O
enable O
any O
difference O
between O
the O
control O
and O
the O
intervention O
group O
greater O
than O
3 O
with O
respect O
to O
the O
secondary O
outcome O
scale O
from O
the O
physical O
functioning O
SF-36 O
and O
MLHQ O
to O
be O
found O
to O
be O
significant O
, O
with O
a O
significance O
level O
of O
5 O
% O
using O
the O
two-tailed O
Student's O
t O
test O
( O
standard O
deviations O
obtained O
from O
prior O
studies O
with O
similar O
population O
to O
that O
of O
our O
project O
: O
SD O
= O
10 O
points O
of O
the O
quality O
of O
life O
questionnaires O
SF-36 O
and O
MLHQ O
) O
12 O
25 O
26 O
. O

The B-Sec
total I-Sec
score I-Sec
will O
represent O
the O
secondary O
outcome O
. O

Loss O
to O
follow O
up O
for O
the O
secondary O
outcome O
of O
HbA1c B-Sec
should O
be O
small O
, O
as O
all O
of O
these O
patients O
will O
be O
attending O
clinic O
on O
a O
regular O
basis O
where O
HbA1c O
is O
monitored O
for O
clinical O
purposes O
. O

The O
secondary O
outcome O
measure O
for O
both O
of O
these O
trials O
is O
the B-Sec
number I-Sec
of I-Sec
CST I-Sec
sessions I-Sec
run I-Sec
for I-Sec
people I-Sec
with I-Sec
dementia I-Sec
. O

The O
data O
will O
be O
analysed O
at O
3 O
, O
6 O
and O
12 O
month O
follow-up O
, O
however O
, O
6 O
months O
is O
the O
secondary O
end O
point O
for O
the O
study O
. O

The O
secondary O
end O
point O
will O
be O
average B-Sec
pain I-Sec
at I-Sec
rest I-Sec
over I-Sec
the I-Sec
first I-Sec
12-hour I-Sec
post-operative I-Sec
period I-Sec
on I-Sec
a I-Sec
verbal I-Sec
analogue I-Sec
pain I-Sec
score I-Sec
. O

All O
randomized O
patients O
will O
be O
included O
in O
the O
intention-to-treat O
analysis O
of O
the O
secondary O
outcome O
. O

The O
secondary O
outcome O
was O
a B-Sec
reduction I-Sec
in I-Sec
depression I-Sec
. O

Using O
t-tests O
for O
continuous O
variables O
and O
chi-square O
tests O
of O
association O
for O
categorical O
variables O
, O
baseline O
differences O
were O
examined O
in O
key O
study O
outcomes O
by O
intervention O
condition O
to O
assess O
the O
equivalence O
of O
the O
study O
intervention O
conditions O
. O

The O
secondary O
outcome O
measured O
was O
time B-Sec
to I-Sec
achieve I-Sec
haemostasis I-Sec
at I-Sec
the I-Sec
suture I-Sec
line I-Sec
. O

secondary O
outcome O
The O
secondary O
outcome O
measure O
will O
be O
self-assessed B-Sec
health I-Sec
related I-Sec
quality I-Sec
of I-Sec
life I-Sec
assessed I-Sec
using I-Sec
the I-Sec
York I-Sec
SF-12 I-Sec
23 I-Sec
. O

Where O
secondary O
outcomes O
reach O
statistical O
significance O
, O
any O
noted O
difference O
in O
the O
baseline O
group O
comparison O
will O
be O
tested O
by O
univariate O
comparison O
with O
stepwise O
addition O
into O
a O
multivariate O
model O
for O
those O
with O
univariate O
significance O
of O
P O
< O
0.1 O
. O

The O
secondary O
outcome O
will O
be O
the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
who I-Sec
are I-Sec
adherent I-Sec
to I-Sec
a I-Sec
complete I-Sec
, I-Sec
guideline-based I-Sec
ACS I-Sec
medication I-Sec
regimen I-Sec
at I-Sec
six I-Sec
and I-Sec
twelve I-Sec
months I-Sec
post-discharge I-Sec
. O

The O
trial O
used O
a O
simple O
, O
relevant O
and O
pragmatic O
secondary O
clinical O
endpoint O
rather O
than O
a O
composite O
score O
such O
as O
symptom O
frequency O
plus O
intensity O
. O

The O
secondary O
NOAAH O
report O
will O
include O
an O
economic O
analysis O
, O
but O
cannot O
address O
cost-benefit O
in O
terms O
of O
hard O
cardiovascular O
outcomes O
, O
because O
blood B-Sec
pressure I-Sec
control I-Sec
is O
the O
secondary O
outcome O
in O
this O
trial O
with O
limited O
sample O
size O
and O
short O
follow-up O
. O

The O
design O
protects O
the O
secondary O
end O
point O
by O
measuring O
attendance O
before O
providing O
further O
information O
about O
the O
trial O
or O
collecting O
questionnaire O
data O
that O
may O
have O
intervention O
effects O
. O

Definition O
of O
end O
points O
secondary O
outcomes O
were O
changes B-Sec
in I-Sec
lifestyle I-Sec
according I-Sec
to I-Sec
established I-Sec
goals I-Sec
that O
have O
been O
shown O
to O
reduce O
incidence O
of O
type O
2 O
diabetes O
, O
improve O
health O
and O
to O
improve O
cardiovascular O
risk O
profile O
. O

The O
secondary O
outcome O
measure O
of O
the O
clinical O
evaluation O
is O
depression B-Sec
severity I-Sec
measured I-Sec
by I-Sec
the I-Sec
Beck I-Sec
Depression I-Sec
Intenvory-II I-Sec
( I-Sec
BDI-II I-Sec
) I-Sec
. O

The O
secondary O
outcome O
at O
10 O
weeks O
post-partum O
was O
parental B-Sec
participation I-Sec
in I-Sec
each I-Sec
arm I-Sec
, I-Sec
as I-Sec
indicated I-Sec
by I-Sec
the I-Sec
respective I-Sec
return I-Sec
or I-Sec
non-return I-Sec
of I-Sec
a I-Sec
reply I-Sec
form I-Sec
( I-Sec
or I-Sec
via I-Sec
telephone I-Sec
or I-Sec
email I-Sec
response I-Sec
) I-Sec
. O

12 O
, O
were O
performed O
for O
the O
3 O
secondary O
outcomes O
( O
for O
all O
: O
power O
0.9 O
; O
alpha O
0.05 O
) O
. O

Diary O
All O
participants O
randomised O
to O
the O
trial O
will O
be O
given O
a O
diary O
to O
complete O
at O
baseline O
( O
nurse O
clinical O
assessment O
) O
and O
at O
6 O
months O
( O
the O
secondary O
end O
point O
) O
. O

Frequency O
domain O
variables O
, O
including O
total O
, O
HF O
and O
low O
frequency O
( O
LF O
) O
power O
and O
LF O
: O
HF O
ratio O
will O
be O
derived O
from O
spectral O
analysis O
of O
successive O
R-R O
intervals O
. O

secondary O
outcome O
, O
troponin B-Sec
T I-Sec
on I-Sec
POD1 I-Sec
, O
reached O
statistical O
significance O
in O
the O
unadjusted O
as O
well O
as O
the O
linear O
regression O
model O
, O
adjusted O
for O
age O
of O
the O
patient O
, O
ECC O
, O
blood O
products O
, O
as O
well O
as O
the O
baseline O
troponin O
level O
. O

Patient O
Assessment O
and O
Measurements O
secondary O
outcome O
measure O
of O
the O
randomized O
trial O
will O
be O
the B-Sec
change I-Sec
in I-Sec
the I-Sec
Global I-Sec
Index I-Sec
of I-Sec
the I-Sec
Outcome I-Sec
Questionnaire I-Sec
( I-Sec
OQ I-Sec
45.2 I-Sec
) I-Sec
. O

The O
secondary O
analysis O
was O
a O
comparison O
between O
the O
pregabalin O
and O
placebo O
groups O
at O
secondary O
assessment O
and O
was O
based O
on O
an O
analysis O
of O
covariance O
model O
, O
including O
dose O
groups O
and O
baseline O
mean O
pain O
score O
as O
factors O
. O

Sample O
size O
The O
secondary O
end-points O
are O
six O
and O
24 O
months O
12 O
. O

Data O
on O
the O
secondary O
outcome O
as O
well O
as O
on O
intensity O
of O
pain O
, O
sick O
leave O
, O
work O
productivity O
, O
and O
health O
care O
costs O
are O
collected O
every O
3 O
months O
. O

We O
calculate O
the O
mean O
from O
the O
first O
two O
measurements O
with O
less O
than O
5 O
mm O
Hg O
difference O
in O
both O
systolic O
and O
diastolic O
blood O
pressure O
49 O
. O

secondary O
endpoint O
secondary O
endpoint O
is O
3-year B-Sec
DFS I-Sec
in I-Sec
study I-Sec
groups I-Sec
( I-Sec
proportion I-Sec
of I-Sec
patients I-Sec
without I-Sec
local I-Sec
or I-Sec
distant I-Sec
recurrence I-Sec
, I-Sec
or I-Sec
second I-Sec
secondary I-Sec
of I-Sec
same I-Sec
of I-Sec
other I-Sec
cancer I-Sec
, I-Sec
death I-Sec
from I-Sec
same I-Sec
cancer I-Sec
of I-Sec
any I-Sec
other I-Sec
cause I-Sec
during I-Sec
the I-Sec
defined I-Sec
period I-Sec
of I-Sec
time I-Sec
) I-Sec
. O

Sample O
size O
Power O
is O
assessed O
for O
the O
secondary O
endpoint O
, O
ie O
increased B-Sec
compliance I-Sec
with I-Sec
cervical I-Sec
cancer I-Sec
screening I-Sec
. O

secondary O
outcomes O
include O
unplanned B-Sec
use I-Sec
of I-Sec
heath I-Sec
services I-Sec
for I-Sec
negative I-Sec
event I-Sec
( I-Sec
frequency I-Sec
calendar I-Sec
) I-Sec
and O
quality B-Sec
of I-Sec
life I-Sec
( I-Sec
EQ-5D I-Sec
and I-Sec
Quality I-Sec
of I-Sec
Life I-Sec
Index I-Sec
) I-Sec
. O

For O
the O
secondary O
outcome O
measure O
of O
this O
substudy O
, O
work B-Sec
functioning I-Sec
, O
no O
information O
on O
probable O
difference O
on O
ward-level O
exists O
. O

Statistical O
analysis O
A O
linear O
regression O
model O
will O
be O
used O
to O
compare O
collaborative O
care O
with O
usual O
care O
on O
the O
secondary O
outcome O
adjusted O
for O
baseline O
depression O
severity O
( O
as O
measured O
by O
the B-Sec
PHQ-9 I-Sec
) O
and O
physical O
/ O
functional O
limitations O
( O
as O
measured O
by O
the O
SF-12 O
physical O
functioning O
scale O
) O
. O

The O
majority O
of O
patients O
would O
reach O
the O
secondary O
endpoint O
after O
extubation O
and O
then O
once O
weaned O
down O
to O
a O
single O
inotrope O
. O

Statistical O
analyses O
and O
data O
management O
The O
secondary O
endpoint O
is O
the B-Sec
maximum I-Sec
absolute I-Sec
AST I-Sec
value I-Sec
( I-Sec
U I-Sec
/ I-Sec
l I-Sec
) I-Sec
on I-Sec
one I-Sec
of I-Sec
the I-Sec
first I-Sec
three I-Sec
post-operative I-Sec
days I-Sec
. O

secondary O
outcome O
variable O
was O
retention B-Sec
in I-Sec
treatment I-Sec
, I-Sec
which I-Sec
was I-Sec
defined I-Sec
as I-Sec
the I-Sec
number I-Sec
of I-Sec
weeks I-Sec
that I-Sec
patients I-Sec
remained I-Sec
in I-Sec
the I-Sec
study I-Sec
before I-Sec
being I-Sec
discharged I-Sec
. O

The O
secondary O
endpoint O
was O
the B-Sec
overall I-Sec
discomfort I-Sec
reported I-Sec
during I-Sec
WC I-Sec
versus I-Sec
SC I-Sec
pH-metry I-Sec
. O

Regarding O
the O
secondary O
outcome O
measure O
, O
Short O
treatment O
is O
definite O
inferior O
to O
Standard O
treatment O
with O
statistical O
significance O
of O
≥ O
95 O
% O
certainty O
and O
2 O
) O
. O

The O
secondary O
outcome O
measure O
is O
the B-Sec
proportion I-Sec
of I-Sec
women I-Sec
continuously I-Sec
enrolled I-Sec
for I-Sec
24 I-Sec
months I-Sec
with I-Sec
≥1 I-Sec
mammogram I-Sec
in I-Sec
the I-Sec
past I-Sec
24 I-Sec
months I-Sec
. O

The O
secondary O
endpoint O
of O
this O
study O
ACR B-Sec
50 I-Sec
improvement I-Sec
compared O
to O
placebo O
was O
reached O
with O
the O
150 O
mg O
sc O
q4wk O
dose O
. O

The O
secondary O
outcomes O
will O
be O
the B-Sec
Cobb I-Sec
angle I-Sec
two I-Sec
years I-Sec
after I-Sec
inclusion I-Sec
and O
health-related B-Sec
quality I-Sec
of I-Sec
life I-Sec
. O

Major B-Sec
bleeding I-Sec
was O
the O
secondary O
safety O
outcome O
. O

In O
order O
to O
provide O
sufficient O
power O
to O
detect O
a O
difference O
in O
secondary O
outcomes O
( O
Body B-Sec
Mass I-Sec
Index-BMI I-Sec
& I-Sec
ESE I-Sec
at I-Sec
12 I-Sec
month I-Sec
follow-up I-Sec
) O
between O
children O
in O
the O
intervention O
schools O
and O
control O
schools O
, O
the O
target O
sample O
size O
is O
396. O

secondary O
outcome O
: O
length B-Sec
of I-Sec
acute I-Sec
hospital I-Sec
stay I-Sec
is O
determined O
by O
a O
blinded O
team O
of O
clinicians O
. O

Outcome O
measures O
The O
secondary O
outcome O
measure O
is O
children's B-Sec
physical I-Sec
activity I-Sec
, I-Sec
as I-Sec
measured I-Sec
by I-Sec
accelerometers I-Sec
. O

secondary O
and O
Secondary O
Outcomes O
There O
will O
be O
a O
composite O
endpoint O
in O
which O
a O
patient O
will O
be O
classified O
as O
having O
a O
positive O
response O
if O
both O
of O
the O
following O
criteria O
are O
satisfied O
: O
• O
Reduction O
in O
proteinuria O
( O
expressed O
as O
the O
protein O
: O
creatinine O
ratio O
in O
a O
first O
morning O
urine O
specimen O
) O
at O
6 O
months O
by O
≥ O
50 O
% O
of O
the O
value O
at O
the O
time O
of O
screening O
, O
AND O
• O
Estimated O
GFR O
( O
eGFR O
) O
at O
6 O
months O
≥ O
75 O
% O
of O
the O
value O
at O
the O
time O
of O
randomization O
in O
those O
with O
an O
initial O
eGFR O
< O
75 O
mL O
/ O
min O
/ O
1.73 O
m O
2 O
OR O
eGFR O
persistently O
≥75 O
mL O
/ O
min O
/ O
1.73 O
m O
2 O
in O
those O
whose O
renal O
function O
was O
≥75 O
mL O
/ O
min O
/ O
1.73 O
m O
2 O
at O
the O
time O
of O
randomization O
. O

Discussion O
This O
randomized O
phase O
2 O
study O
met O
its O
secondary O
endpoint O
of O
improved B-Sec
PFS I-Sec
for I-Sec
the I-Sec
maintenance I-Sec
phase I-Sec
, O
based O
on O
the O
Cox O
regression O
model O
stratified O
by O
the O
best O
overall O
response O
to O
induction O
therapy O
( O
HR O
= O
0.76 O
, O
one-sided O
p-value O
< O
0.2 O
) O
, O
indicating O
that O
continuation O
maintenance O
therapy O
with O
pemetrexed O
following O
first-line O
treatment O
with O
pemetrexed O
and O
cisplatin O
was O
sufficiently O
beneficial O
to O
warrant O
further O
investigation O
. O

Key O
secondary O
outcome O
measures O
were O
breathlessness B-Sec
on I-Sec
the I-Sec
transition I-Sec
dyspnoea I-Sec
index I-Sec
( I-Sec
TDI I-Sec
) I-Sec
and O
health-related B-Sec
quality I-Sec
of I-Sec
life I-Sec
( I-Sec
HRQoL I-Sec
) I-Sec
according I-Sec
to I-Sec
the I-Sec
St. I-Sec
George's I-Sec
Respiratory I-Sec
Questionnaire I-Sec
( I-Sec
SGRQ I-Sec
) I-Sec
at I-Sec
Week I-Sec
26 I-Sec
, O
while O
important O
secondary O
outcomes O
were O
time B-Sec
to I-Sec
first I-Sec
moderate I-Sec
or I-Sec
severe I-Sec
COPD I-Sec
exacerbation I-Sec
and O
mean B-Sec
daily I-Sec
rescue I-Sec
medication I-Sec
use I-Sec
over I-Sec
26 I-Sec
weeks I-Sec
. O

The O
analysis O
of O
the O
secondary O
outcomes O
was O
by O
a O
simple O
2 O
× O
2 O
table O
. O

As O
one O
of O
the O
secondary O
outcomes O
of O
these O
interventions O
is O
their O
impact O
on O
quality O
of O
life O
, O
a O
cost-utility O
analysis O
represents O
the O
preferred O
type O
of O
economic O
evaluation O
. O

To O
correct O
this O
possible O
bias O
, O
self-applied B-Sec
instruments I-Sec
will O
be O
preferred O
as O
secondary O
outcome O
variables O
. O

Assessments O
and O
Analyses O
secondary O
end O
points O
were O
PK B-Sec
parameters I-Sec
and O
safety B-Sec
and O
tolerability B-Sec
. O

Our O
secondary O
outcomes O
were O
improvement B-Sec
of I-Sec
GHbA I-Sec
1c I-Sec
and O
the B-Sec
SF-36 I-Sec
quality I-Sec
of I-Sec
life I-Sec
score I-Sec
. O

The O
secondary O
secondary O
outcome O
measure O
is O
the B-Sec
disease I-Sec
specific I-Sec
disability I-Sec
of I-Sec
daily I-Sec
functioning I-Sec
. O

Our O
post O
hoc O
analysis O
of O
the O
secondary O
outcome O
, O
stratified O
for O
gestational O
age O
, O
demonstrated O
higher O
PIPP O
scores O
in O
infants O
less O
than O
28 O
weeks O
( O
up O
to O
1 O
to O
2 O
points O
) O
than O
in O
those O
28 O
weeks O
or O
greater O
. O

Outcomes O
The O
secondary O
endpoint O
for O
the O
IMOAP O
is O
to B-Sec
assess I-Sec
whether I-Sec
the I-Sec
efficacy I-Sec
of I-Sec
the I-Sec
healthcare I-Sec
professionals' I-Sec
usual I-Sec
practices I-Sec
, I-Sec
together I-Sec
with I-Sec
a I-Sec
motivational I-Sec
group I-Sec
intervention I-Sec
( I-Sec
delivered I-Sec
by I-Sec
a I-Sec
nurse I-Sec
trained I-Sec
by I-Sec
an I-Sec
expert I-Sec
psychologist I-Sec
) I-Sec
, I-Sec
is I-Sec
more I-Sec
effective I-Sec
than I-Sec
an I-Sec
isolated I-Sec
traditional I-Sec
intervention I-Sec
on I-Sec
weight I-Sec
loss I-Sec
and I-Sec
its I-Sec
maintenance I-Sec
in I-Sec
overweight I-Sec
and I-Sec
obese I-Sec
patients I-Sec
. O

Statistical O
analysis O
In O
order O
to O
establish O
the O
noninferiority O
margin O
for O
the O
secondary O
endpoint O
, O
the O
results O
of O
two O
large O
, O
phase O
3 O
, O
placebo-controlled O
trials O
of O
12 O
weeks O
duration O
were O
examined O
: O
one O
in O
patients O
with O
lung O
cancer O
( O
n O
= O
314 O
) O
5 O
, O
and O
one O
in O
patients O
with O
lymphoproliferative O
disease O
( O
n O
= O
344 O
) O
3 O
. O

Measures O
The O
secondary O
outcome O
will O
be O
the B-Sec
level I-Sec
of I-Sec
depressive I-Sec
symptoms I-Sec
at I-Sec
6 I-Sec
, I-Sec
12 I-Sec
, I-Sec
18 I-Sec
and I-Sec
24 I-Sec
months I-Sec
follow I-Sec
up I-Sec
measured I-Sec
with I-Sec
the I-Sec
Child I-Sec
Depression I-Sec
Inventory I-Sec
( I-Sec
CDI I-Sec
) I-Sec
42 I-Sec
, O
which O
is O
reliable O
and O
valid O
43 O
44 O
. O

The O
target O
sample O
size O
is O
273 O
enrolled O
, O
which O
assuming O
a O
20 O
% O
attrition O
rate O
at O
12 O
months O
, O
will O
provide O
us O
with O
84 O
% O
power O
to O
detect O
a O
moderate O
effect O
size O
of O
.50 O
for O
the O
secondary O
outcome O
. O

secondary O
Study O
Endpoints O
The O
secondary O
study O
outcome O
is O
: O
• B-Sec
Neonatal I-Sec
Respiratory I-Sec
Distress I-Sec
Syndrome I-Sec
( I-Sec
defined I-Sec
by I-Sec
the I-Sec
incidence I-Sec
( I-Sec
increasing I-Sec
respiratory I-Sec
distress I-Sec
or I-Sec
oxygen I-Sec
requirement I-Sec
or I-Sec
the I-Sec
need I-Sec
for I-Sec
respiratory I-Sec
support I-Sec
from I-Sec
the I-Sec
first I-Sec
six I-Sec
hours I-Sec
of I-Sec
life I-Sec
, I-Sec
in I-Sec
a I-Sec
term I-Sec
or I-Sec
preterm I-Sec
infant I-Sec
) I-Sec
and I-Sec
severity I-Sec
of I-Sec
neonatal I-Sec
respiratory I-Sec
disease I-Sec
( I-Sec
mild I-Sec
= I-Sec
mean I-Sec
airway I-Sec
pressure I-Sec
( I-Sec
MAP I-Sec
) I-Sec
< I-Sec
7 I-Sec
cm I-Sec
H I-Sec
2 I-Sec
O I-Sec
, I-Sec
and I-Sec
/ I-Sec
or I-Sec
fractional I-Sec
inspired I-Sec
oxygen I-Sec
( I-Sec
FiO I-Sec
2 I-Sec
) I-Sec
< I-Sec
0.4 I-Sec
; I-Sec
moderate I-Sec
= I-Sec
MAP I-Sec
7 I-Sec
– I-Sec
9.9 I-Sec
cm I-Sec
H I-Sec
2 I-Sec
O I-Sec
, I-Sec
and I-Sec
/ I-Sec
or I-Sec
FiO I-Sec
2 I-Sec
0.40 I-Sec
– I-Sec
0.79 I-Sec
; I-Sec
severe I-Sec
= I-Sec
MAP I-Sec
≥ I-Sec
10 I-Sec
cm I-Sec
H I-Sec
2 I-Sec
O I-Sec
, I-Sec
and I-Sec
/ I-Sec
or I-Sec
FiO I-Sec
2 I-Sec
≥ I-Sec
0.80 I-Sec
with I-Sec
need I-Sec
for I-Sec
ventilation I-Sec
) I-Sec
2 I-Sec
. O

The O
background O
and O
secondary O
fluorescent O
intensities O
were O
measured O
5 O
minutes O
after O
treatment O
with O
or O
without O
SIN-1 O
( O
f.c. O

Supplemental O
analyses O
of O
the O
secondary O
efficacy O
parameter O
included O
weekly O
mean O
pain O
scores O
and O
proportion O
of O
responders O
. O

Effect O
sizes O
for O
secondary O
outcome O
measures O
were O
informed O
by O
the O
literature O
and O
agreed O
by O
study O
site O
clinicians O
. O

The O
secondary O
outcome O
measure O
is O
resident B-Sec
agitation I-Sec
, I-Sec
to I-Sec
be I-Sec
assessed I-Sec
with I-Sec
the I-Sec
Cohen-Mansfield I-Sec
Agitation I-Sec
Inventory I-Sec
. O

secondary O
measures O
are O
: O
infant B-Sec
gaze I-Sec
aversion I-Sec
, O
mother-infant B-Sec
gaze I-Sec
coordination I-Sec
, O
infant B-Sec
distress I-Sec
, O
maternal B-Sec
interaction I-Sec
style I-Sec
( I-Sec
affectionate I-Sec
vs. I-Sec
intrusive I-Sec
) I-Sec
, O
and O
responses B-Sec
of I-Sec
mothers I-Sec
and I-Sec
infants I-Sec
to I-Sec
gaze I-Sec
aversion I-Sec
. O

As O
the O
secondary O
outcome O
is O
self-report B-Sec
, O
bias O
is O
minimized O
. O

The O
secondary O
outcome O
will O
be O
an B-Sec
improvement I-Sec
in I-Sec
insulin I-Sec
sensitivity I-Sec
, I-Sec
measured I-Sec
by I-Sec
hyperinsulinaemic I-Sec
euglycaemic I-Sec
clamp I-Sec
. O

We O
recorded O
the O
mean O
of O
three O
serial O
efforts O
of O
the O
key O
pinch O
measurement O
( O
thumb O
pad O
to O
lateral O
aspect O
of O
middle O
phalanx O
of O
the O
index O
finger O
) O
using O
a O
B O
& O
L O
Engineered O
( O
B O
& O
L O
Engineering O
3002 O
Dow O
Ave O
, O
Suite O
416 O
, O
Tuscin O
CA O
92780 O
) O
30 O
lbs. O

Seven O
secondary O
outcomes O
showed O
no O
statistically O
significant O
difference O
between O
MLU O
and O
CLU O
: O
caesarean B-Sec
birth I-Sec
( O
163 O
[ O
14.8 O
% O
] O
vs O
84 O
[ O
15.2 O
% O
] O
; O
relative O
risk O
( O
RR O
) O
0.97 O
, O
95 O
% O
CI O
0.76 O
, O
1.24 O
) O
, O
induction B-Sec
of I-Sec
labour I-Sec
( O
248 O
[ O
22.5 O
% O
] O
vs O
138 O
[ O
25.0 O
% O
] O
; O
RR O
0.90 O
, O
95 O
% O
CI O
0.75 O
, O
1.08 O
) O
, O
episiotomy O
( O
126 O
[ O
11.4 O
% O
] O
vs O
68 O
[ O
12.3 O
% O
] O
; O
RR O
0.93 O
, O
95 O
% O
CI O
0.70 O
, O
1.23 O
) O
, O
instrumental B-Sec
birth I-Sec
( O
139 O
[ O
12.6 O
% O
] O
vs O
79 O
[ O
14.3 O
% O
] O
; O
RR O
0.88 O
, O
95 O
% O
CI O
0.68 O
, O
1.14 O
) O
, O
Apgar B-Sec
scores I-Sec
less I-Sec
than I-Sec
8 I-Sec
( O
10 O
[ O
0.9 O
% O
] O
vs O
9 O
[ O
1.6 O
% O
] O
; O
RR O
0.56 O
, O
95 O
% O
CI O
0.23 O
, O
1.36 O
) O
, O
postpartum B-Sec
haemorrhage I-Sec
( O
PPH O
) O
( O
144 O
[ O
13.1 O
% O
] O
vs O
75 O
[ O
13.6 O
% O
] O
; O
RR O
0.96 O
, O
95 O
% O
CI O
0.74 O
, O
1.25 O
) O
and O
initiation B-Sec
of I-Sec
breastfeeding I-Sec
( O
616 O
[ O
55.9 O
% O
] O
vs O
317 O
[ O
57.4 O
% O
] O
; O
RR O
0.97 O
, O
95 O
% O
CI O
0.89 O
, O
1.06 O
) O
( O
Table O
6 O
) O
. O

The O
three O
co-Secary O
endpoints O
all O
demonstrated O
that O
the O
fluticasone O
/ O
formoterol O
combination O
product O
was O
superior O
in O
efficacy O
compared O
to O
each O
of O
the O
comparators O
. O

secondary O
outcomes O
will O
be O
objectively-measured B-Sec
physical I-Sec
activity I-Sec
, O
sedentary B-Sec
behaviour I-Sec
and O
activity B-Sec
behaviours I-Sec
; O
food B-Sec
intake I-Sec
( I-Sec
measured I-Sec
by I-Sec
3 I-Sec
day I-Sec
diary I-Sec
) I-Sec
and O
food B-Sec
behaviours I-Sec
; O
body B-Sec
composition I-Sec
, O
fitness B-Sec
and O
physical B-Sec
function I-Sec
; I-Sec
mental I-Sec
and I-Sec
social I-Sec
well-being I-Sec
( I-Sec
quality I-Sec
of I-Sec
life I-Sec
, I-Sec
mood I-Sec
and I-Sec
attitudes I-Sec
) I-Sec
, O
and O
family B-Sec
functioning I-Sec
. O

Subgroup O
analysis O
of O
the O
secondary O
clinical O
outcome O
( O
IOP B-Sec
) O
will O
be O
done O
according O
to O
ethnicity O
( O
Chinese O
or O
non-Chinese O
) O
, O
and O
diagnosis O
( O
PAC O
or O
PACG O
) O
. O

S-GGT B-Sec
was O
chosen O
to O
be O
the O
secondary O
outcome O
of O
the O
trial O
because O
it O
is O
widely O
used O
in O
screening O
for O
alcohol O
problems O
and O
correlates O
with O
alcohol O
consumption O
. O

Table O
1 O
demonstrates O
the O
differences O
detectable O
between O
any O
two O
intervention O
groups O
for O
the O
listed O
secondary O
measure O
( O
eg O
erythromycin O
vs. O
erythromycin-placebo O
) O
in O
each O
of O
the O
specified O
sub-groups O
( O
SPL O
and O
PROM O
) O
. O

Table O
2 O
displays O
the O
degree O
of O
correlation O
between O
the O
first O
and O
second O
measurements O
as O
well O
as O
the O
95 O
% O
confidence O
intervals O
. O

The O
secondary O
efficacy O
parameter O
was O
change B-Sec
of I-Sec
lower I-Sec
leg I-Sec
volume I-Sec
, I-Sec
determined I-Sec
by I-Sec
water I-Sec
replacement I-Sec
plethysmometry I-Sec
. O

Analytic O
Strategy O
Sample O
size O
and O
power O
calculations O
are O
based O
on O
the O
assumptions O
regarding O
the O
changes O
under O
treatment O
in O
two O
key O
measures O
of O
interest O
, O
namely O
, O
quality B-Sec
of I-Sec
life I-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
Headache I-Sec
Impact I-Sec
Test I-Sec
( I-Sec
HIT I-Sec
) I-Sec
and O
headache B-Sec
frequency I-Sec
based I-Sec
on I-Sec
headache I-Sec
diary I-Sec
. O

In O
the O
control O
group O
, O
one O
withdrew O
and O
two O
did O
not O
attend O
the O
secondary O
assessment O
. O

Our O
screening O
procedure O
, O
using O
the B-Sec
PRIME-MD I-Sec
as O
the O
secondary O
measure O
to O
diagnose O
major O
depression O
, O
yielded O
many O
patients O
with O
only O
mild O
symptoms O
( O
57 O
% O
) O
. O

The O
secondary O
safety O
variables O
were O
unexpected B-Sec
ocular I-Sec
or I-Sec
systemic I-Sec
findings I-Sec
, O
adverse B-Sec
event I-Sec
rate I-Sec
, O
and O
temporary B-Sec
and I-Sec
permanent I-Sec
discontinuation I-Sec
. O

An O
intention O
to O
treat O
analysis O
will O
be O
carried O
out O
on O
the O
secondary O
and O
secondary O
outcomes O
. O

secondary O
outcome O
is O
tested O
according O
to O
the O
intention O
to O
treat O
principle O
. O

Table O
2 O
Outcome O
measures O
of O
the O
effect O
evaluation O
secondary O
outcome O
measures O
Instrument O
No. O

The O
secondary O
outcome O
variable O
was O
child B-Sec
body I-Sec
mass I-Sec
index I-Sec
( I-Sec
BMI I-Sec
) I-Sec
z-score I-Sec
. O

The O
secondary O
outcome O
was O
the B-Sec
percentage I-Sec
of I-Sec
days I-Sec
on I-Sec
which I-Sec
the I-Sec
prescribed I-Sec
dose I-Sec
of I-Sec
medication I-Sec
was I-Sec
taken I-Sec
, I-Sec
measured I-Sec
objectively I-Sec
over I-Sec
12 I-Sec
weeks I-Sec
with I-Sec
an I-Sec
electronic I-Sec
medication-monitoring I-Sec
device I-Sec
( I-Sec
TrackCap I-Sec
, I-Sec
Aardex I-Sec
, I-Sec
Switzerland I-Sec
) I-Sec
. O

However O
, O
as O
we O
do O
not O
quite O
know O
how O
marked O
the O
effect O
of O
the O
scrotal O
patches O
will O
be O
, O
we O
decided O
to O
make O
the B-Sec
change I-Sec
in I-Sec
sperm I-Sec
count I-Sec
after I-Sec
90 I-Sec
days I-Sec
of I-Sec
wearing I-Sec
the I-Sec
scrotal I-Sec
cooling I-Sec
patches I-Sec
compared I-Sec
with I-Sec
the I-Sec
control I-Sec
group I-Sec
the O
secondary O
outcome O
measure O
, O
because O
if O
statistically O
significant O
differences O
between O
groups O
are O
identified O
, O
a O
post O
hoc O
sample O
size O
calculation O
could O
show O
that O
the O
current O
sample O
size O
( O
20 O
in O
each O
arm O
) O
was O
of O
sufficient O
power O
. O

The O
secondary O
efficacy O
measure O
of O
combined B-Sec
renal I-Sec
parameters I-Sec
was O
calculated O
according O
to O
the O
method O
of O
Hartung O
22 O
; O
eCrCl O
was O
analyzed O
by O
repeated O
measures O
ANOVA O
, O
RRT O
requirement O
by O
Fisher's O
exact O
test O
, O
and O
RRT O
duration O
by O
t-test O
. O

As O
seen O
in O
Additional O
file O
1 O
the O
between O
group O
effect O
size O
for O
the O
secondary O
outcome O
measure O
PDSS B-Sec
was O
d O
= O
0.00 O
( O
CI95 O
% O
= O
-0.41 O
to O
0.41 O
) O
at O
post-treatment O
. O

This O
study's O
secondary O
outcome O
will O
be O
the B-Sec
ADOS I-Sec
social I-Sec
communication I-Sec
algorithm I-Sec
score I-Sec
which O
has O
been O
used O
as O
an O
outcome O
measure O
in O
previous O
RCTs O
investigating O
effects O
of O
interventions O
for O
autism O
6 O
38 O
39 O
. O

secondary O
feasibility O
outcomes O
are O
: O
incidence B-Sec
of I-Sec
the I-Sec
index I-Sec
condition I-Sec
, O
the B-Sec
proportion I-Sec
of I-Sec
eligible I-Sec
patients I-Sec
within I-Sec
the I-Sec
screening I-Sec
cohort I-Sec
, O
recruitment B-Sec
rate I-Sec
for I-Sec
those I-Sec
deemed I-Sec
eligible I-Sec
, O
allocation B-Sec
crossover I-Sec
and O
short-term B-Sec
compliance I-Sec
with I-Sec
the I-Sec
study I-Sec
protocol I-Sec
. O

secondary O
outcome O
measures O
were O
global B-Sec
perceived I-Sec
effect I-Sec
( I-Sec
GPE I-Sec
) I-Sec
and O
the B-Sec
impact I-Sec
of I-Sec
the I-Sec
headache I-Sec
using I-Sec
the I-Sec
Headache I-Sec
Impact I-Sec
Test I-Sec
( I-Sec
HIT-6 I-Sec
) I-Sec
. O

There O
was O
one O
randomization O
error O
and O
secondary O
outcome O
was O
unavailable O
for O
3 O
infants O
owing O
to O
technical O
difficulties O
with O
the O
video O
recordings O
. O

The O
secondary O
outcome O
indicators O
were O
cure B-Sec
and O
severity B-Sec
of I-Sec
IAD I-Sec
. O

Iota-Carrageenan O
nasal O
spray O
was O
superior O
to O
placebo O
( O
p O
< O
0.046 O
) O
with O
respect O
to O
the O
secondary O
endpoint O
mean O
of O
TSS O
over O
days O
2-4 O
( O
Table O
1 O
) O
. O

The O
difference O
between O
the O
groups O
in O
the O
secondary O
end-point O
will O
be O
tested O
by O
means O
of O
the O
two-sided O
log-rank O
test O
. O

Results O
will O
be O
compared O
using O
the O
Generalized O
Linear O
Mixed O
Model O
( O
GLMM O
) O
approach O
to O
focus O
on O
variation O
in O
the O
secondary O
outcome O
: O
early B-Sec
childhood I-Sec
caries I-Sec
levels I-Sec
. O

secondary O
outcome O
The O
secondary O
outcome O
measure O
of O
the O
study O
was O
the B-Sec
Gastrointestinal I-Sec
Symptom I-Sec
Rating I-Sec
Scale-IBS I-Sec
version I-Sec
( I-Sec
GSRS-IBS I-Sec
) I-Sec
42 I-Sec
. O

Sample O
size O
The O
secondary O
outcome O
was O
the B-Sec
EQ-5D I-Sec
utility I-Sec
. O

This O
paper O
presents O
the O
secondary O
outcomes O
of O
Switch™ O
, O
a O
family- O
, O
school- O
, O
and O
community-based O
intervention O
aimed O
at O
changing O
key O
behaviors O
( O
PA O
, O
television O
viewing O
/ O
screen O
time O
, O
and O
nutrition O
) O
related O
to O
childhood O
obesity O
. O

Cure O
will O
be O
defined O
as O
: O
• O
a O
control O
score O
( O
NCS O
) O
of O
0 O
( O
misalignment O
never O
noticed O
by O
parents O
, O
no O
observable O
deviation O
on O
cover O
test O
) O
• O
demonstrable O
near O
stereoacuity O
in O
children O
over O
3 O
years O
of O
age O
Secondary O
outcomes O
include O
age-specific B-Sec
QOL I-Sec
assessments I-Sec
, O
median B-Sec
scores I-Sec
of I-Sec
control I-Sec
of I-Sec
exotropia I-Sec
assessed I-Sec
by I-Sec
parental I-Sec
report I-Sec
and O
clinical B-Sec
components I-Sec
of I-Sec
the I-Sec
NCS I-Sec
and I-Sec
the I-Sec
Mayo I-Sec
Score I-Sec
, O
rates B-Sec
of I-Sec
amblyopia I-Sec
, O
use B-Sec
of I-Sec
health-care I-Sec
resources I-Sec
, O
NHS B-Sec
costs I-Sec
, O
costs B-Sec
to I-Sec
families I-Sec
accessing I-Sec
the I-Sec
treatments I-Sec
being I-Sec
evaluated I-Sec
and O
incremental B-Sec
cost I-Sec
per I-Sec
cured I-Sec
patient I-Sec
( I-Sec
with I-Sec
cure I-Sec
as I-Sec
defined I-Sec
by I-Sec
the I-Sec
secondary I-Sec
outcome I-Sec
) I-Sec
, O
and O
a I-Sec
cost-consequences I-Sec
analysis I-Sec
based I-Sec
on I-Sec
the I-Sec
incremental I-Sec
cost I-Sec
with I-Sec
respect I-Sec
to I-Sec
changes I-Sec
in I-Sec
all I-Sec
relevant I-Sec
outcomes I-Sec
where O
possible O
. O

Endpoints O
The O
secondary O
endpoint O
was O
the B-Sec
proportion I-Sec
of I-Sec
children I-Sec
aged I-Sec
9-23 I-Sec
months I-Sec
completely I-Sec
vaccinated I-Sec
. O

Conclusions O
The O
IN O
TOUCH O
study O
is O
the O
first O
to O
investigate O
the O
effect O
of O
telemonitoring O
on O
top O
of O
ICT O
guided O
DM O
on O
the O
quality O
and O
efficiency O
of O
care O
in O
patients O
with O
worsening O
HF O
and O
will O
use O
a B-Sec
composite I-Sec
score I-Sec
as O
its O
secondary O
endpoint O
. O

secondary O
endpoint O
: O
level B-Sec
of I-Sec
physical I-Sec
activity I-Sec
secondary O
endpoint O
is O
the B-Sec
level I-Sec
of I-Sec
physical I-Sec
activity I-Sec
, I-Sec
as I-Sec
measured I-Sec
with I-Sec
a I-Sec
7-day I-Sec
recall I-Sec
, I-Sec
based I-Sec
on I-Sec
an I-Sec
interview-based I-Sec
physical I-Sec
activity I-Sec
questionnaire I-Sec
, I-Sec
the I-Sec
LAPAQ I-Sec
35 I-Sec
. O

Outcome O
measures O
The O
secondary O
outcome O
measure O
was O
HR B-Sec
and O
lnHF B-Sec
( I-Sec
to I-Sec
determine I-Sec
adaptations I-Sec
in I-Sec
autonomic I-Sec
control I-Sec
specifically I-Sec
vagal I-Sec
autonomic I-Sec
control I-Sec
) I-Sec
. O

In O
light O
of O
these O
considerations O
, O
the O
DSMB O
recommended O
: O
( O
a O
) O
to O
reduce O
the O
number O
of O
cohorts O
to O
4 O
( O
to O
conserve O
budget O
) O
; O
( O
b O
) O
to O
focus O
recruitment O
in O
Cohort O
4 O
on O
patients O
who O
were O
not O
in O
BP O
control O
at O
baseline O
( O
to O
ensure O
that O
the O
study O
population O
approximated O
the O
original O
target O
population O
as O
much O
as O
possible O
) O
; O
and O
( O
c O
) O
to O
change O
the O
secondary O
outcome O
to O
change O
in O
SBP O
, O
measured O
as O
a O
continuous O
variable O
, O
while O
maintaining O
the O
dichotomous O
measure O
of O
BP B-Sec
control I-Sec
as O
a O
secondary O
outcome O
( O
to O
increase O
statistical O
power O
by O
, O
for O
example O
, O
being O
able O
to O
differentiate O
between O
greater O
decreases O
in O
SBP O
among O
patients O
who O
were O
in O
BP O
control O
at O
baseline O
) O
. O

From O
this O
, O
we O
estimated O
that O
with O
a O
sample O
size O
of O
60 O
we O
would O
have O
a O
finding O
of O
clinical O
and O
statistical O
significance O
for O
differences O
in O
the O
secondary O
outcome O
. O

Outcomes O
When O
the O
data O
analysis O
takes O
place O
, O
the O
secondary O
outcomes O
will O
be O
percentage B-Sec
reductions I-Sec
in I-Sec
binge I-Sec
drinking I-Sec
, O
weekly B-Sec
and I-Sec
weekend I-Sec
drinking I-Sec
, O
and O
drinking-related B-Sec
problems I-Sec
. O

Consumption O
of O
acetaminophen O
( O
up O
to O
four O
325-mg O
tablets O
per O
day O
) O
was O
permitted O
for O
residual O
knee O
or O
other O
body O
pain O
throughout O
the O
treatment O
period O
, O
but O
not O
during O
the O
washout O
period O
prior O
to O
baseline O
assessment O
or O
during O
the O
week O
prior O
to O
secondary O
assessment O
at O
week O
6. O

Outcome O
measures O
The O
secondary O
outcome O
measure O
will O
be O
the B-Sec
incidence I-Sec
of I-Sec
new I-Sec
falls I-Sec
, I-Sec
fallers I-Sec
, I-Sec
based I-Sec
on I-Sec
the I-Sec
Falls I-Sec
Calendar I-Sec
. O

The O
secondary O
efficacy O
measure O
was O
the B-Sec
serum I-Sec
phosphorus I-Sec
at I-Sec
12 I-Sec
weeks I-Sec
. O

Clinical O
outcomes O
secondary O
clinical O
endpoint O
will O
be O
the B-Sec
improvement I-Sec
in I-Sec
health-related I-Sec
quality I-Sec
of I-Sec
life I-Sec
( I-Sec
HRQoL I-Sec
) I-Sec
at I-Sec
one I-Sec
year I-Sec
follow-up I-Sec
after I-Sec
the I-Sec
12 I-Sec
weeks I-Sec
of I-Sec
therapy I-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
Mental I-Sec
Component I-Sec
Summary I-Sec
Score I-Sec
of I-Sec
the I-Sec
SF-36 I-Sec
. O

secondary O
outcome O
is O
to B-Sec
recruit I-Sec
at I-Sec
least I-Sec
four I-Sec
patients I-Sec
every I-Sec
month I-Sec
with I-Sec
80 I-Sec
% I-Sec
of I-Sec
eligible I-Sec
patients I-Sec
being I-Sec
recruited I-Sec
. O

Table O
1 O
Baseline O
characteristics O
of O
study O
participants O
described O
for O
secondary O
and O
secondary O
outcome O
measures O
. O

Statistical O
Analyses O
/ O
Sample O
Size O
and O
Power O
Calculations O
Sample O
Size O
and O
Power O
The O
secondary O
endpoint O
is O
cotinine B-Sec
verified I-Sec
continuous I-Sec
abstinence I-Sec
at I-Sec
12 I-Sec
months I-Sec
. O

The O
secondary O
outcome O
variables O
of O
heart B-Sec
rate I-Sec
and O
heart B-Sec
rate I-Sec
variability I-Sec
were O
measured O
to O
assess O
autonomic O
function O
associated O
with O
cardiovascular O
disease O
. O

Trial O
phase O
The O
secondary O
outcomes O
( O
Table O
1 O
) O
include O
quality B-Sec
of I-Sec
life I-Sec
, I-Sec
measured I-Sec
across I-Sec
four I-Sec
dimensions I-Sec
( I-Sec
physical I-Sec
, I-Sec
psychological I-Sec
, I-Sec
environmental I-Sec
, I-Sec
social I-Sec
) I-Sec
using I-Sec
the I-Sec
WHOQoL-Bref I-Sec
58 I-Sec
, O
and O
mental B-Sec
health I-Sec
status I-Sec
, I-Sec
using I-Sec
the I-Sec
mental I-Sec
component I-Sec
of I-Sec
the I-Sec
SF-12 I-Sec
59 I-Sec
. O

For O
both O
secondary O
and O
secondary O
outcomes O
, O
the O
change O
from O
study O
baseline O
for O
a O
given O
parameter O
was O
calculated O
( O
ie O
, O
Day O
28 O
value O
minus O
baseline O
value O
) O
. O

secondary O
outcomes O
will O
undergo O
a O
two-way O
analysis O
of O
variance O
controlling O
for O
covariants O
such O
as O
operating O
room O
ambient O
temperature O
and O
volume O
of O
intraoperative O
irrigation O
solution O
. O

The B-Sec
duration I-Sec
and O
severity B-Sec
of I-Sec
diarrhea I-Sec
were O
the O
secondary O
endpoint O
variables O
of O
the O
study O
performed O
in O
a O
metabolic O
unit O
. O

For O
stratified O
analyses O
of O
the O
secondary O
outcome O
we O
will O
use O
formal O
tests O
of O
interaction O
between O
allocated O
interventions O
and O
subgroup O
in O
multivariable O
logistic O
regression O
models O
40 O
. O

The O
secondary O
outcome O
of O
the O
study O
was O
lung B-Sec
function I-Sec
. O

All O
pre-planned O
sensitivity O
analyses O
of O
the O
secondary O
endpoint O
confirmed O
non-inferiority O
. O

Figure O
6 O
Medical O
Outcome O
Study O
Short O
Form O
36 O
( O
SF-36 O
) O
domain O
scores O
at O
end O
point O
( O
last O
observation O
carried O
forward O
) O
for O
pooled O
intent-to O
with O
≥ O
50 O
% O
or O
< O
50 O
% O
reductions O
in O
monthly O
migraine O
frequency O
Medical O
Outcome O
Study O
Short O
Form O
36 O
( O
SF-36 O
) O
domain O
scores O
at O
end O
point O
( O
last O
observation O
carried O
forward O
) O
for O
pooled O
intent-to O
with O
* O
#8805 O
; O
50 O
% O
or O
< O
50 O
% O
reductions O
in O
monthly O
migraine O
frequency O
. O

At O
3 O
months O
, O
secondary O
outcome O
( O
psychosocial B-Sec
functions I-Sec
) O
and O
secondary O
outcome O
variables O
( O
HRQOL B-Sec
) O
will O
be O
re-assessed O
. O

Separate O
calculations O
were O
performed O
using O
two O
of O
the O
secondary O
outcome O
measures O
, O
so O
as O
to O
determine O
the O
sample-size O
requirements O
based O
on O
stepping O
reactions O
( O
average O
number O
of O
' O
extra O
' O
steps O
taken O
to O
recover O
balance O
) O
and O
grasping O
reactions O
( O
handrail-contact O
time O
) O
. O

Difference B-Sec
in I-Sec
plasma I-Sec
bone I-Sec
marker I-Sec
concentration I-Sec
between I-Sec
treatment I-Sec
groups I-Sec
was O
the O
secondary O
outcome O
. O

secondary O
efficacy O
endpoint O
analysis O
consisted O
of O
all O
randomized O
and O
dispensed O
subjects O
with O
baseline O
and O
at O
least O
1 O
post-treatment O
VA O
recorded O
. O

In O
the O
present O
study O
, O
efficacy O
of O
sodium O
hyaluronate O
, O
as O
measured O
by O
the O
secondary O
outcome O
variable O
, O
did O
not O
show O
signs O
of O
waning O
at O
the O
25-week O
timepoint O
. O

secondary O
outcomes O
are O
distress B-Sec
and O
MS-related B-Sec
social I-Sec
and I-Sec
role I-Sec
impairment I-Sec
at I-Sec
twelve I-Sec
month I-Sec
follow-up I-Sec
. O

The O
secondary O
endpoint O
was O
the B-Sec
percent I-Sec
of I-Sec
subjects I-Sec
meeting I-Sec
TR I-Sec
during I-Sec
the I-Sec
initial I-Sec
30 I-Sec
minutes I-Sec
of I-Sec
treatment I-Sec
. O

The O
secondary O
measure O
is O
the B-Sec
total I-Sec
score I-Sec
of I-Sec
this I-Sec
task I-Sec
( I-Sec
max I-Sec
= I-Sec
18 I-Sec
) I-Sec
. O

The O
secondary O
end-point O
of O
this O
trial O
is O
the B-Sec
overall I-Sec
quality I-Sec
of I-Sec
end-of-life I-Sec
care I-Sec
provided I-Sec
on I-Sec
the I-Sec
ward I-Sec
to I-Sec
dying I-Sec
cancer I-Sec
patients I-Sec
and I-Sec
their I-Sec
families I-Sec
. O

It O
is O
anticipated O
that O
the O
secondary O
economic O
endpoint O
will O
involve O
a O
clinically O
significant O
improvement O
in O
fatigue O
( O
eg O
cost O
per O
unit O
change O
in O
the O
fatigue O
outcome O
measure O
) O
. O

secondary O
efficacy O
variable O
was O
response B-Sec
rate I-Sec
based I-Sec
on I-Sec
a I-Sec
20 I-Sec
% I-Sec
improvement I-Sec
in I-Sec
WOMAC I-Sec
pain I-Sec
scores I-Sec
. O

We O
will O
use O
evidence O
on O
the O
association O
between O
walking O
capacity O
( O
distance O
and O
speed O
) O
and O
mortality O
risk O
to O
extrapolate O
our O
intermediate O
endpoints O
( O
distance O
walked O
in O
6 O
minutes O
and O
timed O
up-and-go O
assessment O
) O
to O
secondary O
outcomes O
. O

A O
result O
was O
considered O
statistically O
significant O
when O
the O
P O
value O
was O
< O
0.05 O
for O
secondary O
outcomes O
( O
BMD B-Sec
) O
and O
< O
0.01 O
for O
secondary O
outcomes O
. O

The O
secondary O
endpoint O
was O
the B-Sec
proportion I-Sec
of I-Sec
patients I-Sec
relapse-free I-Sec
at I-Sec
Week I-Sec
26. I-Sec

The O
secondary O
outcome O
measure O
is O
the B-Sec
patient's I-Sec
admission I-Sec
to I-Sec
a I-Sec
nursing I-Sec
home I-Sec
or I-Sec
home I-Sec
for I-Sec
the I-Sec
elderly I-Sec
at I-Sec
12 I-Sec
months I-Sec
of I-Sec
follow-up I-Sec
. O

The O
secondary O
outcome O
measure O
is O
perception B-Sec
of I-Sec
recovery I-Sec
measured I-Sec
on I-Sec
a I-Sec
7-point I-Sec
Likert I-Sec
scale I-Sec
ranging I-Sec
from I-Sec
" I-Sec
completely I-Sec
recovered I-Sec
" I-Sec
to I-Sec
" I-Sec
worse I-Sec
than I-Sec
ever I-Sec
" I-Sec
at I-Sec
12 I-Sec
months I-Sec
. O

Outcome O
measures O
and O
data O
collection O
The O
secondary O
end O
point O
was O
improvement B-Sec
in I-Sec
oxygenation I-Sec
( I-Sec
improvement I-Sec
of I-Sec
PaO I-Sec
2 I-Sec
/ I-Sec
FiO I-Sec
2 I-Sec
( I-Sec
PF I-Sec
) I-Sec
ratio I-Sec
) I-Sec
. O

secondary O
outcomes O
are O
death B-Sec
from I-Sec
causes I-Sec
at I-Sec
study I-Sec
end I-Sec
( I-Sec
follow-up I-Sec
until I-Sec
at I-Sec
least I-Sec
46 I-Sec
weeks I-Sec
after I-Sec
randomization I-Sec
) I-Sec
. O

secondary O
and O
secondary O
outcomes O
will O
be O
evaluated O
pre- O
and O
post-intervention O
with O
a O
follow-up O
of O
12 O
months O
. O

The O
mean O
( O
standard O
deviation O
) O
scores O
of O
CRF O
, O
for O
the O
pre-specified O
secondary O
outcome O
, O
CRF B-Sec
as I-Sec
measured I-Sec
by I-Sec
the I-Sec
BFI I-Sec
, O
were O
6.33 O
( O
1.39 O
) O
and O
6.00 O
( O
1.09 O
) O
at O
baseline O
for O
the O
treatment O
and O
control O
groups O
, O
respectively O
( O
See O
Table O
3 O
) O
. O

The O
secondary O
endpoint O
was O
disease B-Sec
free I-Sec
survival I-Sec
( I-Sec
DFS I-Sec
) I-Sec
and O
the O
secondary O
endpoints O
overall B-Sec
survival I-Sec
and O
toxicity B-Sec
. O

After O
12 O
weeks O
, O
the O
intervention O
group O
showed O
statistically O
as O
well O
as O
clinically O
significant O
differences O
compared O
with O
the O
control O
group O
on O
the O
secondary O
and O
secondary O
outcome O
measures O
. O

The O
secondary O
efficacy O
measure O
was O
the B-Sec
mean I-Sec
number I-Sec
of I-Sec
oocytes I-Sec
retrieved I-Sec
; O
secondary O
efficacy O
measures O
included O
the B-Sec
total I-Sec
dose I-Sec
and I-Sec
duration I-Sec
of I-Sec
gonadotropin I-Sec
treatment I-Sec
; O
peak B-Sec
serum I-Sec
estradion I-Sec
levels I-Sec
; O
embryo B-Sec
transfer I-Sec
and I-Sec
implantation I-Sec
rates I-Sec
; O
chemical B-Sec
, I-Sec
clinical I-Sec
and I-Sec
continuing I-Sec
pregnancies I-Sec
; O
and O
live B-Sec
birth I-Sec
rates I-Sec
. O

We O
feel O
that O
this O
can O
be O
justified O
as O
our O
previous O
work O
has O
shown O
that O
less O
than O
8 O
% O
of O
children O
with O
X O
( O
T O
) O
had O
surgery O
within O
the O
first O
year O
following O
initial O
assessment O
when O
treated O
in O
a O
routine O
setting O
18 O
; O
in O
some O
centres O
, O
no O
children O
had O
surgery O
within O
2 O
years O
of O
diagnosis O
19 O
. O

The O
secondary O
outcome O
measure O
is O
changes B-Sec
in I-Sec
regional I-Sec
cerebral I-Sec
blood I-Sec
flow I-Sec
from I-Sec
baseline I-Sec
in I-Sec
the I-Sec
arterial I-Sec
territories I-Sec
of I-Sec
the I-Sec
anterior I-Sec
cerebral I-Sec
artery I-Sec
, I-Sec
medial I-Sec
cerebral I-Sec
artery I-Sec
and I-Sec
the I-Sec
posterior I-Sec
cerebral I-Sec
artery I-Sec
, I-Sec
measured I-Sec
by I-Sec
CT I-Sec
perfusion I-Sec
scan I-Sec
. O

Analyses O
of O
secondary O
and O
secondary O
outcomes O
will O
be O
by O
intention O
to O
treat O
including O
all O
those O
recruited O
, O
and O
will O
compare O
differences O
between O
MMHU O
and O
standard O
care O
: O
• O
Mean O
/ O
median O
days O
at O
home O
, O
and O
total O
length O
of O
hospital O
stay O
( O
and O
95 O
% O
confidence O
intervals O
for O
the O
differences O
) O
• O
Proportions O
dead O
, O
at O
home O
, O
in O
new O
care O
homes O
and O
readmitted O
( O
and O
95 O
% O
confidence O
intervals O
for O
the O
differences O
) O
• O
Mean O
/ O
median O
scaled O
outcomes O
for O
patients O
and O
carers O
( O
and O
95 O
% O
confidence O
intervals O
for O
the O
differences O
) O
. O

Statistical O
analysis O
An O
a O
priori O
analysis O
of O
sample O
size O
revealed O
that O
at O
least O
17 O
patients O
per O
group O
were O
required O
to O
demonstrate O
a O
minimum O
difference O
of O
20 O
% O
between O
groups O
in O
the O
secondary O
endpoint O
with O
an O
estimated O
standard O
deviation O
of O
20 O
% O
, O
a O
test O
power O
of O
80 O
% O
, O
and O
an O
alpha O
error O
of O
5 O
% O
. O

Sensitivity O
analysis O
will O
test O
uncertainty O
in O
key O
parameters O
such O
as O
the O
selection O
of O
cost O
weights O
and O
statistical O
variation O
in O
quality O
of O
life O
scores O
. O

Statistical O
analysis O
Confirmatory O
analysis O
The O
confirmatory O
analysis O
of O
the O
secondary O
efficacy O
endpoint O
will O
be O
conducted O
according O
to O
the O
intention-to-treat O
principle O
, O
ie O
, O
all O
randomised O
patients O
will O
be O
included O
and O
will O
be O
analysed O
in O
the O
treatment O
group O
where O
they O
were O
allocated O
to O
by O
randomisation O
. O

secondary O
toddler O
outcomes O
include O
: O
a B-Sec
) I-Sec
increased I-Sec
fruit I-Sec
and I-Sec
vegetable I-Sec
consumption I-Sec
and I-Sec
decreased I-Sec
sweetened I-Sec
beverage I-Sec
consumption I-Sec
; O
and O
b B-Sec
) I-Sec
improved I-Sec
toddler-eating I-Sec
skills I-Sec
( I-Sec
self-feeding I-Sec
and I-Sec
self-serving I-Sec
) I-Sec
. O

If O
there O
was O
no O
data O
for O
the O
secondary O
endpoint O
( O
sRaw B-Sec
) O
at O
week O
4 O
, O
the O
last O
observation O
from O
week O
2 O
was O
carried O
forward O
. O

The O
secondary O
outcome O
measure O
was O
Chlamydia B-Sec
screening I-Sec
rates I-Sec
. O

